


STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD
AND COMPOSITIONS CONTAINING SAME

The present invention relates to group B
streptogramin derivatives of general formula:



in which

- Y is a nitrogen atom or a radical $=CR_3-$,
 R_1 is a hydrogen atom, a radical alkyl (1 to 8 carbons),
 alkenyl (2 to 8 carbons), cycloalkyl (3 to 8 carbons),
 heterocyclyl which is saturated or unsaturated (3 to
 8 members), phenyl, phenyl which is substituted [with
 one or more halogen atoms or hydroxyl, alkyl, alkyloxy,
 alkylthio, alkylsulphinyl, alkylsulphonyl, amino,
 alkylamino or dialkylamino radicals] or a radical
 $NR'R''$, R' and R'' , which are identical or different,
 being capable of being hydrogen atoms or alkyl radicals
 (1 to 3 carbons), or being capable of forming together

with the nitrogen atom to which they are attached a 3-
to 8-membered heterocycle optionally containing another
heteroatom chosen from oxygen, sulphur or nitrogen
which is optionally substituted [with a radical alkyl,
5 alkenyl (2 to 8 carbons), cycloalkyl (3 to 6 carbons),
heterocyclyl which is saturated or unsaturated (4 to
6 members), benzyl, phenyl or phenyl which is
substituted as defined above for the definition of R_1]
or alternatively when Y is a radical $=CR_3-$, R_1 may also
10 be halomethyl, hydroxymethyl, alkyloxymethyl,
alkylthiomethyl in which the alkyl portion is
optionally substituted with $NR'R''$,
alkylsulphinylmethyl, alkylsulphonylmethyl,
acyloxymethyl, benzoyloxymethyl, cyclopropylaminomethyl
15 or $-(CH_2)_nNR'R''$ (n being an integer from 1 to 4 and R'
and R'' being defined as above), or alternatively if R_3
is a hydrogen atom, R_1 may also be formyl, carboxyl,
alkyloxycarbonyl, or $-CONR'R''$ for which R' and R'' are
defined as above,
20 or alternatively when Y is a nitrogen atom, R_1 may also
be a radical $-XR^\circ$ for which X is an oxygen or sulphur
atom, a sulphinyl or sulphonyl radical, or an NH
radical and R° is a radical alkyl (1 to 8 carbons),
cycloalkyl (3 to 6 carbons), heterocyclyl which is
25 saturated or unsaturated (3 to 8 members),
heterocyclylmethyl (3 to 8 members) in which the
heterocyclyl portion is attached to the methyl radical
by a carbon atom, phenyl, phenyl which is substituted

09643197 082200

[with one or more halogen atoms or hydroxyl, alkyl, alkyloxy, alkylthio, alkylsulphanyl, alkylsulphonyl, amino, alkylamino or dialkylamino radicals] or a radical $-(CH_2)_nNR'R''$ for which R' and R'' are defined as above and n is an integer from 2 to 4, or alternatively if X represents NH , R^o may also represent the hydrogen atom,

R_2 is a hydrogen atom or an alkyl radical (1 to 3 carbons),

R_3 is a hydrogen atom or an alkyl, carboxyl, alkyloxycarbonyl or carbamoyl radical having the structure $-CO-NR'R''$ in which R' and R'' are defined as above,

R_a is a methyl or ethyl radical, and

R_b , R_c and R_d have the definitions below:

1) R_b and R_c are hydrogen atoms and R_d is a hydrogen atom or a methylamino or dimethylamino radical,

2) R_b is a hydrogen atom, R_c is a hydrogen, chlorine or bromine atom, or represents an alkenyl radical

(3 to 5C), and R_d is a radical $-NMe-R'''$ for which R''' represents a radical alkyl, hydroxyalkyl (2 to 4C), or alkenyl (2 to 8C) which is optionally substituted with phenyl, cycloalkyl (3 to 6C) methyl, benzyl, benzyl which is substituted

[with one or more halogen atoms or hydroxyl, alkyl, alkyloxy, alkylthio, alkylsulphanyl, alkylsulphonyl, amino, alkylamino or dialkylamino radicals], heterocyclylmethyl or heterocyclylethyl

002280 26 FEB 66 09543197 082200

- in which the heterocyclyl portion is saturated or unsaturated and contains 5 to 6 members and 1 or 2 heteroatoms chosen from sulphur, oxygen or nitrogen which is optionally substituted [with a radical alkyl, alkenyl (2 to 8 carbons), cycloalkyl (3 to 6 carbons), heterocyclyl which is saturated or unsaturated (4 to 6 members), phenyl, phenyl which is substituted as defined above for the definition of R_1 or benzyl], or alternatively R'' represents a radical cyanomethyl, or $-CH_2CORE$ for which either Re is $-OR'e$, $R'e$ being hydrogen, alkyl (1 to 6 carbons), alkenyl (2 to 6 carbons), benzyl or heterocyclylmethyl in which the heterocyclyl portion contains 5 to 6 members and 1 or 2 heteroatoms chosen from sulphur, oxygen or nitrogen, or Re is an alkylamino, alkylmethyldamino, heterocyclylamino or heterocyclylmethyldamino radical in which the heterocyclyl portion is saturated and contains 5 to 6 members and 1 or 2 heteroatoms chosen from sulphur, oxygen or nitrogen which is optionally substituted with an alkyl, benzyl or alkyloxycarbonyl radical,
- 3) Rb is a hydrogen atom, Rd is a radical $-NHCH_3$ or $-N(CH_3)_2$ and Rc is a chlorine or bromine atom, or represents an alkenyl radical (3 to 5C), [if Rd is $-N(CH_3)_2$],
- 4) Rb and Rd are hydrogen atoms and Rc is a halogen

002280 6643197 082200

atom, or an alkylamino or dialkylamino, alkyloxy, trifluoromethoxy, thioalkyl, alkyl (1 to 6C) or trihalomethyl radical,

5) Rb and Rc are hydrogen atoms and Rd is a halogen atom, or an ethylamino, diethylamino or methylethylamino, alkyloxy or trifluoromethoxy, alkylthio, alkylsulphanyl, alkylsulphonyl, alkyl (1 to 6C), phenyl or trihalomethyl radical,

6) Rb is a hydrogen atom and Rc is a halogen atom or an alkylamino or dialkylamino, alkyloxy or trifluoromethoxy, thioalkyl or alkyl (1 to 3C) radical, and Rd is a halogen atom or an amino, alkylamino or dialkylamino, alkyloxy or trifluoromethoxy, thioalkyl, alkyl (1 to 6C) or trihalomethyl radical,

7) Rc is a hydrogen atom and Rb and Rd represent a methyl radical,

as well as their salts, which exhibit a particularly advantageous antibacterial activity, alone or combined with a group A streptogramin derivative.

In the general formula (I) above, the halogen atoms may be chosen from fluorine, chlorine, bromine or iodine; the alkyl or acyl radicals are straight or branched and, unless otherwise stated, contain 1 to 4 carbon atoms. The same is true for the alkyl radicals which will be mentioned below. The alkenyl radicals may also be in the form of a straight or branched chain.

Moreover, by way of example, when R' and R"


002280 2674960

together form a heterocycle with the nitrogen atom to which they are attached, the latter contains 1 or 2 heteroatoms and may for example be chosen from pyrrolidinyl, piperidino, morpholino, thiomorpholino, 5 piperazinyl, methyl piperazinyl, imidazolidinyl, methylimidazolidinyl. By way of example, when R_1 or R^o represents heterocyclyl, when $-NR'R''$ and/or R''' are substituted with heterocyclyl or when R''' represents heterocyclylmethyl, the heterocyclyl radical contains 1 10 or 2 heteroatoms and may for example be chosen from pyridyl, pyrazinyl, pyrimidinyl, thienyl, furyl, imidazolyl, which are optionally substituted, or from the heterocycles mentioned above at a preference for $-NR'R''$.

15 Among the known streptogramins, pristinamycin (RP 7293), an antibacterial of natural origin produced by *Streptomyces pristinaespiralis* was first isolated in 1955. The pristinamycin marketed under the name Pyostacine® consists mainly of pristinamycin I_A combined 20 with pristinamycin II_A .

Another antibacterial of the class of streptogramins: virginiamycin, has been prepared from *Streptomyces virginiae*, ATCC 13161 [Antibiotics and Chemotherapy, 5, 632 (1955)]. Virginiamycin 25 (Staphylomycin®) consists mainly of the factor S combined with factor M_1 .

Semisynthetic derivatives of streptogramins represented by the structure:



in which,

Ra is a radical having the structure $-\text{CH}_2\text{R}'\text{a}$ for which R'a is a radical of the heterocyclylthio type which may be substituted or alternatively represents a radical having the structure $=\text{CHR}'\text{a}$ for which R'a is an alkylamino, alkyloxy or alkylthio radical which are substituted, or a radical of the heterocyclylamino, heterocycliloxy or heterocyclylthio type which may be substituted, Rb and Rc are hydrogen atoms and Rd is a hydrogen atom or a dimethylamino radical, or alternatively

Ra is a hydrogen atom and Rb is hydrogen or methyl, Rc and Rd are hydrogen or various substituents have been described in patents or patent applications EP 133097, EP 248703, EP 770132 and EP 772630. Combined with a semisynthetic component of the group A streptogramins, they manifest a synergistic action and can be used as antibacterial agents either by the injection route alone, or solely by the oral route.


The streptogramin derivatives of general

formula (I) are particularly advantageous because of their potent activity both by the oral and parenteral routes, which offers them an undeniable advantage in the case especially of treatments of serious

5 infections, in a hospital setting by the injection route, followed by an ambulatory treatment by the oral route which is easier to administer to patients. Thus, the practitioner is no longer obliged to change the patient's medicament between the end of the hospital

10 treatment and the overall end of the treatment.


According to the invention, the streptogramin derivatives for which Y is a radical $=CR_3-$ and R_3 is other than an alkyl radical may be prepared by the action of an enamino ester of general formula:



15

in which R_1 is defined as above and R represents the residue of an easily hydrolysable ester or an alkyl radical, on the corresponding 5 δ -methylenepristinamycin derivative of general formula:

09643197-082200



in which Ra, Rb, Rc and Rd are defined as above, R₂ is defined as above and R₄ is a hydrogen atom, or R₂ represents a hydrogen atom and R₄ is a hydrogen atom or a dialkylamino radical, followed where appropriate by the conversion of the ester obtained to an acid, and then optionally by its decarboxylation, or by the conversion of the acid to a carbamoyl radical according to the derivative of general formula (I) desired, and/or followed where appropriate by the conversion of the derivative of general formula (I) for which R₁ is hydroxymethyl to a derivative for which R₁ is a radical formyl, and then where appropriate carboxyl, and then where appropriate alkyloxycarbonyl or -CONR'R" and/or optionally followed by the mono- N-demethylation of the derivative of general formula (I) for which Rd is a dimethylamino radical to a derivative for which Rd is methylamino, and then optionally followed by the conversion to a salt when they exist.

Residue of an easily hydrolysable ester is

understood to mean, for example and with no limitation being implied, the residue of the benzyl, methyl, trimethylsilylethyl, ethyl, allyl or t-butyl ester.

The reaction is generally carried out in an
5 organic solvent such as an alcohol for example (methanol, ethanol in particular), at a temperature of between 40°C and the reflux temperature of the reaction mixture.

The conversion to an acid, an amide, or the
10 decarboxylation in order to obtain a derivative in which R₃ is carboxyl, carbamoyl having the structure -CO-NR'R" or a hydrogen atom, is carried out according to known methods which do not adversely affect the rest of the molecule and more particularly according to the
15 methods mentioned below in the examples.

In particular, when it is desired to obtain a pristinamycin derivative of general formula (I) for which R₃ is a carboxyl radical, the benzyl ester is advantageously prepared. The hydrolysis of the esters
20 is carried out according to known methods which do not adversely affect the rest of the molecule, for example the methods mentioned by T.W. Greene Protective Groups in Organic Synthesis, A. Wiley - Interscience Publication (1981), or by Mc Omie, Protective Groups in
25 Organic Chemistry, Plenum Press (1973). By way of example, the residue of the benzyl ester may be hydrolysed by treatment with 1,4-cyclohexadiene in the presence of palladium hydroxide on carbon, in an

002280 26T4960

alcoholic medium (methanol, ethanol for example), at a temperature of between 0 and 60°C.

When it is desired to prepare a derivative of general formula (I) for which R_3 is $-CO-NR'R''$, the product of general formula (I) obtained for which R_3 is carboxyl is treated according to the usual methods for converting acids to amides, which do not adversely affect the rest of the molecule. In particular, the corresponding amine is reacted with the acid in the presence of a condensing agent (carbodiimide for example) at a temperature of between 0 and 60°C, in an organic solvent such as a chlorinated solvent (chloroform, dichloromethane for example), an amide (dimethylformamide, N-methylpyrrolidone for example).

When it is desired to obtain a streptogramin derivative of general formula (I) for which R_3 is a hydrogen atom, the product for which R_3 is carboxyl is decarboxylated according to the customary methods which do not adversely affect the rest of the molecule. In particular, the procedure may be carried out according to the method described by Barton, Tetrahedron, 44(17), 5479-86 (1988), by formation of the N-hydroxypyridine-2-thione ester, and then photolysis in the presence of tert-butylthiol for example.

The mono-N-demethylation of the streptogramin derivative of general formula (I) for which R_d is dimethylamino may be carried out according to the method described in patent application EP 821697 by

treatment with a periodate in an acetic medium followed by a treatment in an aqueous acid medium or a treatment with an agent capable of consuming formaldehyde in situ.

- 5 The conversion of the radical $R_1 =$ hydroxymethyl to a formyl radical may be carried out by the action of selenium oxide by analogy with J. Korean Chem. Soc., 38(7), 537-8 (1994).

- 10 The conversion of the radical $R_1 =$ formyl to a carboxyl radical is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular, tin oxide may be used as described in Heterocycles 32(10), 1933-40 (1991).

- 15 The conversion of the radical $R_1 =$ carboxyl to an alkyloxycarbonyl radical is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular as described in The Chemistry of Acid Derivatives, Part I, page 411, Ed. S. Patai, John Wiley & Sons (1979).
- 20


- The conversion of the radical $R_1 =$ carboxyl to a carbamoyl radical having the structure $-CO-NR'R''$ is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular, the corresponding amine is reacted with the acid in the presence of a condensing agent according to conventional methods of peptide chemistry:
- 25

M. Bodanszky, Principles of Peptides Synthesis,

002280" 26TE4960

Springer Verlag, Berlin - Heidelberg - New-York - Tokyo
(1984).

According to the invention, the streptogramin
derivatives of general formula (I) for which Y is a
5 radical $=CR_3-$ and R_3 is a hydrogen atom or an alkyl
radical may be prepared by the action of a pyridinium
salt of general formula:



in which R_3 is defined as above, R_5 is the residue of a
10 ketone R_1-CO- for which R_1 is defined as above with the
exception of representing a radical $-NR'R''$, or
optionally represents a protected hydroxyl radical or a
nitrophenyl radical or alternatively R_5 represents the
cyano radical so as to obtain a streptogramin
15 derivative for which R_1 is an amino radical, and X^- is
an anion, on the corresponding 5 δ -methylene-
pristinamycin of general formula (III) in which R_4 is a
hydrogen atom and R_a, R_b, R_c, R_d and R_2 are defined as
above optionally followed by the liberation of the
20 hydroxyl radical or where appropriate the reduction of
the nitrophenyl radical so as to obtain a derivative
for which R_1 is an aminophenyl radical, or optionally
followed by the action of an amine of general formula
 $HNR'R''$ on the streptogramin derivative of general
25 formula (I) for which R_1 is halomethyl, so as to obtain

002280" 26 FEB 96

the corresponding derivative for which R_1 is a radical
-CH₂NR'R", or followed where appropriate by the
conversion of the derivative of general formula (I) for
which R_1 is hydroxymethyl to a derivative for which R_1
5 is a radical formyl, and then where appropriate
carboxyl, and then where appropriate alkyloxycarbonyl
or -CONR'R" and/or optionally the mono- N-demethylation
of the derivative of general formula (I) for which R_d
is a dimethylamino radical to a derivative for which R_d
10 is methylamino, and then optionally followed by the
conversion to a salt, when they exist.

With no limitation being implied, the anion X^-
advantageously represents a halide anion (bromide,
chloride or iodide for example).

15 The reaction is generally carried out in the
presence of an ammonium salt (ammonium acetate for
example), in a solvent such as an alcohol (methanol,
ethanol for example), a nitrile (acetonitrile for
example), an ester (ethyl acetate for example) or a
20 ketone (acetone for example), at a temperature of
between 40°C and the reflux temperature of the reaction
mixture.

When the radical R_1 contains a hydroxyl
substituent, it is preferable to protect this radical
25 beforehand according to the methods which do not
adversely affect the rest of the molecule. The
protection and deprotection of the hydroxyl radical is
carried out according to the customary methods. For

0032280" 46T4960

example, the protection is carried out using an acetyl radical or using any other hydroxyl-protecting group whose introduction and removal are mentioned for example by T.W. Greene Protective Groups in Organic Synthesis, A. Wiley - Interscience Publication (1981), or by Mc Omie, Protective Groups in Organic Chemistry, Plenum Press (1973).

When it is desired to obtain a product for which R_1 is aminophenyl, it is preferable to prepare the corresponding nitrophenyl derivative and then to carry out the reduction of the nitro radical of the derivative obtained. In particular, it is possible to carry out the procedure by reduction in an acid medium (hydrochloric acid) in the presence of iron.

When it is desired to obtain the streptogramin derivative of general formula (I) for which R_1 is a radical $-CH_2NR'R''$, an amine $HNR'R''$ is reacted with the corresponding streptogramin derivative of general formula (I) for which R_1 is halomethyl, by carrying out the procedure in the presence of a tertiary amine (triethylamine, diisopropylethylamine for example) or an excess of the amine, in an organic solvent such as an ether (tetrahydrofuran, dioxane for example), an alcohol (methanol for example), a chlorinated solvent (chloroform, dichloromethane for example), a nitrile (acetonitrile for example) or dimethyl sulphoxide at a temperature of between 40°C and the reflux temperature of the reaction mixture.

002280 2674960

The mono-N-demethylation of the streptogramin derivative of general formula (I) for which Rd is dimethylamino may be carried out according to the method described in patent application EP 821697. The
5 conversion of the radical R_1 = hydroxymethyl to a formyl radical may be carried out by the action of selenium oxide by analogy with J. Korean Chem. Soc., 38(7), 537-
8 (1994).

The conversion of the radical R_1 = formyl to a
10 carboxyl radical is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular, tin oxide may be used as described in Heterocycles 32(10), 1933-40
(1991).


The conversion of the radical R_1 = carboxyl to
15 an alkyloxycarbonyl radical is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular as described in The Chemistry of Acid Derivatives, Part I, page 411, Ed. S.
20 Patai, John Wiley & Sons (1979).

The conversion of the radical R_1 = carboxyl to a carbamoyl radical having the structure $-CO-NR'R''$ is carried out according to the customary methods which do not adversely affect the rest of the molecule. In
25 particular, the corresponding amine is reacted with the acid in the presence of a condensing agent according to conventional methods of peptide chemistry:
M. Bodanszky, Principles of Peptides Synthesis,

002280 26 FEB 95 09643197 082200

Springer Verlag, Berlin - Heidelberg - New-York - Tokyo
(1984).

According to the invention, the streptogramin derivatives of general formula (I) for which Y is a
5 nitrogen atom may be prepared by the action of a salt of an amidine or of a derivative of isourea or of isothiurea of general formula:



in which R₁ is defined as for the general formula (I),
10 with the exception of representing a radical XR° for which X is sulphonyl or sulphinyl, or a radical NR'R" other than amino, on a streptogramin derivative of general formula (III) for which R₄ is dialkylamino, and then in order to obtain a streptogramin derivative of
15 general formula (I) for which R₁ is a radical XR° for which X is sulphonyl or sulphinyl, oxidation of the corresponding derivative for which X is a sulphur atom, and then in order to obtain the streptogramin derivative of general formula (I) for which R₁ is a
20 radical NR'R", substitution of the sulphonyl derivative obtained by the action of the corresponding amine HNR'R" and/or optionally in order to obtain a derivative for which R_d is methylamino, demethylation of the derivative of general formula (I) for which R_d
25 is a dimethylamino radical, and then optionally conversion to a salt, when they exist.

002280" 26134950

002280" 2674960

The reaction of the derivative of general formula (V) is generally carried out in an organic solvent such as an amide (dimethylformamide, dimethylacetamide for example) or a nitrile (acetonitrile for example), in the presence of a base such as in particular a tertiary amine (diisopropylethylamine, triethylamine for example) or an alkali metal bicarbonate (sodium or potassium bicarbonate for example), at a temperature of between 50 and 100°C. The reaction is advantageously carried out using the hydrochloride, the sulphate or the hydrogen sulphate of the derivative of general formula (V).

The oxidation to a sulphonyl or sulphonyl derivative is carried out respectively by treatment with 1 or 2 equivalents of Oxone® in an acid medium (for example 0.1 to 2N, preferably 0.5 to 1N sulphuric acid), at a temperature of between -60 and 60°C, in a solvent such as an alcohol (methanol, ethanol, i-propanol for example). Depending on the product prepared, it may be optionally necessary for the oxidation operation to be followed by a treatment which reduces N-oxides by any known and specific method which does not adversely affect the rest of the molecule. In particular, it is possible to carry out the procedure by heating in the presence of iron in acetic acid, or by treatment with sodium bisulphite.

The subsequent operation of substituting with

an amine may be carried out by the action of the corresponding amine of formula $\text{HNR}'\text{R}''$, either in excess or in the presence of a base such as for example an alkali metal bicarbonate (sodium or potassium

- 5 bicarbonate for example), by carrying out the procedure at a temperature of between 20 and 100°C, in an organic solvent such as an amide (dimethylformamide, dimethylacetamide for example) or a nitrile (acetonitrile for example).

- 10 The mono- N-demethylation of the streptogramin derivative of general formula (I) for which R_d is dimethylamino may be carried out according to the method described in patent application EP 821697.

- 15 The conversion of the radical $\text{R}_1 =$ hydroxymethyl to a formyl radical may be carried out by the action of selenium oxide by analogy with J. Korean Chem. Soc., 38(7), 537-8 (1994).

- 20 The conversion of the radical $\text{R}_1 =$ formyl to a carboxyl radical is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular, tin oxide may be used as described in Heterocycles 32(10), 1933-40 (1991).

- 25 The conversion of the radical $\text{R}_1 =$ carboxyl to an alkyloxycarbonyl radical is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular as described in The


002280 " 082200 09643197

Chemistry of Acid Derivatives, Part I, page 411, Ed. S. Patai, John Wiley & Sons (1979).

The conversion of the radical R_1 = carboxyl to a carbamoyl radical having the structure $-CO-NR'R''$ is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular, the corresponding amine is reacted with the acid in the presence of a condensing agent according to conventional methods of peptide chemistry: M.

- 10 Bodanszky, Principles of Peptides Synthesis, Springer Verlag, Berlin - Heidelberg - New-York - Tokyo (1984).

According to the invention, the streptogramin derivatives of general formula (I) for which Y is a radical $=CR_3-$, R_1 is a hydrogen atom, an alkyl, alkenyl, cycloalkyl, aromatic heterocyclyl, phenyl, substituted phenyl, halomethyl, hydroxymethyl, alkyloxymethyl, alkylthiomethyl, alkylsulphinylmethyl, alkylsulphonylmethyl or $-(CH_2)_nNR'R''$ radical, or alternatively when R_3 is a hydrogen atom, for which R_1 is formyl, carboxyl, alkoxy carbonyl or $-CONR'R''$ as defined above and R_2 is a hydrogen atom, may also be prepared by the action of the formyl enamine of general formula:




25

in which R_1 is a hydrogen atom, an alkyl, alkenyl,

cycloalkyl, aromatic heterocyclyl, phenyl, substituted phenyl, hydroxymethyl, alkyloxymethyl, alkylthiomethyl or $-(CH_2)_nNR'R''$ radical and R_3 is defined as above with the exception of representing carboxyl, on a

5 streptogramin derivative of general formula:



in which R_a , R_b , R_c and R_d are defined as above, followed where appropriate by the conversion of the derivative for which R_3 is amide or ester to a

10 derivative for which R_3 is carboxyl and/or followed where appropriate by the oxidation of the derivative for which R_1 is alkylthiomethyl to a derivative for which R_1 is alkylsulphinylmethyl or alkylsulphonylmethyl, or followed where appropriate by

15 the conversion of the derivative for which R_1 is a hydroxymethyl radical to a derivative for which R_1 is halomethyl, and then where appropriate the conversion of the derivative for which R_1 is halomethyl to a derivative for which R_1 is $-CH_2NR'R''$, or followed where

20 appropriate by the conversion of the derivative of

0022280 2674960

general formula (I) for which R_1 is hydroxymethyl to a derivative for which R_1 is a radical formyl, and then where appropriate carboxyl, alkyloxy carbonyl and/or -CONR'R", and/or optionally the mono-N-demethylation of
5 the derivative of general formula (I) for which R_d is a dimethylamino radical to a derivative for which R_d is methylamino, and then optionally followed by conversion to a salt, when they exist.

The reaction is carried out in an organic
10 solvent such as an alcohol (methanol, ethanol for example) at a temperature of between 20°C and the reflux temperature of the reaction mixture, in the presence of an ammonia donor such as for example ammonium acetate.

15 The oxidation of the alkylthiomethyl radical to an alkylsulphinylmethyl or alkylsulphonylmethyl radical is carried out under the conditions described above, by treatment with Oxone®.

The production of a streptogramin derivative
20 of general formula (I) for which R_1 is halomethyl from a derivative for which R_1 is hydroxymethyl is carried out according to the customary methods. In particular by the action of a halogenating agent such as for example thionyl chloride.

25 The reaction of an amine HNR'R" on the streptogramin derivative of general formula (I) for which R_1 is halomethyl is carried out as described above.

002280" 2674950

The conversion of the radical $R_1 =$ hydroxymethyl to a formyl radical may be carried out by the action of selenium oxide by analogy with J. Korean Chem. Soc., 38(7), 537-8 (1994).

5 The conversion of the radical $R_1 =$ formyl to a carboxyl radical is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular, tin oxide may be used as described in Heterocycles 32(10), 1933-40
10 (1991).

 The conversion of the radical $R_1 =$ carboxyl to an alkyloxycarbonyl radical is carried out according to the customary methods which do not adversely affect the rest of the molecule. In particular as described in The
15 Chemistry of Acid Derivatives, Part I, page 411, Ed. S. Patai, John Wiley & Sons (1979).

 The conversion of the radical $R_1 =$ carboxyl to a carbamoyl radical having the structure $-CO-NR'R''$ is carried out according to the customary methods which do
20 not adversely affect the rest of the molecule. In particular, the corresponding amine is reacted with the acid in the presence of a condensing agent according to conventional methods of peptide chemistry: M. Bodanszky, Principles of Peptides Synthesis, Springer
25 Verlag, Berlin - Heidelberg - New-York - Tokyo (1984).
The direct conversion of the radical $R_1 =$ formyl to a carbamoyl radical may be carried out as described in the examples.

002280" 4644960

The mono-N-demethylation of the streptogramin derivative of general formula (I) for which Rd is dimethylamino may be carried out according to the method described in patent application EP 821697.

5 The enamino esters of general formula (II) are either commercially available or may be prepared according to or by analogy with the methods described in Tetrahedron Letters 38(3), 443-6(1997) and FR 2216270.

10 The 5 δ -methylenepristinamycin derivatives of general formula (III) for which Ra is a methyl radical, or for which Ra is an ethyl radical but Rb, Rc and Rd do not simultaneously have the definitions: "Rb and Rc represent hydrogen and Rd represents hydrogen or
15 dimethylamino", may be prepared from pristinamycin Ic, virginiamycin S4, vernamycin B δ , pristinamycin Ib, or from their derivatives or analogues of general formula (VII) in which Ra is defined as above and the substituents Rb, Rc and Rd are either defined as in the
20 general formula (I) in 1), with the exception of simultaneously representing Rb = Rc = hydrogen and Rd = hydrogen or dimethylamino, when Ra is ethyl, or are defined as for the general formula (I) in 2) to 7), by carrying out the procedure by analogy with the methods
25 described in European applications EP 133097 or EP 133098 or by analogy with the methods described below in the examples.

The pyridinium salts of general formula (IV)

002280 461E4950

are prepared according to or by analogy with the method described by F. Kröhnke, *Synthesis*, (1976) 1-24, or according to or by analogy with the methods described below in the examples.

5 The amidines of formula (V) are commercially available or are prepared according to or by analogy with the method described by S. Patai, *The Chemistry of amidines and Imidates*, Interscience Publication, J. Wiley & Sons, Chap. 7, p. 283 (1975).

10 The formyl enamines of general formula (VI) may be prepared by analogy in *J. Chem. Soc., Perkin trans I*, 9, 2103 (1984).

 The products of general formula (VII) for which Ra, Rb, Rc and Rd are defined as for the general
15 formula (I) in 1) are natural group B streptogramins.

 The preparation and separation of the components of the natural group B streptogramins is carried out by fermentation and isolation of the constituents from fermentation broth according to or by
20 analogy with the method described by J. Preud'homme et al., *Bull. Soc. Chim. Fr.*, vol. 2, 585 (1968) or according to *Antibiotics and Chemotherapy*, 5, 632 (1955).

 Components of the group B streptogramins are
25 also described in *Streptogramine als Modellsysteme für den Kationentransport durch Membranen*, Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Georg-August

002280" 26 FEB 1980

Universität zu Göttingen, Göttingen 1979, in
Antibiotics III, 521 (1975) and in Antibiotics of the
virginiamycin family, Inhibitors which contain
synergistic components, C. Cocito, Microbiological
5 Reviews, 145-98 (1979).

Alternatively, the preparation of the natural
components of group B may be carried out by specific
fermentation, as described in patent application FR
2,689,518.

10 The streptogramin derivatives of general
formula (VII) for which Ra, Rb, Rc and Rd are defined
as for the general formula (I) in 3) are prepared as
described in European application EP 772630.

The streptogramin derivatives of general
15 formula (VII) for which Ra, Rb, Rc and Rd are defined
as for the general formula (I) in 4) to 7) are prepared
as described in European application EP 770132.

The streptogramin derivatives of general
formula (VII) for which Ra, Rb and Rc are defined as
20 for the general formula (I) in 5) and Rd is
alkylsulphanyl or alkylsulphonyl may be prepared by
oxidation of the corresponding product for which Rd is
alkylthio.

The streptogramin derivatives of general
25 formula (VII) for which Ra, Rb, Rc and Rd are defined
as for the general formula (I) in 2) may be prepared
from pristinamycin I_B (Ra = ethyl) or from vernamycin Bδ
(Ra = methyl) or from a streptogramin derivative of

002230" 46FF4950

general formula (I) for which Ra, Rb and Rc are defined as in 3) and Rd is -NHCH₃, by the action of a halogenated derivative of general formula:



- 5 in which R'' is defined as for the general formula (I) in 2) and X is an iodine, bromine or chlorine atom, followed where appropriate by the chlorination or the bromination of the product obtained, when it is desired to obtain a derivative for which Rc is a chlorine or
10 bromine atom, after starting with pristinamycin I_B or with vernamycin Bδ.

- The reaction is generally carried out in an organic solvent such as an amide (dimethylformamide for example), a chlorinated solvent (chloroform,
15 dichloromethane for example), an alcohol (methanol, ethanol for example)/chlorinated solvent mixture, a nitrile (acetonitrile for example), in dimethyl sulphoxide or N-methylpyrrolidone, at a temperature of between 20 and 100°C, optionally in the presence of
20 sodium iodide or an alkali metal bicarbonate (sodium or potassium). Preferably, the procedure is carried out under nitrogen. It is understood that when the radical R'' contains an amino radical, it is preferable to protect this radical prior to the reaction. The
25 protection and deprotection are carried out according to the methods indicated in the references cited above.

Where appropriate, the halogenation is advantageously carried out with an N-halosuccinimide,

002280 1644950

in an organic solvent such as a chlorinated solvent (dichloromethane, chloroform for example) or a nitrile (acetonitrile for example), at a temperature of between 20 and 80°C.

5 According to another alternative, the streptogramin derivatives of general formula (VII) for which Ra and Rb are defined as for the general formula (I), Rc is a hydrogen atom and Rd is a cyanomethyl methyl amino or alkyloxycarbonylmethyl methyl amino
10 radical may also be prepared from pristinamycin Ia (Ra = ethyl) or from pristinamycin Ic (Ra = methyl) by the action of a halogenated derivative of general formula (VIII) in which R'' represents cyanomethyl or alkyloxycarbonylmethyl.


15 The reaction is generally carried out in an organic solvent such as an amide (dimethylformamide for example) at a temperature of between 70 and 100°C. Preferably, the procedure is carried out under nitrogen.

20 The streptogramin derivatives of general formula (III) for which Ra is a methyl radical and Rb, Rc and Rd are defined as in the general formula (I) or for which Ra is an ethyl radical and Rb, Rc and Rd are defined as in the general formula (I) in 2) to 7) as
25 well as the streptogramin derivatives of general formula (VII) for which Ra, Rb, Rc and Rd are defined as for the general formula (I) in 2), except for R'' representing ethyl if Rb and Rc are hydrogen, are new

002220 082200 09643197

products.

All these new intermediate products can be represented by the general formula:



5 in which Ra is a methyl radical and Rb, Rc and Rd are defined as in the general formula (I) or Ra is an ethyl radical and Rb, Rc and Rd are defined as in the general formula (I) in 2) to 7) and R₅ represents a disubstituted methylenyl radical having the structure



10 for which R₂ and R₄ are defined as above, or alternatively in which Ra, Rb, Rc and Rd are defined as for the general formula (I) in 2), except for R'' representing ethyl if Rb and Rc are hydrogen, and R₅ is a hydrogen atom.

15 It is understood that the products of general formula (IX) are also within the scope of the present invention.

The streptogramin derivatives of general formula (I) or (IX) may be purified where appropriate

002280" 26E4960

by physical methods such as crystallization or chromatography.

Some of the streptogramin derivatives of general formula (I) may be converted to the state of addition salts with acids, by known methods. It is understood that these salts, when they exist, are also included within the scope of the present invention.

As examples of addition salts with pharmaceutically acceptable acids, there may be mentioned the salts formed with inorganic acids (hydrochlorides, hydrobromides, sulphates, nitrates, phosphates) or with organic acids (succinates, fumarates, tartrates, acetates, propionates, maleates, citrates, methanesulphonates, ethanesulphonates, phenyl sulphonates, p-toluenesulphonates, isethionates, naphthylsulphonates or camphorsulphonates, or with substitution derivatives of these compounds).

The derivatives carrying a carboxyl substituent may be converted to metal salts or to addition salts with nitrogenous bases according to methods known per se. These salts may be obtained by the action of a metal base (for example an alkali metal or alkaline-earth metal base), of ammonia or of an amine, on a product according to the invention, in an appropriate solvent such as an alcohol, an ether or water, or by an exchange reaction with a salt of an organic acid. The salt formed precipitates after optional concentration of the solution, it is separated

002230" 4674960

by filtration, decantation or freeze-drying. As examples of pharmaceutically acceptable salts, there may be mentioned the salts with the alkali metals (sodium, potassium, lithium) or with the alkaline-earth metals (magnesium, calcium), the ammonium salt, the salts of nitrogenous bases (ethanolamine, diethanolamine, trimethylamine, triethylamine, methylamine, propylamine, diisopropylamine, N,N-dimethylethanolamine, benzylamine, dicyclohexylamine, N-benzyl- β -phenethylamine, N,N'-dibenzylethylenediamine, diphenylenediamine, benzhydrylamine, quinine, choline, arginine, lysine, leucine, dibenzylamine).


The streptogramin derivatives according to the present invention have antibacterial properties and properties synergizing the antibacterial activity of the group A streptogramin derivatives. They are particularly advantageous because of their activity alone or combined with components of the group A streptogramins and especially because of their activity both by the oral and parenteral route which opens the way for an ambulatory relay treatment without modifying the nature of the medicament.

When they are combined with a component or a group A streptogramin derivative, they may in particular be chosen, depending on whether it is desired to obtain an orally or parenterally administrable form, from the natural components:

002280-1614960

pristinamycin II_A, pristinamycin II_B, pristinamycin II_C, pristinamycin II_D, pristinamycin II_E, pristinamycin II_F, pristinamycin II_G or from the semisynthetic derivatives as described in patents or patent applications

- 5 US 4,590,004 and EP 191662 or alternatively from the semisynthetic derivatives of general formula:



- in which R₁ is a radical -NR'R'' for which R' is a hydrogen atom or a methyl radical, R'' is a hydrogen atom, an alkyl, cycloalkyl, allyl, propargyl, benzyl or
- 10 -OR''' radical, R''' being a hydrogen atom, an alkyl, cycloalkyl, allyl, propargyl or benzyl radical, or -NR₃R₄, it being possible for R₃ and R₄ to represent a methyl radical, or to form together with the nitrogen
- 15 atom to which they are attached a saturated or unsaturated 4- or 5-membered heterocycle which may in addition contain another heteroatom chosen from nitrogen, oxygen or sulphur, R₂ is a hydrogen atom or a methyl or ethyl radical, and the bond --- represents a
- 20 single bond or a double bond, as well as their salts.

It is understood that the combinations of the derivatives according to the invention and of the group A streptogramins are also included within the scope of the present invention.

In vitro, combined with pristinamycin II_B, the products of general formula (I), according to the invention, have proved active at concentrations of between 0.25 and 16 mg/l on Staphylococcus aureus 209P.

- 5 In vivo, on experimental infections of mice with Staphylococcus aureus IP 8203, the streptogramin derivatives of general formula (I) have proved active at doses of between 15 and 150 mg/kg orally, combined with pristinamycin II_B and between 5 and 150 mg/kg
- 10 subcutaneously, combined with dalfopristin (CD₅₀), [30/70 combinations].

- Finally, the products according to the invention are particularly advantageous because of the low toxicity observed in the Staphylococcus aureus
- 15 IP 8203 Septicaemia model in mice. All the products, in a 30/70 combination with a group A component proved atoxic with the exception of a few of them for which a low mortality was observed at the maximum administered dose of 300 mg/kg orally or subcutaneously, in 2
- 20 administrations at an interval of 5 hours.

- Some of the intermediate products defined by the general formula (IX) also exhibit antibacterial properties, especially the subgroup of streptogramin derivatives of general formula (VII). In vivo, on
- 25 experimental infections of mice with Staphylococcus aureus IP 8203, they proved active orally combined with pristinamycin II_B (30/70 combinations) at doses of between 25 and 150 mg/kg.

002280" 267E960
09643197-082200

Of particular interest are the products of general formula (I) for which

Y is a nitrogen atom or a radical $=CR_3-$,

R_1 is a hydrogen atom, a radical alkyl (1 to 8 carbons),

5 cycloalkyl (3 to 8 carbons), heterocyclyl which is saturated or unsaturated (3 to 8 members), phenyl, phenyl which is substituted [with one or more amino, alkylamino or dialkylamino radicals] or a radical $NR'R''$, R' and R'' , which are identical or different, 10 being capable of being hydrogen atoms or alkyl radicals (1 to 3 carbons), or being capable of forming together with the nitrogen atom to which they are attached a 3- to 8-membered heterocycle optionally containing another heteroatom chosen from oxygen, sulphur or nitrogen

15 which is optionally substituted with an alkyl radical, or alternatively when Y is a radical $=CR_3-$, R_1 may also be halomethyl, hydroxymethyl, alkylthiomethyl in which the alkyl portion is optionally substituted with $NR'R''$, alkylsulphinylmethyl, alkylsulphonylmethyl, 20 alkyloxymethyl, cyclopropylaminomethyl or $-(CH_2)_nNR'R''$ (n being an integer from 1 to 4 and R' and R'' being defined as above), or alternatively if R_3 is a hydrogen atom, R_1 may also be formyl or $-CONR'R''$ for which R' and R'' are defined as above,

25 or alternatively when Y is a nitrogen atom, R_1 may also be a radical- XR° for which X is an oxygen or sulphur atom, a sulphinyl or sulphonyl radical, or an NH radical and R° is a radical alkyl (1 to 8 carbons),

002280" 457E950

heterocyclymethyl (3 to 8 members) in which the heterocyclyl portion is attached to the methyl radical by a carbon atom, or a radical $-(CH_2)_nNR'R''$ for which R' and R'' are defined as above and n is an integer from 2 to 4,

R_2 is hydrogen atom or an alkyl radical (1 to 3 carbons),

R_3 is a hydrogen atom or a carboxyl or alkyloxycarbonyl radical,

10 R_a is a methyl or ethyl radical, and

R_b , R_c and R_d have the definitions below:

• R_b and R_c are hydrogen atoms and R_d is a hydrogen atom or a methylamino or dimethylamino radical,

• R_b is a hydrogen atom, R_d is a radical $-NHCH_3$ or

15 $-N(CH_3)_2$ and R_c is a chlorine or bromine atom.

And among these products, more particularly preferred are the products of general formula (I) for which

Y is a nitrogen atom or a radical $=CR_3-$,

20 R_1 is a hydrogen atom, a radical alkyl (1 to 3 carbons), cycloalkyl (3 to 8 carbons), heterocyclyl which is saturated or unsaturated (3 to 8 members), phenyl, phenyl which is substituted with an amino radical, or alternatively when Y is a radical $=CR_3-$, R_1 may also
25 be acyloxymethyl,

or alternatively when Y is a nitrogen atom, R_1 may also be a radical $-XR^\circ$ for which X is an oxygen or sulphur atom or a radical NH and R° is an alkyl radical (1 to 4

0022280 16TETH960

carbons) or a radical $-(CH_2)_nNR'R''$ for which R' and R'' which are identical or different may be hydrogen atoms or alkyl radicals (1 to 3 carbons), or form together with the nitrogen atom to which they are attached a 3-
 5 to 8-membered heterocycle optionally containing another heteroatom chosen from oxygen, sulphur or nitrogen optionally substituted with an alkyl radical, and n is an integer from 2 to 4,

R_2 is a hydrogen atom or an alkyl radical (1 to 3
 10 carbons),

R_3 is a hydrogen atom or an alkyloxycarbonyl radical,

R_a is a methyl or ethyl radical, and

R_b , R_c and R_d have the definitions below:

• R_b and R_c are hydrogen atoms and R_d is a hydrogen
 15 atom or a methylamino or dimethylamino radical,


• R_b is a hydrogen atom, R_d is a radical $-NHCH_3$ or $-N(CH_3)_2$ and R_c is a chlorine atom.

And most particularly the following products:

- 2"-methylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E ;
- 20 • 2"-cyclopropylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E ;
- pyrido[2,3-5 γ ,5 δ]pristinamycin I_E ;
- 2"-ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -
 dedimethylamino)pristinamycin I_E ;
- 4 ϵ -chloro-2"-ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -
 25 methylamino) (4 ζ -dedimethylamino)pristinamycin I_E .

The streptogramin derivatives of general formula (α) are prepared from components of natural pristinamycin of general formula:

002230" / 6T4960



in which R_2 is defined as for the general formula (α),
by the action of an amine of general formula:




- 5 in which R'' is defined as for the general formula (α),
followed by the action of an agent for reducing the
intermediate enamine (or oxime) obtained, and then,
when it is desired to obtain a streptogramin derivative
of general formula (α) for which R' is a methyl
10 radical, followed by a second reductive amination, by
the action of formaldehyde or of a derivative
generating formaldehyde in situ and the reduction of
the intermediate enamine.

The action of the amine is carried out in an
15 organic solvent such as an alcohol (methanol, ethanol
for example), a chlorinated solvent (dichloromethane,
dichloroethane, chloroform for example), a nitrile
(acetonitrile for example), pyridine, at a temperature
of between 0 and 30°C, and optionally in the presence
20 of a dehydrating agent such as for example magnesium
sulphate, sodium sulphate or molecular sieves.
Preferably, the procedure is carried out under an inert
atmosphere (argon for example). It is also possible to
cause the amine salt to react.

Preferably, to prepare the derivatives for which the bond --- represents a double bond, the reaction is carried out in an organic solvent such as a nitrile (acetonitrile for example) in the presence of an acid such as an organic acid (acetic acid for example); in this case, the addition of a dehydrating agent is not necessary.

When a streptogramin derivative of general formula (α) for which R'' is a radical $-OR''$ is prepared, it is possible to isolate the intermediate oxime of general formula:



in which R_2 and R'' are defined as for the general formula (α), and then to reduce this product to a derivative of general formula (α) for which R' is a hydrogen atom, and optionally use it in the subsequent reductive amination operation.


The reduction is carried out by the action of a reducing agent, for example an alkali metal borohydride (sodium cyanoborohydride or triacetoxyborohydride for example) in the presence of an organic acid (acetic acid for example) in an organic solvent as mentioned above for the amination reaction. Where appropriate, the subsequent reductive amination

operation, intended to obtain the disubstituted amine, is carried out under similar conditions.

The following examples, given with no limitation being implied, illustrate the present invention.

In the text which follows, examples A to AF illustrate the preparation of the intermediate products, especially of products of general formula (IX). Examples 1 to 33 illustrate the streptogramin derivatives of general formula (I) according to the invention.

In the examples which follow, the NMR spectra were studied in deuterochloroform, the nomenclature used is that of J.O. Anteunis et al., Eur. Biochem., 58, 259 (1975) and in particular:



The column chromatographies are performed, unless otherwise stated, at atmospheric pressure using a 0.063-0.02 mm silica. In a few specified cases, the purifications are done by flash chromatography using a 0.04-0.063 mm silica, or by high-performance liquid chromatography (HPLC) on C₈ or C₁₈ graft silica.

PREPARATION OF THE DERIVATIVES OF GENERAL FORMULA (I)

Example 1

2 g of 5 δ -methylenepristinamycin I_A and 0.26 g (2.3 mmol) of methyl 3-aminocrotonate are introduced into a three-necked flask containing 20 cm³ of methanol. The mixture is refluxed for 6 hours and then an additional 0.1 g of methyl 3-aminocrotonate is added and the reflux is maintained for 1 hour. The reaction mixture is concentrated to dryness at 40°C under reduced pressure (2.7 kPa) to give 2.4 g of a yellow solid which is purified by chromatography on 30 g of silica [eluent: dichloromethane-methanol 95/5 by volume] to give a solid which is concreted from 60 cm³ of an ether-petroleum ether mixture, filtered and then dried at 40°C under reduced pressure (90 Pa). 0.96 g of 3"-methoxycarbonyl-2"-methylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E is thus obtained in the form of a yellow solid melting at 195°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm) :

0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.50 (dd, J = 16.5 and 5 Hz, 1H : 1H of CH₂ at position 5 β); from 1.50 to 1.85 (mt : the 3H corresponding to the other H of CH₂ at position 3 γ and to CH₂ at position 2 β); 2.05 (mt, 1H : the other H of CH₂ at position 3 β); 2.77 (s, 3H : ArCH₃); 2.85 (s, 6H : ArN(CH₃)₂); 2.94 (mt, 1H : 1H of CH₂ at position 4 β);

002280" 4674960

3.11 (d, $J = 16.5$ Hz, 1H : the other H of CH_2 at position 5β); from 3.20 to 3.35 (mt, 2H : the other H of CH_2 at position 4β and 1H of CH_2 at position 3δ); 3.25 (s, 3H : NCH_3); 3.50 (mt, 1H : the other H of CH_2 at position 3δ); 3.90 (mt, 1H : 1H of CH_2 at position 5ϵ); 3.95 (s, 3H : COOCH_3); 4.61 (dd, $J = 7$ and 4.5 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.89 (broad d, $J = 10$ Hz, 1H : CH at position 1α); 5.14 (dd, $J = 11$ and 5 Hz, 1H : CH at position 4α); 5.40 (broad d, $J = 5$ Hz, 1H : CH at position 5α); 5.46 (d, $J = 17$ Hz, 1H : the other H of CH_2 at position 5ϵ); 5.60 (d, $J = 8.5$ Hz, 1H : CH at position 6α); 5.88 (broad q, $J = 7$ Hz, 1H : CH at position 1β); 6.33 (d, $J = 8$ Hz, 2H : aromatic H at position 4ϵ); 6.55 (d, $J = 9.5$ Hz, 1H : CONH at position 2); 6.86 (d, $J = 8$ Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6α); 7.45 (mt, 2H : $1' \text{ H}_4$ and $1' \text{ H}_5$); 7.89 (s, 1H : aromatic H at position γ with respect to N); 7.95 (broad s, 1H : $1' \text{ H}_6$); 8.40 (d, $J = 10$ Hz, 1H : CONH at position 1); 8.66 (d, $J = 8.5$ Hz, 1H : CONH at position 6); 11.64 (s, 1H : OH).

Example 2

20.8 g of 5 δ -methylenepristinamycin I_A, 3.94 g of ethyl 3,3-diaminoacrylate hydrochloride and 3.3 cm³ of triethylamine are introduced into a three-necked flask containing 200 cm³ of ethanol. The mixture is refluxed for 3 hours. After cooling, the precipitate formed is filtered, taken up in 100 cm³ of water and the

pH adjusted to 8 with a solution of sodium bicarbonate and then the product is extracted with twice 100 cm³ of ethyl acetate. The organic phases are combined, dried over magnesium sulphate, filtered and concentrated to dryness at 40°C under reduced pressure (2.7 kPa) to give 22 g of a yellow solid which is purified by chromatography on 500 g of silica [eluent: dichloromethane/methanol 97.5/2.5 by volume] to give a solid which is dissolved in 20 cm³ of dichloromethane and then precipitated by addition of 60 cm³ of diisopropyl ether. After filtration and drying at 40°C under reduced pressure (90 Pa), 1.35 g of 3"-ethoxycarbonyl-2"-aminopyrido [2,3-5 γ ,5 δ]pristinamycin I_E are obtained in the form of a yellow solid melting at 190°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm) :
 0.86 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.30 (mt, 3H : 1H of CH₂ at position 3 β - 1H of CH₂ at position 3 γ and 1H of CH₂ at position 5 β); 1.26 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.35 (t, J = 7Hz, 3H : CH₃ of ethyl); 1.53 (mt, 1H : the other H of CH₂ at position 3 γ); 1.61 and 1.70 (2 mts, 1H each : CH₂ at position 2 β); 2.00 (mt, 1H : the other H of CH₂ at position 3 β); from 2.75 to 2.95 (mt, 1H : the other H of CH₂ at position 5 β); 2.84 (s, 6H : ArN(CH₃)₂); 2.90 (dd, J = 13 and 5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.10 to 3.25 (mt, 2H : the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.20 (s, 3H :

002280" 6T8660

NCH₃); 3.45 (mt, 1H : the other H of CH₂ at position
 3δ); 3.74 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε);
 4.30 (mt, 2H : COOCH₂ of ethyl); 4.55 (dd, J = 8 and
 5 Hz, 1H : CH at position 3α); 4.77 (mt, 1H : CH at
 5 position 2α); 4.86 (dd, J = 10 and 1.5 Hz, 1H : CH at
 position 1α); 5.12 (dd, J = 11 and 5 Hz, 1H : CH at
 position 4α); 5.28 (2 d, respectively J = 6 Hz and J =
 17 Hz, 1H each : CH at position 5α and the other H of
 CH₂ at position 5ε); 5.58 (d, J = 8.5 Hz, 1H : CH at
 10 position 6α); 5.83 (dq, J = 7 and 1.5 Hz, 1H : CH at
 position 1β); from 6.00 to 6.50 (broad unresolved
 complex, 2H : ArNH₂); 6.36 (d, J = 8 Hz, 2H : aromatic H
 at position 4ε); 6.61 (d, J = 9.5 Hz, 1H : CONH at
 position 2); 6.84 (d, J = 8 Hz, 2H : aromatic H at
 15 position 4δ); from 7.15 to 7.35 (mt : the 5 aromatic H
 at position 6α); 7.40 (mt, 2H : 1' H₄ and 1' H₅); 7.78
 (s, 1H : aromatic H at position γ with respect to N);
 7.89 (broad d, J = 4 Hz, 1H : 1' H₅); 8.40 (d, J =
 10 Hz, 1H : CONH at position 1); 8.60 (d, J = 8.5 Hz,
 20 1H : CONH at position 6); 11.61 (unresolved complex, 1H
 : OH).

Ethyl 3,3-diaminoacrylate hydrochloride may
 be prepared according to H. Meyer et al., Liebigs Ann.
 Chem., 1895-1908 (1977).

25 Example 3

By carrying out the procedure as in Example 1
 but starting with 50 cm³ of methanol, 3 g of 5δ-
 methylenepristinamycin I_A and 0.65 g of benzyl

3-aminocrotonate and heating under reflux for 36 hours, a precipitate is obtained, after cooling the reaction mixture to room temperature and adding 50 cm³ of distilled water, which is filtered on sintered glass and then washed successively with 50 cm³ of distilled water and 25 cm³ of diisopropyl ether. The solid obtained is dissolved hot in 25 cm³ of methanol and after cooling, the crystals formed are filtered, washed with 10 cm³ of methanol, dried at 40°C (90 Pa) to give 1.2 g of 3"-benzyloxycarbonyl-2"-methylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E in the form of a pale-yellow solid melting at 250°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm) :

0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.10 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.50 (dd, J = 17 and 5 Hz, 1H : 1H of CH₂ at position 5 β); 1.58 (mt, 1H : the other H of CH₂ at position 3 γ); 1.67 and 1.75 (2 mts, 1H each : CH₂ at position 2 β); 2.06 (mt, 1H : the other H of CH₂ at position 3 β); 2.78 (s, 3H : ArCH₃); 2.85 (s, 6H : ArN(CH₃)₂); 2.95 (mt, 1H : 1H of CH₂ at position 4 β); 3.10 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 β); from 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.26 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3 δ); 3.90 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.62 (dd, J = 8 and 6.5 Hz, 1H : CH at position 3 α);

4.81 (mt, 1H : CH at position 2 α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.15 (dd, J = 11 and 5 Hz, 1H : CH at position 4 α); 5.37 (s, 2H : COOCH₂Ar); 5.40 (d, J = 5 Hz, 1H : CH at position 5 α); 5.45 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.61 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.33 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.58 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.87 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.50 (mt : the 12H corresponding to the 5 aromatic H at position 6 α - to 1' H₄ - to 1' H₅ and to the aromatic H of benzyloxycarbonyl); 7.92 (s, 1H : aromatic H at position γ with respect to N); 7.95 (mt, 1H : 1' H₆); 8.41 (d, J = 10 Hz, 1H : CONH at position 1); 8.68 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.66 (s, 1H : OH).

1.95 g of 3"-benzyloxycarbonyl-2"-methyl-pyrido[2,3-5 γ ,5 δ]pristinamycin I_E and then 1.6 g of 20% palladium hydroxide on carbon and 2 cm³ of 1,4-cyclohexadiene are introduced under a nitrogen stream into a three-necked flask containing 50 cm³ of methanol. The mixture is heated at 60°C for 30 minutes and then cooled to room temperature. The catalyst is filtered on Whatman filter paper and the filtrate concentrated at 45°C under reduced pressure (2.7 kPa) so as to obtain a final volume of 5 cm³. 100 cm³ of diisopropylether are then added and the precipitate formed is filtered,

002280" 082200 09643197

washed with 25 cm³ of diisopropylether and then dried at 40°C under reduced pressure (90 Pa) to give 0.95 g of 3"-carboxy-2"-methylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E in the form of a cream-coloured solid melting at 234°C.

5 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm) :
 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.32 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.39 (mt, 1H : 1H of CH₂ at position 5 β); 1.60 (mt,
 10 1H : the other H of CH₂ at position 3 γ); 1.71 and 1.80 (2 mts, 1H each : CH₂ at position 2 β); 2.05 (mt, 1H : 1H of CH₂ at position 3 β); 2.67 (s, 3H : ArCH₃); 2.78 (s, 6H : ArN(CH₃)₂); 2.92 (mt, 1H : 1H of CH₂ at position 4 β); 3.05 (very broad d, J = 16 Hz, 1H : the other H of
 15 CH₂ at position 5 β); from 3.15 to 3.35 (mt, 1H : the other H of CH₂ at position 4 β); 3.25 (s, 3H : NCH₃); 3.48 (mt, 1H : 1H of CH₂ at position 3 δ); 3.57 (mt, 1H : the other H of CH₂ at position 3 δ); 4.01 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.60 (mt, 1H : CH at
 20 position 3 α); 4.88 (mt, 1H : CH at position 2 α); 4.94 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.12 (mt, 1H : CH at position 4 α); 5.40 (unresolved complex, 1H : CH at position 5 α); 5.43 (d, HzJ = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.69 (d, J = 8.5 Hz, 1H
 25 : CH at position 6 α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.29 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); 7.13 (broad d, 1H : CONH at position 2);

002280 26E4960

from 7.20 to 7.45 (mt : the 7H corresponding to the 5 aromatic H at position 6 α - to 1' H₄ and to 1' H₅); 7.79 (broad s, 1H : aromatic H at position γ with respect to N); 7.92 (broad s, 1H : 1' H₆); 8.34 (d, J = 10 Hz, 1H : CONH at position 1); 8.65 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.61 (s, 1H : OH).

Benzyl 3-aminocrotonate may be prepared as described by J. Daxoll, J. Chem. Soc., 3802-3808 (1953).

10 Example 4

By carrying out the procedure as in Example 1 but starting with 150 cm³ of methanol, 20 g of 5 δ -methylenepristinamycin I_B and 0.26 g of methyl 3-aminocrotonate and after refluxing for 6 hours, 20 g of a yellow product are obtained, which product is purified by two successive chromatographies on 1 kg and 200 g of silica respectively [eluent: dichloromethane/methanol 98/2 by volume] to give after drying at 40°C, under reduced pressure (90 Pa), 13.4 g of 3"-methoxycarbonyl-2"-methylpyrido [2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E in the form of a yellow solid melting at 208°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm) : 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.29 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); from 1.55 to 1.80 (mt : the 3H corresponding to the other H of CH₂ at position 3 γ and to CH₂ at position

0022280 1674960

2 β); 1.57 (dd, J = 16 and 5.5 Hz, 1H : 1H of CH₂ at position 5 β); 2.03 (mt, 1H : the other H of CH₂ at position 3 β); 2.67 (s, 3H : ArCH₃); 2.76 (s, 6H : ArNCH₃); 2.91 (dd, J = 13 and 5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.10 to 3.30 (mt, 2H : the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.13 (d, J = 16 Hz, 1H : the other H of CH₂ at position 5 β); 3.22 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at position 3 δ); 3.88 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 3.92 (s, 3H : COOCH₃); 4.60 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3 α); 4.78 (mt, 1H : CH at position 2 α); 4.87 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.12 (dd, J = 11 at position 5 Hz, 1H : CH at position 4 α); 5.38 (d, J = 5.5 Hz, 1H : CH at position 5 α); 5.44 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.61 (d, J = 8.5 Hz, 1H : CH at 6 α); 5.87 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.18 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.52 (broad d, 1H : CONH at position 2); 6.79 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.15 to 7.35 (mt : the 5 aromatic H at position 6 α); 7.42 (mt, 2H : 1' H₄ and 1' H₅); 7.88 (s, 1H : aromatic H at position γ with respect to N); 7.92 (mt, 1H : 1' H₆); 8.39 (d, J = 10 Hz, 1H : CONH at position 1); 8.64 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.62 (s, 1H : OH).

Example 5

3.4 g of 5 δ -methylenepristinamycin I_A, 1 g of

0022280 " 08243197 09643197

3,3-dimethyl-2-oxo-1-butylpyridinium bromide and then 3 g of ammonium acetate are introduced into a three-necked flask containing 100 cm³ of methanol. The mixture is refluxed for 3 hours and then concentrated to dryness at 40°C under reduced pressure (2.7 kPa). 100 cm³ of distilled water are then added and then the mixture is extracted with twice 100 cm³ of ethyl acetate. The organic phases are decanted off, combined, dried over sodium sulphate, filtered and then concentrated to dryness at 40°C under reduced pressure (2.7 kPa) to give 3.6 g of an orange-coloured solid which is purified by two successive chromatographies on 40 g of silica (eluent: dichloromethane/methanol 95/5 by volume) to give a product which is taken up in 60 cm³ of an ether-petroleum ether mixture. After filtration and drying at 40°C under reduced pressure (90 Pa), 0.64 g of 2"-tert-butylpyrido[2,3-5γ,5δ]pristinamycin I_E is obtained in the form H₂O of a cream-coloured solid melting at 196°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm) :
 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.15 to 1.40 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.32 (s, 9H : ArC(CH₃)₃); 1.60 (mt, 1H : the other H of CH₂ at position 3γ); 1.66 and 1.75 (2 mts : the 2H corresponding to CH₂ at position 2β); 1.98 (dd, J = 16 and 5.5 Hz, 1H : 1H of CH₂ at position 5β); 2.02 (mt, 1H : the other H of CH₂ at position 3β); 2.86 (s, 6H :

ArN(CH₃)₂); 3.01 (dd, J = 14 and 6.5 Hz, 1H : 1H of CH₂ at position 4β); from 3.10 to 3.40 (mt, 3H : the other H of CH₂ at position 4β - the other H of CH₂ at position 5β and 1H of CH₂ at position 3δ); 3.18 (s, 3H : NCH₃);

5 3.51 (mt, 1H : the other H of CH₂ at position 3δ); 3.94 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.58 (t, J = 7.5 Hz, 1H : CH at position 3α); 4.81 (mt, 1H : CH at position 2α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1α); from 5.35 to 5.50 (mt, 3H : CH at

10 position 4α - the other H of CH₂ at position 5ε and CH at position 5α); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.43 (d, J = 8 Hz, 2H : aromatic H at 4ε); 6.75 (d, J = 10 Hz, 1H : CONH at position 2); 6.87

15 (d, J = 8 Hz, 2H : aromatic H at position 4δ); 7.12 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.25 to 7.45 (mt : the 8H corresponding to the 5 aromatic H at position 6α - to the aromatic H at position γ with respect to N - to 1' H₄ and to 1' H₅);

20 7.87 (mt, 1H : 1' H₆); 8.49 (d, J = 10 Hz, 1H : CONH at position 1); 8.73 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.70 (s, 1H : OH).

3,3-dimethyl-2-oxo-1-butylpyridinium bromide may be prepared as described by F. Kroencke, Chem.

25 Ber., 69, 921-923 (1936).

Example 6

404 g of 5δ-methylenepristinamycin I_A, 78.8 g of 1-acetonylpyridinium chloride and then 354 g of

002230" 4649960

5 distilled water are then added and then the mixture is
extracted with 500 cm³ of dichloromethane and then with
3 litres of ethyl acetate. The organic phases are
decanted off, combined, dried over sodium sulphate,
filtered and then concentrated to dryness at 40°C under
10 reduced pressure (2.7 kPa) to give 205 g of an orange-
coloured solid which is purified by chromatography on
1 kg of silica (eluent: dichloromethane/methanol 98/2
by volume) to give 64.7 g of a product which is taken
up in 60 cm³ of diisopropyl ether and then
15 recrystallized twice from 100 cm³ of methanol. After
filtration and drying at 40°C under reduced pressure
(90 Pa), 23.3 g of a product which is 2"-methylpyrido
[2,3-5γ,5δ]pristinamycin I_E are obtained in the form of
a yellow solid melting at 253°C.

20 ^1H NMR spectrum (400 MHz, CDCl_3 , δ in ppm) :
0.94 (t, $J = 7.5$ Hz, 3H : CH_3 at position 2γ); from 1.20
to 1.35 (mt, 2H : 1H of CH_2 at position 3β and 1H of CH_2
at position 3γ); 1.31 (d, $J = 7$ Hz, 3H : CH_3 at position
1 γ); 1.59 (mt, 1H : the other H of CH_2 at position 3γ);
25 from 1.60 to 1.85 (mt: the 2H corresponding to CH_2 at
position 2β); 1.69 (dd, $J = 16$ and 6 Hz, 1H : 1H of CH_2
at position 5β); 2.06 (mt, 1H : the other H of CH_2 at
position 3β); 2.48 (s, 3H : ArCH_3); 2.86 (s, 6H :

ArN(CH₃)₂); 2.98 (dd, J = 13.5 and 5.5 Hz, 1H : 1H of CH₂ at position 4β); 3.15 (d, J = 16 Hz, 1H : the other H of CH₂ at position 5β); from 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.24 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3δ); 3.92 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.61 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3α); 4.81 (mt, 1H : CH at position 2α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.23 (dd, J = 10 and 5.5 Hz, 1H : CH at position 4α); 5.42 (d and broad d respectively, J = 17 Hz and J = 5.5 Hz, 1H each : the other H of CH₂ at position 5e and CH at position 5α); 5.63 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.90 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.36 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.61 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.87 (d, J = 8 Hz, 2H : aromatic H at 4δ); 6.96 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6α); 7.34 (d, J = 8 Hz, 1H : aromatic H at position γ with respect to N); 7.41 (limiting AB, 2H : 1' H₄ and 1' H₅); 7.92 (mt, 1H : 1' H₆); 8.44 (d, J = 10 Hz, 1H : CONH at position 1); 8.65 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.66 (s, 1H : OH).

1-acetonylpyridinium chloride may be prepared according to H. Dreser, Arch. Pharm., 232, 183 (1894).

Example 7

By carrying out the procedure as in Example 6

- but starting with 50 g of 5 δ -methylenepristinamycin I_A in 1 litre of acetone, 13.7 g of 1-(2-oxobutyl)-pyridinium bromide, 44 g of ammonium acetate and heating for 1 hour under reflux and then adding 2.6 g of 1-(2-oxobutyl)pyridinium bromide and refluxing for an additional one hour, 19.5 g of a product are obtained after purification by chromatography on 200 g of silica (eluent: dichloromethane/methanol 97/3 by volume), which product can be purified by crystallization in the following manner. 8 g of this solid are dissolved hot in a mixture of 30 cm³ of methanol and 1 cm³ of distilled water. After cooling, the crystals obtained are collected to give 3.9 g of a solid which is recrystallized under similar conditions. After filtration and drying at 40°C under reduced pressure (90 Pa), 1.7 g of 2"-ethylpyrido[2,3-5 γ ,5 δ]-pristinamycin I_E are obtained in the form of a white solid melting at 263°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

- 0.89 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.22 (t, J = 7.5 Hz, 3H : CH₃ of ethyl); 1.28 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.53 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.80 (mt: the 2H corresponding to CH₂ at position 2 β); 1.76 (dd, J = 16 and 5.5 Hz, 1H : 1H of CH₂ at position 5 β); 2.00 (mt, 1H : the other H of CH₂ at position 3 β); 2.72 (q, J = 7.5 Hz, 2H: ArCH₂ of

002280" 16TEH960

ethyl); 2.82 (s, 6H: ArN(CH₃)₂); 2.94 (dd, J = 13.5 and 5.5 Hz, 1H : 1H of CH₂ at position 4β); from 3.10 to 3.25 (mt, 3H : the other H of CH₂ at position 4β - the other H of CH₂ at position 5β and 1H of CH₂ at position 3β); 3.18 (s, 3H : NCH₃); 3.46 (mt, 1H : the other H of CH₂ at position 3β); 3.90 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.57 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3α); 4.75 (mt, 1H : CH at position 2α); 4.84 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.21 (dd, J = 9 and 5.5 Hz, 1H : CH at position 4α); 5.38 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.39 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.60 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.85 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.32 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.53 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.82 (d, J = 8 Hz, 2H : aromatic H at position 4δ); 6.93 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.25 to 7.40 (mt: the 5 aromatic H at position 6α); 7.29 (d, J = 8 Hz, 1H : the aromatic H at position γ with respect to N); 7.33 (mt, 2H : 1' H₄ and 1' H₅); 7.85 (mt, 1H : 1' H₆); 8.39 (d, J = 10 Hz, 1H : CONH at position 1); 8.63 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.62 (s, 1H: OH).

25 1-(2-Oxobutyl)pyridinium bromide may be prepared by analogy with 1-(2-oxobutyl)pyridinium iodide as described by R.P. Soni, J.P. Saxena, J. Indian Chem. Soc. 58, 885-887 (1981).

15 g of 1-bromo-2-butanone and 40 cm³ of pyridine are introduced into a three-necked flask containing 150 cm³ of ethanol and the mixture is heated for 2 hours under reflux. After concentrating to dryness at 40°C under reduced pressure (2.7 kPa), the residue is taken up in 100 cm³ of diethyl ether. After filtration, washing with twice 70 cm³ of diethyl ether, the precipitate is dried to give 22 g of a yellow solid melting at 181°C.

¹H NMR spectrum (250 MHz, (CD₃)₂SO d₆, δ in ppm): 1.06 (t, J = 7 Hz, 3H : CH₃ of ethyl); 2.70 (q, J = 7 Hz, 2H : COCH₂ of ethyl); 5.83 (s, 2H : NCH₂CO); 8.25 (dd, J = 8 and 5 Hz, 2H : aromatic H at position β of pyridine); 8.69 (t, J = 8 Hz, 2H : aromatic H at position γ of pyridine); 8.91 (d, J = 5 Hz, 2H : aromatic H at position α of pyridine).

Example 8

By carrying out the procedure as in Example 5 but starting with 9.8 g of 5δ-methylenepristinamycin I_A in 500 cm³ of methanol, 2.7 g of 1-cyclopropylcarbonylmethylpyridinium bromide, 8.6 g of ammonium acetate and heating for 40 minutes under reflux, 1.1 g of product are obtained after purification by chromatography on 150 g of silica (eluent: dichloromethane/methanol 97/3 by volume), which product may be recrystallized from 11 cm³ of boiling methanol. After cooling, the crystals obtained are filtered and then rinsed with 5 cm³ of methanol to give 0.47 g of 2"-cyclopropylpyrido-

002280" / 64960

[2,3-5 γ ,5 δ]pristinamycin I_E in the form of white crystals melting at 198°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 from 0.80 to 1.00 (mt, 4H : the 2 CH₂ of cyclopropyl);
 5 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15
 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂
 at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position
 1 γ); from 1.55 to 1.80 (mt : the 2H corresponding to CH₂
 at position 2 β); 1.57 (mt, 1H : the other H of CH₂ at
 10 position 3 γ); 1.68 (dd, J = 16 and 6.5 Hz, 1H : 1H of
 CH₂ at position 5 β); 1.96 (mt, 1H : ArCH₂ of
 cyclopropyl); 2.04 (mt, 1H : the other H of CH₂ at
 position 3 β); 2.86 (s, 6H: ArN(CH₃)₂); 2.96 (dd, J = 13
 and 6 Hz, 1H : 1H of CH₂ at position 4 β); 3.10 (d,
 15 J = 16 Hz, 1H : the other H of CH₂ at position 5 β); from
 3.10 to 3.30 (mt, 2H : the other H of CH₂ at position 4 β
 and 1H of CH₂ at position 3 δ); 3.22 (s, 3H : NCH₃); 3.49
 (mt, 1H : the other H of CH₂ at position 3 β); 3.90 (d,
 J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.60 (dd,
 20 J = 8 and 6 Hz, 1H : CH at position 3 α); 4.79 (mt, 1H :
 CH at position 2 α); 4.88 (broad d, J = 10 Hz, 1H : CH
 at position 1 α); 5.23 (dd, J = 10 and 6 Hz, 1H : CH at
 position 4 α); 5.36 (broad d, J = 6.5 Hz, 1H : CH at
 position 5 α); 5.38 (d, J = 17 Hz, 1H : the other H of
 25 CH₂ at position 5 ϵ); 5.62 (d, J = 8.5 Hz, 1H : CH at
 position 6 α); 5.88 (broad q, J = 7 Hz, 1H : CH at
 position 1 β); 6.34 (d, J = 8 Hz, 2H : aromatic H at
 position 4 ϵ); 6.58 (d, J = 9.5 Hz, 1H : CONH at

002220 " 082200

position 2); from 6.75 to 6.90 (mt, 3H : aromatic H at position 4 δ and aromatic H at position β with respect to N); 7.08 (d, J = 8 Hz, 1H : aromatic H at position γ with respect to N); from 7.20 to 7.35 (mt : the 5 aromatic H at position 6 α); 7.40 (limiting AB, 2H : 1' H₄ and 1' H₅); 7.91 (mt, 1H : 1' H₆); 8.43 (d, J = 10 Hz, 1H : CONH at position 1); 8.63 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.62 (s, 1H: OH).

10 1-Cyclopropylcarbonylmethylpyridinium bromide may be prepared in the following manner:

2.4 g of 1-bromomethylcyclopropylketone and 5.8 cm³ of pyridine are introduced into a three-necked flask containing 40 cm³ of ethanol and then the mixture is heated for 2 hours under reflux. After concentrating to dryness at 40°C under reduced pressure (2.7 kPa), the residue is taken up in twice 30 cm³ of diethyl ether. After filtration, washing with diethyl ether, the precipitate is dried under reduced pressure (90 Pa) to give 3.4 g of 1-cyclopropylcarbonylmethylpyridinium bromide in the form of a cream-coloured solid melting at 160°C.

¹H NMR spectrum (300 MHz, (CD₃)₂SO d₆, δ in ppm): 1.08 and 1.16 (2 mts, 2H each : the 2 CH₂ of cyclopropane); 2.34 (mt, 1H : COCH of cyclopropane); 6.06 (s, 2H : NCH₂CO); 8.24 (dd, J = 8 and 5 Hz, 2H : aromatic H at position β of pyridine); 8.70 (t, J = 8 Hz, 2H : aromatic H at position γ of pyridine);

8.96 (d, $J = 5$ Hz, 2H : aromatic H at position α of pyridine).

Bromomethylcyclopropylketone may be prepared according to V.K. Jinaraj et al., Ind. J. Chem.,
 5 Sect. B, 22, 841-45 (1983).

Example 9

By carrying out the procedure as in Example 5 but starting with 10 g of 5 δ -methylenepristinamycin I_A in 300 cm³ of methanol, 2.2 g of 1-cyanomethylpyridinium
 10 bromide, 8.5 g of ammonium acetate and heating for 3 hours under reflux, a product is obtained after purification by chromatography on 70 g of silica (eluent: dichloromethane/methanol 90/10 by volume), which product is repurified 3 times by the same method,
 15 changing the nature of the eluent (dichloromethane/methanol 95/5, and then dichloromethane/methanol 97/3 and then dichloromethane/methanol 95/5) to give 0.16 g of 2"-aminopyrido[2,3-5 γ ,5 δ]pristinamycin I_E in the form of a white solid melting at 222°C.

20 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.90 (t, $J = 7.5$ Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.28 (d, $J = 7$ Hz, 3H : CH₃ at position 1 γ); from 1.45 to 1.80 (mt, the 4H corresponding to the
 25 other H of CH₂ at position 3 γ - to 1H of CH₂ at position 5 β and to CH₂ at position 2 β); 2.01 (mt, 1H : the other H of CH₂ at position 3 β); from 2.80 to 3.00 (mt, 2H : the other H of CH₂ at position 5 β and 1H of CH₂ at

0022280" 082200 09643197

position 4 β); 2.89 (s, 6H : ArN(CH₃)₂); from 3.10 to 3.25 (mt, 2H : the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.20 (s, 3H : NCH₃); 3.45 (mt, 1H : the other H of CH₂ at position 3 δ); 3.80 (d, 5 J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.27 (unresolved complex, 2H : ArNH₂); 4.57 (dd, J = 8.5 and 5.5 Hz, 1H : CH at position 3 α); 4.76 (mt, 1H : CH at position 2 α); 4.86 (dd, J = 10 and 1.5 Hz, 1H : CH at position 1 α); 5.18 (dd, J = 10 and 6 Hz, 1H : CH at 10 position 4 α); 5.27 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.32 (broad d, J = 5.5 Hz, 1H : CH at position 5 α); 5.60 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.86 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.30 (d, J = 8 Hz, 1H : aromatic H at 15 position β with respect to N); 6.37 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.54 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.83 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); 7.09 (d, J = 8 Hz, 1H : aromatic H at position γ with respect to N); from 7.15 to 7.40 (mt : 20 the 7H corresponding to the 5 aromatic H at position 6 α - to 1' H₄ and to 1' H₅); 7.84 (dd, J = 4 and 1.5 Hz, 1H : 1' H₆); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.55 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.61 (s, 1H: OH).

25 Example 10

By carrying out the procedure as in Example 5 but starting with 30 g of 5 δ -methylenepristinamycin I_A in 300 cm³ of methanol, 7.1 g of 1-(3-chloro-

0022280 264E4660

2-oxopropyl)pyridinium chloride (at 50%), 26 g of ammonium acetate and heating for 10 minutes under reflux, 1.4 g of a product are obtained after 2 successive chromatographies on 400 g of silica (eluent: 5 dichloromethane/methanol 98/2 by volume), which product is purified by HPLC on 10 μ m C₈ silica (eluent: water:acetonitrile:70/30 by volume containing 0.1% trifluoroacetic acid). The fractions are combined, the acetonitrile removed at 40°C under reduced pressure 10 (2.7 kPa) and the aqueous phase adjusted to pH 7 with 3 cm³ of water saturated with sodium bicarbonate. The aqueous phase is washed with twice 60 cm³ of dichloromethane. The organic phases are pooled, dried over sodium sulphate, filtered and then concentrated to 15 dryness under reduced pressure (2.7 kPa) to give 0.4 g of a yellow solid which is concreted from 60 cm³ of a diethyl ether/petroleum ether mixture, filtered and then dried under reduced pressure (90 Pa). 0.3 g of 2"-chloromethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E is thus 20 obtained in the form of a cream-coloured solid melting at 194°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ 25 at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.57 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.80 (mt : the 2H corresponding to CH₂ at position 2 β); 1.63 (dd, J = 16 and 6 Hz, 1H : 1H of CH₂

at position 5 β); 2.03 (mt, 1H : the other H of CH₂ at position 3 β); 2.85 (s, 6H : ArN(CH₃)₂); 2.95 (dd, J = 13 and 5.5 Hz, 1H : 1H of CH₂ at position 4 β); 3.12 (d, J = 16 Hz, 1H : the other H of CH₂ at position 5 β); from 5 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.23 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at position 3 δ); 3.93 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.58 (limiting AB, J = 14 Hz, 2H : ArCH₂Cl); from 4.55 to 10 4.75 (mt, 1H : CH at position 3 α); 4.79 (mt, 1H : CH at position 2 α); 4.88 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.18 (dd, J = 10.5 and 5.5 Hz, 1H : CH at position 4 α); 5.40 (broad d, J = 6 Hz, 1H : CH at position 5 α); 5.46 (d, J = 17 Hz, 1H : the other H of 15 CH₂ at position 5 ϵ); 5.60 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.87 (broad q, J = 7 Hz: 1H : CH at position 1 β); 6.36 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.55 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.86 (d, J = 8 Hz, 2H : aromatic H at 20 position 4 δ); 7.22 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.25 to 7.40 (mt : the 5 aromatic H at position 6 α); 7.38 (d, J = 8 Hz, 1H : aromatic H at position γ with respect to N); 7.42 (mt, 2H : 1' H₄ and 1' H₅); 7.89 (mt, 1H : 1' H₆); 8.40 25 (d, J = 10 Hz, 1H : CONH at position 1); 8.68 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.64 (s, 1H: OH).

1-(3-Chloro-2-oxopropyl)pyridinium chloride

002280 16TE960

may be prepared in the following manner:

66.9 g of 1,3-dichloroacetone chloride are introduced into a three-necked flask containing 800 cm³ of diethyl ether. 28 cm³ of pyridine are added dropwise and the mixture is kept stirring overnight. The precipitate obtained is filtered, washed with twice 100 cm³ of diethyl ether and then dried at 40°C under 90 Pa to give 29.2 g of 1-(3-chloro-2-oxopropyl)-pyridinium chloride in the form of a cream-coloured solid melting at 92°C and which is used as it is.

Example 11

By carrying out the procedure as in Example 6 but starting with 36.5 g of 5 δ -methylenepristinamycin I_A in 350 cm³ of methanol, 9.6 g of 1-(3-acetoxy-2-oxopropyl)pyridinium chloride, 32.2 g of ammonium acetate and heating for 40 minutes under reflux, a solid is obtained which is chromatographed on 350 g of silica (eluent: dichloromethane/methanol gradient 100/0 then 99/1 then 98/2 then 96/4 by volume) to give 1.3 g of a yellow solid. The latter is purified by HPLC on 10 μ m C₈ silica (eluent: water/acetonitrile 70/30 by volume, containing 0.1% trifluoroacetic acid). The fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the pH of the aqueous phase adjusted to 7 by addition of water saturated with sodium bicarbonate. The aqueous phase is extracted with 3 times 200 cm³ of dichloromethane. The organic phases are pooled, dried over magnesium

sulphate, filtered and concentrated at 40°C under reduced pressure (2.7 kPa to give 0.5 g of 2"-hydroxymethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E in the form of a white solid melting at 190°C.

5 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.50 (dd, J = 16 and 6 Hz, 1H : 1H of CH₂ at
 10 position 5 β); from 1.50 to 1.70 (mt : the 2H corresponding to 1H of CH₂ at position 2 β and the other H of CH₂ at position 3 γ); 1.75 (mt, 1H : the other H of CH₂ at position 2 β); 2.05 (mt, 1H : the other H of CH₂ at position 3 β); 2.82 (s, 6H : ArN(CH₃)₂); 2.93 (dd,
 15 J = 12 and 5 Hz, 1H : 1H of CH₂ at position 4 β); 3.11 (d, J = 16 Hz, 1H : the other H of CH₂ at position 5 β); from 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.25 (s, 3H : NCH₃); 3.48 (mt, 1H : the other H of CH₂ at position
 20 3 δ); 3.91 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 3.94 (unresolved complex, 1H : OH); 4.61 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3 α); 4.67 Hz (broad s, 2H : ArCH₂O); 4.80 (mt, 1H : CH at position 2 α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.14 (dd, J = 12
 25 and 5 Hz, 1H : CH at position 4 α); 5.37 (broad d, J = 6 Hz, 1H : CH at position 5 α); 5.44 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.60 (d, J = 8.5 Hz, 1H :

002280" 467E4960

Example 12

By carrying out the procedure as in Example 5 but starting with 6 g of 5 δ -methylenepristinamycin I_A in 100 cm³ of methanol, 1.9 g of 1-phenacylpyridinium bromide, 5.3 g of ammonium acetate and heating for 30 minutes under reflux, a solid is obtained after purification by chromatography on 90 g of silica [eluent: dichloromethane/methanol 95/5 by volume] which is taken up in 60 cm³ of an ether-petroleum ether mixture. After filtration and drying at 40°C under reduced pressure (90 Pa), 0.8 g of 2"-phenylpyrido-[2,3-5 γ ,5 δ]pristinamycin I_E is obtained in the form of a yellow solid melting at 212°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.32 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); from 1.50 to 1.85 (mt : the 4H corresponding to 1H of CH₂ at position 5 β) - to the other H of CH₂ at position 3 γ and to CH₂ at position 2 β); 2.06 (mt, 1H : the other 1H of CH₂ at position 3 β); 2.70 (s, 6H : ArN(CH₃)₂); 2.98 (dd, J = 13 and 5.5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.35 (mt, 3H : the other H of CH₂ at position 5 β - the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.26 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3 δ); 4.00 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.64 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3 α); 4.82 (mt, 1H

002280" 0824960

: CH at position 2 α); 4.89 (broad d, J = 10 Hz, 1H : CH
 at position 1 α); 5.23 (dd, J = 11 and 5.5 Hz, 1H : CH
 at position 4 α); 5.46 (broad d, J = 5.5 Hz, 1H : CH at
 position 5 α); 5.50 (d, J = 17 Hz, 1H : the other H of
 5 CH₂ at position 5 ϵ); 5.66 (d, J = 8.5 Hz, 1H : CH at
 position 6 α); 5.90 (broad q, J = 7 Hz, 1H : CH at
 position 1 β); 6.34 (d, J = 8 Hz, 2H : aromatic H at
 position 4 ϵ); 6.60 (d, J = 10 Hz, 1H : CONH at position
 2); 6.88 (d, J = 8 Hz, 2H : aromatic H at position 4 δ);
 10 from 7.25 to 7.50 (mt: the 11H corresponding to the 5
 aromatic H at position 6 α - to the aromatic H at
 position γ with respect to N - to the aromatic H at the
 para position of the phenyl - to the aromatic H at the
 meta position of the phenyl - to 1' H₄ and to 1' H₅);
 15 7.56 (d, J = 8 Hz, 1H : aromatic H at position β with
 respect to N); 8.00 (mt, 3H : 1' H₆ and aromatic H. at
 the ortho position of the phenyl); 8.45 (d, J = 10 Hz,
 1H : CONH at position 1); 8.58 (d, J = 8.5 Hz, 1H :
 CONH at position 6); 11.66 (s, 1H: OH).

20 1-Phenacylpyridinium bromide may be prepared
 according to F. Kroencke and H. Timmler, Chem. Ber.,
 69, 614 (1936).

Example 13

By carrying out the procedure as in Example 5
 25 but starting with 29.6 g of 5 δ -methylenepristinamycin I_A
 in 200 cm³ of methanol, 10.9 g of 1-(4-nitrophenacyl)-
 pyridinium bromide and 26 g of ammonium acetate and
 heating for 40 minutes under reflux, a solid is

0022280" 6543197" 082200

obtained after purification by chromatography on 500 g of silica [eluent: dichloromethane/methanol 95/5 by volume] which is taken up in 60 cm³ of an ether-petroleum ether mixture. After filtration and drying at 40°C under reduced pressure (90 Pa), 16 g of 2"-(4-nitrophenyl)pyrido[2,3-5 γ ,5 δ]pristinamycin I_E are obtained in the form of an orange-coloured solid melting at 345°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

0.94 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); from 1.55 to 1.85 (mt : the 4H corresponding to the other H of CH₂ at position 3 γ - to 1H of CH₂ at position 5 β and to CH₂ at position 2 β); 2.08 (mt, 1H : the other H of CH₂ at position 3 β); 2.68 (s, 6H : ArN(CH₃)₂); 2.96 (dd, J = 13 and 5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.35 (mt, 3H : the other H of CH₂ at position 5 β - the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.26 (s, 3H : NCH₃); 3.61 (mt, 1H : the other H of CH₂ at position 3 δ); 3.99 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.64 (dd, J = 7 and 6 Hz, 1H : CH at position 3 α); 4.81 (mt, 1H : CH at position 2 α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.17 (dd, J = 11.5 and 5 Hz, 1H : CH at position 4 α); 5.44 (broad d, J = 5 Hz, 1H : CH at position 5 α); 5.53 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.63 (d, J = 8.5 Hz, 1H : CH at

002280" 06TET4960

position 6 α); 5.88 (broad q, $J = 7$ Hz, 1H : CH at position 1 β); 6.32 (d, $J = 8$ Hz, 2H : aromatic H at position 4 ϵ); 6.58 (d, $J = 9.5$ Hz, 1H : CONH at position 2); 6.88 (d, $J = 8$ Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6 α); from 7.45 to 7.55 (mt, 2H : 1' H₄ and 1' H₅); 7.49 (d, $J = 8$ Hz, 1H : aromatic H at position γ with respect to N); 7.64 (d, $J = 8$ Hz, 1H : aromatic H at position β with respect to N); 7.90 (broad d, $J = 4$ Hz, 1H : 1' H₆); 8.20 and 8.31 (2 d, $J = 8.5$ Hz, 2H each : respectively the aromatic H at the meta position with respect to the NO₂ and the aromatic H at the ortho position with respect to the NO₂); 8.42 (d, $J = 10$ Hz, 1H : CONH at position 1); 8.70 (d, $J = 8.5$ Hz, 1H : CONH at position 6); 11.66 (s, 1H: OH).

9.1 g of 2"-(4-nitrophenyl)pyrido[2,3-5 γ ,5 δ]-pristinamycin I_E and then 50 g of iron powder and 1 cm³ of concentrated hydrochloric acid are introduced into a three-necked flask containing 90 cm³ of ethanol and 20 cm³ of distilled water and then the mixture is refluxed for 30 minutes. The insoluble matter is removed by filtration, washed with 60 cm³ of ethanol and then the filtrate is concentrated to dryness at 40°C under reduced pressure (2.7 kPa). The residue obtained is taken up in 300 cm³ of water, the pH adjusted to 8 by addition of sodium bicarbonate and the aqueous phase extracted with twice 100 cm³ of dichloromethane. After

drying over sodium sulphate, filtration and concentration to dryness under reduced pressure, 11.5 g of a chestnut-coloured solid are obtained, which solid is purified by chromatography on 120 g of silica [eluent: dichloromethane/methanol 95/5 by volume]. The solid obtained is concreted from 60 cm³ of an ether-petroleum ether mixture, filtered and dried at 40°C under reduced pressure (90 Pa) to give 1.5 g of 2"-(4-aminophenyl)pyrido[2,3-5 γ ,5 δ]pristinamycin I_E in the form of a yellow solid melting at 226°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); from 1.50 to 1.85 (mt : the 4H corresponding to the other H of CH₂ at position 3 γ - to 1H of CH₂ at position 5 β and to CH₂ at position 2 β); 2.04 (mt, 1H : the other H of CH₂ at position 3 β); 2.73 (s, 6H : ArN(CH₃)₂); 2.96 (dd, J = 13 and 4.5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.35 (mt, 3H : the other H of CH₂ at position 5 β - the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.24 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3 δ); 3.80 (unresolved complex, 2H : NH₂); 3.97 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.63 (mt, 1H : CH at position 3 α); 4.81 (mt, 1H : CH at position 2 α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.21 (dd, J = 10 and 4.5 Hz, 1H : CH at position 4 α); 5.42 (mt, 1H : CH

0022280 " 082200 2674397

at position 5 α); 5.45 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.64 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.89 (mt, 1H : CH at position 1 β); 6.33 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.58 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.74 (d, J = 8 Hz, 2H : aromatic H at the ortho position with respect to the NH₂); 6.88 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.50 (mt : the 9H corresponding to the 5 aromatic H at position 6 α - to 1' H₄ - to 1' H₅ - to the aromatic H at position γ with respect to N and to the aromatic H at position β with respect to N); 7.82 (d, J = 8 Hz, 2H : aromatic H at the meta position with respect to NH₂); 7.98 (unresolved complex, 1H : 1' H₆); 8.44 (d, J = 10 Hz, 1H : CONH at position 1); 8.64 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.66 (s, 1H: OH).

Example 14

By carrying out the procedure as in Example 5 but starting with 10 g of 5 δ -methylenepristinamycin I_A in 100 cm³ of methanol, 4 g of 1-(4-diethylamino-phenacyl)pyridinium bromide and 9 g of ammonium acetate and heating for 40 minutes under reflux, a solid is obtained after purification by chromatography on 150 g of silica [eluent: dichloromethane/methanol 95/5 by volume] which is taken up in 60 cm³ of an ether-petroleum ether mixture. After filtration and drying at 40°C under reduced pressure (90 Pa), 2.4 g of 2''-(4-diethylaminophenyl)pyrido[2,3-5 γ ,5 δ]pristinamycin

I_E are obtained in the form of a yellow solid melting at 210°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.15
 5 to 1.40 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂
 at position 3γ); 1.22 (t, J = 7 Hz, 6H : the 2 CH₃ of
 diethylamino); 1.31 (d, J = 7 Hz, 3H : CH₃ at position
 1γ); 1.58 (mt : 1H : the other H of CH₂ at position 3γ);
 from 1.60 to 1.85 (mt: the 3H corresponding to 1H of CH₂
 10 at position 5β and to CH₂ at position 2β); 2.05 (mt, 1H
 : the other H of CH₂ at position 3β); 2.75 (s, 6H :
 ArN(CH₃)₂); 2.98 (dd, J = 13 and 5.5 Hz, 1H : 1H of CH₂
 at position 4β); from 3.15 to 3.35 (mt, 3H : the other
 H of CH₂ at position 5β - the other H of CH₂ at position
 15 4β and 1H of CH₂ at position 3δ); 3.24 (s, 3H : NCH₃);
 3.42 (mt, 4H : the 2 NCH₂ of diethylamino); 3.50 (mt, 1H
 : the other H of CH₂ at position 3δ); 3.97 (d,
 J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.62 (dd,
 J = 8 and 5.5 Hz, 1H : CH at position 3α); 4.81 (mt,
 20 1H : CH at position 2α); 4.90 (broad d, J = 10 Hz, 1H :
 CH at position 1α); 5.24 (dd, J = 10 and 5.5 Hz, 1H :
 CH at position 4α); 5.43 (2 d, respectively J = 6 Hz
 and J = 17 Hz, 2H : CH at position 5α and the other H
 of CH₂ at position 5ε); 5.66 (d, J = 8.5 Hz, 1H : CH at
 25 position 6α); 5.89 (broad q, J = 7 Hz, 1H : CH at
 position 1β); 6.34 (d, J = 8 Hz, 2H : aromatic H at
 position 4ε); 6.60 (d, J = 9.5 Hz, 1H : CONH at
 position 2); 6.72 (d, J = 8 Hz, 2H : aromatic H at the

002280" 2644960

ortho position with respect to diethylamino); 6.87 (d, $J = 8$ Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.40 (mt : the 6H corresponding to the 5 aromatic H at position 6 α and to the aromatic H at position γ with respect to N); from 7.40 to 7.50 (mt, 3H : 1' H₄ - 1' H₅ and aromatic H at position β with respect to N); 7.85 (d, $J = 8$ Hz, 2H : aromatic H at the meta position with respect to diethylamino); 7.98 (mt, 1H : 1' H₆); 8.44 (d, $J = 10$ Hz, 1H : CONH at position 1); 8.63 (d, $J = 8.5$ Hz, 1H : CONH at position 6); 11.67 (s, 1H: OH).

1-(4-Diethylaminophenacyl)pyridinium bromide may be prepared in the following manner:

10 g of 4-diethylaminophenacyl bromide are introduced into a three-necked flask containing 200 cm³ of tetrahydrofuran and then 15 cm³ of pyridine are added dropwise. The stirring is continued for 90 hours and then the precipitate formed is filtered and then washed with 60 cm³ of diethyl ether. After drying at 40°C under reduced pressure (90 Pa), 14.1 g of 4-diethylamino-phenylpyridinium bromide are obtained in the form of a white solid melting at > 260°C.

¹H NMR spectrum (300 MHz, (CD₃)₂SO d₆, δ in ppm): 1.18 (t, $J = 7$ Hz, 6H : the 2 CH₃ of diethylamino); 3.50 (q, $J = 7$ Hz, 4H : the 2 NCH₂ of diethylamino); 6.39 (s, 2H : NCH₂COAr); 6.84 (d, $J = 8$ Hz, 2H : aromatic H at the ortho position with respect to diethylamino); 7.88 (d, $J = 8$ Hz, 2H :

aromatic H at the meta position with respect to diethylamino); 8.28 (dd, $J = 8$ and 5 Hz, $2H$: aromatic H at position β of pyridine); 8.74 (t, $J = 8$ Hz, $2H$: aromatic H at position γ of pyridine); 9.02 (d, $J = 5$ Hz, $2H$: aromatic H at position α of pyridine).

Example 15

By carrying out the procedure as in Example 5 but starting with 5 g of 5 δ -methylenepristinamycin I_A in 75 cm³ of methanol, 2.05 g of 1-[2-oxo-2-(2-pyridyl)-ethyl]pyridinium bromide hydrobromide and 4.3 g of ammonium acetate and heating for 3 hours under reflux, a solid is obtained which is purified by preparative HPLC on 400 g of 10 μ m Kromasil[®] C₈ silica [eluent: water/acetonitrile 70/30 by volume containing 0.1% trifluoroacetic acid]. After concentrating the fractions in order to remove the acetonitrile, the aqueous phase is neutralized to pH 7-8 with a 10% solution of sodium bicarbonate. The precipitate obtained during the neutralization is filtered, taken up in 25 cm³ of dry dichloromethane and then the organic phase dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure to give a solid which is taken up in 10 cm³ of diisopropyl ether. After filtration and drying at 40°C under reduced pressure (90 Pa), 0.94 g of 2"-(2-pyridyl)pyrido[2,3-5 γ ,5 δ]pristinamycin I_E is obtained in the form of a beige solid 1.38 g melting at 190°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.32 (d, J = 7 Hz, 3H : CH₃ at position 5 1γ); 1.58 (mt : 1H : the other H of CH₂ at position 3γ) ; from 1.60 to 1.85 (mt: the 2H corresponding to CH₂ at position 2β); 1.66 (dd, J = 16 and 5 Hz, 1H : 1H of CH₂ at position 5β); 2.07 (mt, 1H : the other H of CH₂ at position 3β); 2.65 (s, 6H : ArN(CH₃)₂); 2.96 (dd, 10 J = 13 and 5.5 Hz, 1H : 1H of CH₂ at position 4β); from 3.15 to 3.35 (mt, 3H : the other H of CH₂ at position 4β - the other H of CH₂ at position 5β and 1H of CH₂ at position 3δ); 3.26 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of CH₂ at position 3δ); 4.00 (d, J = 17 Hz, 1H : 15 1H of CH₂ at position 5ε); 4.64 (dd, J = 8 and 6.5 Hz, 1H : CH at position 3α); 4.82 (mt, 1H : CH at position 2α); 4.91 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.19 (dd, J = 12 and 5.5 Hz, 1H : CH at position 4α); 5.44 (broad d, J = 5 Hz, 1H : CH at position 5α); 5.52 20 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.66 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.90 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.31 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.58 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.88 (d, 25 J = 8 Hz, 2H : aromatic H at position 4δ); from 7.25 to 7.40 (mt : the 6H corresponding to the 5 aromatic H at position 6α and to H₅ of pyridine); from 7.40 to 7.55 (mt, 3H : aromatic H at position γ with respect to N -

002280" 032200 09643197

1' H₅ and 1' H₄); 7.78 (split t, J = 8 and 1.5 Hz, 1H : H₄ of pyridine); 8.02 (broad d, J = 4 Hz, 1H : 1' H₆); 8.23 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); 8.42 (mt, 2H : H₃ of pyridine and CONH at position 1); 8.66 (d, J = 8.5 Hz, 1H : CONH at position 6); 8.68 (broad mt, 1H : H₆ of pyridine); 11.67 (s, 1H: OH).

1-[2-Oxo-2-(2-pyridyl)ethyl]pyridinium bromide hydrobromide may be prepared by analogy with
 10 F. Kröhnke et al., Synthesis, 1-24 (1976):

5 g of 2-bromoacetylpyridine hydrobromide and 7 cm³ of pyridine are introduced into a three-necked flask containing 50 cm³ of tetrahydrofuran. The stirring is maintained for 2 days at room temperature and then
 15 the precipitate formed is filtered, washed with 30 cm³ of tetrahydrofuran and then dried at 40°C under reduced pressure (90 Pa) to give 6.9 g of 1-[2-oxo-2-(2-pyridyl)ethyl]pyridinium hydrobromide in the form of a beige solid which is used as it is.

20 2-Bromoacetylpyridine hydrobromide may be prepared as described by J.L. Garcia Ruano et al., Tetrahedron, 43, 4407-4416 (1987).

Example 16

5 g of 5δ-methylenepristinamycin I_A, 2.1 g of
 25 1-[2-oxo-2-(3-pyridyl)ethyl]pyridinium hydrobromide and 4.4 g of ammonium acetate are introduced into a three-necked flask containing 75 cm³ of methanol. After refluxing for 1 hour, the reaction mixture is

002280" 082200 09543197

concentrated by half and then poured over 200 cm³ of distilled water. The orange precipitate which appeared is filtered to give 3.5 g of a solid which is purified by chromatography on 50 g of silica [eluent:

- 5 dichloromethane/methanol 97/3]. After concentrating the fractions, 1 g of a yellow solid is obtained which is crystallized from 30 cm³ of methanol. 0.4 g of 2"-(3-pyridyl)pyrido[2,3-5 γ ,5 δ]pristinamycin I_E is obtained after filtration and drying at 40°C under
10 reduced pressure (90 Pa) in the form of a white solid melting at 265°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

- 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂
15 at position 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.58 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.50 to 1.85 (mt : the 3H corresponding to CH₂ at position 2 β and to 1H of CH₂ at position 5 β); 2.05 (mt, 1H : the other H of CH₂ at position 3 β); 2.68 (s, 6H :
20 ArN(CH₃)₂); 2.95 (dd, J = 13 and 5.5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.20 to 3.35 (mt, 3H : the other H of CH₂ at position 4 β - the other H of CH₂ at position 5 β and 1H of CH₂ at position 3 δ); 3.26 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at position 3 δ); 3.98
25 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.61 (dd, J = 8 and 6 Hz, 1H : CH at position 3 α); 4.80 (mt, 1H : CH at position 2 α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.17 (dd, J = 12 and 5.5 Hz, 1H : CH

at position 4 α); 5.43 (broad d, J = 5.5 Hz, 1H : CH at position 5 α); 5.49 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.63 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.30 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.55 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.86 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.25 to 7.40 (mt : the 6H corresponding to the 5 aromatic H at position 6 α - to H₅ of pyridine); from 7.40 to 7.55 (mt, 3H : aromatic H at position γ with respect to N - 1' H₅ and 1' H₄); 7.58 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); 8.00 (dd, J = 4 and 1.5 Hz, 1H : 1' H₆); 8.31 (dt, J = 8 and 1.5 Hz, 1H : H₄ of pyridine); 8.40 (d, J = 10 Hz, 1H : CONH at position 1); 8.63 (dd, J = 5 and 1.5 Hz, 1H : H₆ of pyridine); 8.67 (d, J = 8.5 Hz, 1H : CONH at position 6); 9.20 (d, J = 1.5 Hz, 1H : H₂ of pyridine); 11.64 (s, 1H: OH).

1-[2-Oxo-2-(3-pyridyl)ethyl]pyridinium

hydrobromide may be prepared according to F. Kröhnke, Synthesis, 1-24 (1976).

Example 17

2 g of 2"-ethylpyrido[2,3-5 γ ,5 δ]-pristinamycin I_E, 0.17 cm³ of ethylene glycol, 2.2 cm³ of acetic acid and 0.44 g of tetra-n-butylammonium periodate are introduced into a three-necked flask containing 30 cm³ of dichloromethane. The mixture is stirred for 18 hours at room temperature and then

washed with 3 times 20 cm³ of water. The organic phase is decanted off, dried over magnesium sulphate, filtered and concentrated at 45°C under reduced pressure (2.7 kPa). The residue obtained is taken up in 5 50 cm³ of water and 10 cm³ of 0.5 N sulphuric acid and stirred for 5 minutes. The insoluble matter is removed by filtration and the aqueous phase extracted with 3 times 30 cm³ of ethyl acetate. The aqueous phase is adjusted to about pH 8 with a saturated solution of 10 sodium bicarbonate and then extracted with 3 times 30 cm³ of dichloromethane. The chloromethylene phases are pooled, dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure to give 1.7 g of a beige foam which is purified by 15 chromatography on 50 g of silica [eluent: dichloromethane/methanol 97/3 by volume]. 0.4 g of 2"-ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -methylamino)-(4 ζ -dedimethylamino)pristinamycin I_E is thus obtained after drying at 40°C under 90 Pa in the form of a 20 cream-coloured solid melting at 194°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.27 (t, J = 7.5 Hz, 3H : CH₃ of 25 ethyl); 1.32 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.59 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.85 (mt : the 2H corresponding to CH₂ at position 2 β); 1.81 (dd, J = 16 and 5.5 Hz, 1H : 1H of

CH₂ at position 5 β); 2.06 (mt, 1H : the other H of CH₂ at position 3 β); 2.72 (s, 3H : ArNCH₃); 2.77 (q, J = 7.5 Hz, 2H : ArCH₂ of ethyl); 2.97 (dd, J = 13.5 and 5.5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 5 3.30 (mt, 3H : the other H of CH₂ at position 4 β - the other H of CH₂ at position 5 β and 1H of CH₂ at position 3 δ); 3.22 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of CH₂ at position 3 δ); 3.67 (unresolved complex, 1H : ArNH); 3.93 (d, J = 17 Hz, 1H : 1H of CH₂ at position 10 5 ϵ); 4.61 (dd, J = 8 and 6 Hz, 1H : CH at position 3 α); 4.81 (mt, 1H : CH at position 2 α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.26 (dd, J = 10 and 5.5 Hz, 1H : CH at position 4 α); 5.42 (broad d and d respectively, J = 5.5 Hz and J = 17 Hz, 1H each : CH 15 at position 5 α and the other H of CH₂ at position 5 ϵ); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.90 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.24 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.60 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.82 (d, 20 J = 8 Hz, 2H : aromatic H at position 4 δ); 6.99 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.25 to 7.40 (mt : the 5 aromatic H at position 6 α); 7.33 (d, J = 8 Hz, 1H : aromatic H at position γ with respect to N); 7.40 (limiting AB, 2H : 25 1' H₄ and 1' H₅); 7.92 (mt, 1H : 1' H₆); 8.47 (d, J = 10 Hz, 1H : CONH at position 1); 8.69 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.67 (s, 1H: OH).

002280" 46TE4960

Example 18

By carrying out the procedure as in Example 5 but starting with 10 g of 5 δ -methylenepristinamycin I_B in 150 cm³ of methanol, 4.1 g of 1-[2-oxo-2-(2-pyridyl)-ethyl]pyridinium hydrobromide and 8.7 g of ammonium acetate and heating for 3 hours under reflux, 7.5 g of a solid are obtained, which solid is purified by preparative HPLC on 400 g of 10 μ m Kromasil[®] C₈ silica [eluent: water-acetonitrile 70/30 by volume containing 0.1% trifluoroacetic acid]. After concentrating the fractions in order to remove the acetonitrile, the aqueous phase is neutralized to pH 7-8 with a 10% solution of sodium bicarbonate. The precipitate obtained during the neutralization is filtered, taken up in 50 cm³ of dry dichloromethane and then the organic phase dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure to give a solid which is taken up in 50 cm³ of diisopropyl ether. After filtration and drying at 40°C under reduced pressure (90 Pa), 1.12 g of 2''-(2-pyridyl)pyrido[2,3-5 γ ,5 δ](4 ζ -methylamino)-(4 ζ -dedimethylamino)pristinamycin I_E are obtained in the form of a pink solid melting at 200°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.32 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.58 (mt : 1H : the other H of CH₂ at position 3 γ);

from 1.60 to 1.85 (mt, 2H : CH₂ at position 2β); 1.70
 (dd, J = 16 and 5.5 Hz, 1H : 1H of CH₂ at position 5β);
 2.06 (mt, 1H : the other H of CH₂ at position 3β); 2.53
 (s, 3H : ArNCH₃); 2.94 (dd, J = 13 and 5.5 Hz, 1H : 1H
 5 of CH₂ at position 4β); from 3.15 to 3.30 (mt, 2H : the
 other H of CH₂ at position 4β and 1H of CH₂ at position
 3δ); 3.25 (s, 3H : NCH₃); 3.29 (d, J = 16 Hz, 1H : the
 other H of CH₂ at position 5β); 3.50 (mt, 1H : the other
 H of CH₂ at position 3δ); 3.99 (d, J = 17 Hz, 1H : 1H of
 10 CH₂ at position 5ε); 4.62 (dd, J = 8 and 6 Hz, 1H : CH
 at position 3α); 4.81 (mt, 1H : CH at position 2α);
 4.90 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.16
 (dd, J = 10.5 and 5.5 Hz, 1H : CH at position 4α); 5.43
 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.52 (d,
 15 J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.67
 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.90 (broad q,
 J = 7 Hz, 1H : CH at position 1β); 6.15 (d, J = 8 Hz,
 2H : aromatic H at position 4ε); 6.58 (d, J = 9.5 Hz,
 1H : CONH at position 2); 6.81 (d, J = 8 Hz, 2H :
 20 aromatic H at position 4δ); from 7.25 to 7.40 (mt : the
 6H corresponding to the 5 aromatic H at position 6α and
 to H₅ of pyridine); from 7.40 to 7.55 (mt, 3H : aromatic
 H at position γ with respect to N - 1' H₅ and 1' H₄);
 7.78 (split t, J = 8 and 1.5 Hz, 1H : H₄ of pyridine);
 25 8.01 (broad d, J = 4 Hz, 1H : 1' H₆); 8.20 (d, J = 8 Hz,
 1H : aromatic H at position β with respect to N); 8.38
 (d, J = 8 Hz, 1H : H₃ with respect to pyridine); 8.46
 (d, J = 10 Hz, 1H : CONH at position 1); 8.66 (d,

002280 082200 064349

J = 8.5 Hz, 1H : CONH at position 6); 8.70 (broad d, J = 4 Hz, 1H : H₆ of pyridine); 11.68 (s, 1H: OH).

1-[2-Oxo-2-(2-pyridyl)ethyl]pyridinium hydrobromide may be prepared according to F. Kröhnke et al., Synthesis, 1-24 (1976).

Example 19

15 g of 2"-methylpyrido[2,3-5γ,5δ]-pristinamycin I_E, 1.25 cm³ of ethylene glycol, 16.4 cm³ of acetic acid and 3.33 g of tetra-n-butylammonium periodate are introduced into a three-necked flask containing 60 cm³ of methylene chloride. The mixture is stirred for 10 hours at room temperature and then the reaction mixture is washed with twice 50 cm³ of distilled water. The organic phase is decanted off and then concentrated to dryness at 40°C under reduced pressure (2.7 kPa). The residue is taken up in 100 cm³ of water and 200 cm³ of 0.5 N sulphuric acid and then washed with 5 times 100 cm³ of ethyl acetate. The aqueous phase is decanted off, adjusted to pH 7-8 with 200 cm³ of a saturated sodium bicarbonate solution and then extracted with twice 150 cm³ of ethyl acetate. The organic phase is dried over magnesium sulphate and then concentrated to dryness (40°C-2.7 kPa) to give 32 g of a solid which is chromatographed on 1 kg of silica [eluent: dichloromethane/methanol gradient 99/1 to 97.5/2.5]. After concentration to dryness of the fractions and then crystallization from ethyl acetate, 4.7 g of 2"-methylpyrido[2,3-5γ,5δ]-

002220 082200 09643497

(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I₂ are obtained after drying at 40°C under reduced pressure (90 Pa) in the form of white crystals melting at 244°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

- 5 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.57 (mt : 1H : the other H of CH₂ at position 3γ); from 1.60 to 1.85 (mt, 2H : CH₂ at position 2β); 1.73
- 10 (dd, J = 16 and 6.5 Hz, 1H : 1H of CH₂ at position 5β); 2.05 (mt, 1H : the other H of CH₂ at position 3β); 2.49 (s, 3H : ArCH₃); 2.69 (s, 3H : ArNCH₃); 2.95 (dd, J = 13.5 and 5.5 Hz, 1H : 1H of CH₂ at position 4β); from 3.15 to 3.30 (mt, 2H : the other H of CH₂ at
- 15 position 4β and 1H of CH₂ at position 3δ); 3.16 (d, J = 16 Hz, 1H : the other H of CH₂ at position 5β); 3.22 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at position 3β); 3.68 (unresolved complex, 1H : ArNH); 3.91 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.60
- 20 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3α); 4.79 (mt, 1H : CH at position 2α); 4.88 (dd, J = 10 and 1.5 Hz, 1H : CH at position 1α); 5.21 (dd, J = 10 and 5.5 Hz, 1H : CH at position 4α); 5.40 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.41 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.63 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.88 (dq, J = 7 and 1.5 Hz, 1H : CH at position 1β); 6.23 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.58 (d, J = 9.5 Hz,

0022280-082200

1H : CONH at position 2); 6.81 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); 6.96 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6 α); 7.33
 5 (d, J = 8 Hz, 1H : aromatic H at position γ with respect to N); 7.40 (limiting AB, 2H : 1' H₄ and 1' H₅); 7.91 (mt, 1H : 1' H₆); 8.44 (d, J = 10 Hz, 1H : CONH at position 1); 8.65 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.65 (s, 1H: OH).

10 **Example 20**

1.7 g of 2"-chloromethylpyrido[2,3-5 γ ,5 δ]-pristinamycin I_E and 0.6 cm³ of morpholine are added successively to a three-necked flask containing 30 cm³ of tetrahydrofuran and then the mixture is refluxed.
 15 After 18 hours, an additional 0.3 cm³ of morpholine is added and 0.3 cm³ of triethylamine and then the reflux is maintained for 6 hours. The reaction mixture is then concentrated to dryness under reduced pressure at 40°C at 2.7 kPa. The residue obtained is taken up in twice
 20 50 cm³ of water and then the aqueous phase is extracted with twice 50 cm³ of dichloromethane. The organic phases are combined, dried over sodium sulphate, filtered and then concentrated to dryness to give 1.3 g of product which is purified by chromatography on 80 g of silica
 25 [eluent: dichloromethane/methanol gradient from 98/2 to 97.3 by volume] to give 0.3 g of a solid which is concreted in a mixture with 0.26 g of the same product obtained from another test, from 60 cm³ of an ether-

002230" 082200 09643197 26464960

petroleum ether mixture (20/80 by volume). After filtration and drying at 40°C under reduced pressure (90 Pa), 0.3 g of 2"-(N-morpholinomethyl)pyrido-[2,3-5 γ ,5 δ]pristinamycin I_E is obtained in the form of a yellow solid melting at 189°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.29 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); from 1.50 to 1.70 (mt, the 2H corresponding to the other H of CH₂ at position 3 γ and to 1H of CH₂ at position 2 β); 1.75 (mt, 1H : the other H of CH₂ at position 2 β); 1.87 (dd, J = 16 and 6 Hz, 1H : 1H of CH₂ at position 5 β); 2.03 (mt, 1H : the other H of CH₂ at position 3 β); 2.50 (mt, 4H : the 2 NCH₂ of morpholine); 2.87 (s, 6H : ArN(CH₃)₂); 2.98 (dd, J = 13.5 and 6 Hz, 1H : 1H of CH₂ at position 4 β); from 3.10 to 3.35 (mt, 3H : the other H of CH₂ at position 5 β - the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.22 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3 δ); 3.59 (s, 2H : ArCH₂N); 3.74 (mt, 4H : the 2 OCH₂ of morpholine); 3.94 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.60 (dd, J = 8 and 5 Hz, 1H : CH at position 3 α); 4.79 (mt, 1H : CH at position 2 α); 4.88 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.29 (dd, J = 9 and 6 Hz, 1H : CH at position 4 α); 5.43 (mt, 1H : CH at position 5 α); 5.45 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.63 (d, J = 8.5 Hz, 1H :

002280" 464960

CH at position 6 α); 5.90 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.36 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.58 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.45 (mt : the 9H corresponding to the 5 aromatic H at position 6 α - to the aromatic H at position β with respect to N - to the aromatic H at position γ with respect to N - to 1' H₅ and 1' H₄); 7.84 (broad d, J = 4 Hz, 1H : 1' H₆); 8.43 (d, J = 10 Hz, 1H : CONH at position 1); 8.70 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.66 (s, 1H : OH).

2"-Chloromethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E may be obtained as described in Example 10.

15 Example 21

By carrying out the procedure as in Example 20 but starting with 50 cm³ of tetrahydrofuran, 3.2 g of 2"-chloromethylpyrido[2,3-5 γ ,5 δ]-pristinamycin I_E and 1.1 cm³ of N-methylpiperazine, 2.3 g of a solid are obtained after refluxing for 2 hours, which solid is purified by two successive chromatographies on 100 g of silica [eluent: dichloromethane/methanol 95/5 by volume] to give 0.4 g of 2"-(4-methyl-1-piperazinylmethyl)pyrido[2,3-5 γ ,5 δ]-pristinamycin I_E in the form of a yellow solid melting at 221°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20

to 1.40 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1γ) ; from 1.50 to 1.85 (mt : the 4H corresponding to the other H of CH₂ at position 3γ - to CH₂ at position 2β and to 1H of CH₂ at position 5β); 2.03 (mt, 1H : the other H of CH₂ at position 3β); 2.32 (s, 3H : NCH₃ of piperazine); from 2.40 to 2.70 (mt, 8H : the 4 NCH₂ of piperazine); 2.90 (s, 6H : ArN(CH₃)₂); 2.99 (dd, J = 13.5 and 6 Hz, 1H : 1H of CH₂ at position 4β); from 3.15 to 3.35 (mt, 3H : the other H of CH₂ at position 5β - the other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.22 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3δ); 3.62 (s, 2H : ArCH₂N); 3.95 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.60 (dd, J = 7.5 and 5.5 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.28 (dd, J = 9 and 6 Hz, 1H : CH at position 4α); 5.51 (mt, 1H : CH at position 5α); 5.55 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.89 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.37 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.59 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.86 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.45 (mt : the 9H corresponding to the 5 aromatic H at position 6α - to the aromatic H at position β with respect to N - to the aromatic H at position γ with respect to N - to 1' H₅ and 1' H₄); 7.87 (broad d,

002280" 1674960

J = 4 Hz, 1H : 1' H₆); 8.43 (d, J = 10 Hz, 1H : CONH at position 1); 8.70 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.64 (unresolved complex, 1H: OH).

Example 22

5 4.6 g of 5δ-dimethylaminomethylene-pristinamycin I_A, 1.1 g of O-methylisourea hydrogen sulphate and 1.75 g of sodium bicarbonate are introduced into a three-necked flask containing 30 cm³ of dimethylformamide. The mixture is heated at 65°C for
10 18 hours. After cooling, 100 cm³ of distilled water are added and the product is extracted with 3 times 100 cm³ of ethyl acetate. The organic phases are combined, washed with 200 cm³ of brine, dried over magnesium sulphate, filtered and concentrated to dryness at 40°C
15 under reduced pressure (2.7 kPa) to give 5.05 g of a yellow oil which is purified by chromatography on 90 g of silica [eluent: dichloromethane/methanol 97/3 by volume] to give 1.2 g of a solid. The solid obtained is purified by HPLC on 450 g of 10 μm C₈ silica (eluent:
20 phosphate buffer pH 2.9/acetonitrile: 60/40 by volume). The fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the aqueous phase adjusted to pH 7 with water saturated with sodium bicarbonate and then extracted with dichloromethane.
25 The organic phase is decanted off, dried over magnesium sulphate, filtered and concentrated at 40°C under reduced pressure (2.7 kPa) to give a solid which is triturated in 10 cm³ of diisopropyl ether. After

002230" 16T4960

filtration and drying at 40°C (90 Pa), 0.40 g of 2"-methoxypyrimido[4,5-5 γ ,5 δ]pristinamycin I_E is obtained in the form of a white solid melting at 195-198°C.

5 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20
 to 1.35 (mt, 3H : 1H of CH₂ at position 3 β - 1H of CH₂
 at position 3 γ and 1H of CH₂ at position 5 β); 1.31 (d,
 J = 7 Hz, 3H : CH₃ at position 1 γ); 1.58 (mt, 1H : the
 10 other H of CH₂ at position 3 γ); from 1.60 to 1.85 (mt,
 the 2H corresponding to CH₂ at position 2 β); 2.05 (mt,
 1H : the other H of CH₂ at position 3 β); 2.85 (s, 6H :
 ArN(CH₃)₂); 2.91 (dd, J = 12 and 4.5 Hz, 1H : 1H of CH₂
 at position 4 β); 2.93 (d, J = 16.5 Hz, 1H : the other H
 15 of CH₂ at position 5 β); from 3.15 to 3.30 (mt, 1H : 1H
 of CH₂ at position 3 δ); 3.21 (t, J = 12 Hz, 1H : the
 other H of CH₂ at position 4 β); 3.25 (s, 3H : NCH₃);
 3.50 (mt, 1H : the other H of CH₂ at position 3 δ); 3.76
 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 3.95 (s,
 20 3H : ArOCH₃); 4.61 (dd, J = 8 and 5.5 Hz, 1H : CH at
 position 3 α); 4.80 (mt, 1H : CH at position 2 α); 4.88
 (dd, J = 10 and 1.5 Hz, 1H : CH at position 1 α); 5.07
 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4 α); 5.33
 (broad d, J = 5.5 Hz, 1H : CH at position 5 α); 5.41 (d,
 25 J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.64
 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.88 (split q,
 J = 7 and 1.5 Hz, 1H : CH at position 1 β); 6.33 (d,
 J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.51 (d,

0022280" 082200 09643197

J = 10 Hz, 1H : CONH at position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6α); 7.44 (dd, J = 8.5 and 1.5 Hz, 1H : 1' H₄); 7.49 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.94 (dd, J = 4 and 1.5 Hz, 1H : 1' H₆); 8.16 (s, 1H : CH=N); 8.37 (d, J = 10 Hz, 1H : CONH at position 1); 8.69 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.63 (s, 1H: OH).

Example 23

10 By carrying out the procedure as in Example 22 but starting with 12 cm³ of dimethylformamide, 2.76 g of 5δ-dimethylaminomethylene-pristinamycin I_A, 0.54 g of S-methylisothiouronium sulphate and 0.35 g of sodium bicarbonate and after
15 4 hours at 65°C, 2.5 g of a yellow solid are obtained after cooling, addition of 100 cm³ of ethyl acetate to the reaction mixture, washing of the organic phase with 3 times 80 cm³ of water, decantation of the organic phase which is dried over magnesium sulphate, filtered
20 and concentrated to dryness at 40°C under reduced pressure (2.7 kPa). The solid is chromatographed on 200 g of silica [eluent: dichloromethane/methanol 95/5 by volume] to give 1.9 g of a solid which is purified by HPLC on 450 g of 10 μm C₈ silica [eluent: water-
25 acetonitrile 35-65 by volume containing 0.1% trifluoroacetic acid]. The fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the aqueous phase adjusted to pH 7-8 with

0022280" 26 FEB 1990 09543197 032200

5 pristinamycin I_E in the form of a cream-coloured solid
melting at 197°C.

0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.15 to 1.40 (mt, 3H : 1H of CH₂ at position 3β - 1H of CH₂ at position 3γ and 1H of CH₂ at position 5β); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.59 (mt, 1H : the other H of CH₂ at position 3γ); 1.67 and 1.76 (2 mts, 1H each : CH₂ at position 2β); 2.06 (mt, 1H : the other H of CH₂ at position 3β); 2.52 (s, 3H : ArSCH₃); from 2.80 to 3.00 (mt, 2H : 1H of CH₂ at position 4β and the other H of CH₂ at position 5β); 2.88 (s, 6H : ArN(CH₃)₂); from 3.15 to 3.35 (mt, 2H : 1H of CH₂ at position 3δ and the other H of CH₂ at position 4β); 3.26 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3δ); 3.77 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.61 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.06 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4α); 5.32 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.41 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.35 (d, J = 8 Hz, 2H : aromatic H at

position 4ε); 6.52 (d, J = 10 Hz, 1H : CONH at position 2); 6.86 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6α); 7.47 (broad d, J = 8,5 Hz, 1H : 1' H₄); 7.52 (dd, 5 J = 8.5 and 4 Hz, 1H : 1' H₅); 7.96 (broad d, J = 4 Hz, 1H : 1' H₆); 8.18 (s, 1H : CH=N); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.70 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.64 (s, 1H: OH).

Example 24

10 16.2 g of 2"-methylthiopyrimido[4,5-5γ,5δ]-
pristinamycin I_E at 95% purity are introduced into a
three-necked flask containing 130 cm³ of methanol and
then 551 cm³ of 0.5 N sulphuric acid are added at 4°C
followed by 19.94 g of Oxone® over 6 minutes. The
15 mixture is stirred for 2 hours at 4°C and then for
18 hours at room temperature. The reaction mixture is
cooled to 4°C, diluted with 150 cm³ of dichloromethane
and then the pH adjusted to 3 with a dilute sodium
hydroxide solution. The aqueous phase is decanted off
20 and then washed with twice 100 cm³ of dichloromethane.
The organic phases are combined, washed with 50 cm³ of a
saturated sodium chloride solution, dried and
concentrated under reduced pressure (2.7 kPa) so as to
obtain a final volume of 200 cm³. To the chloromethylene
25 solution obtained, placed in a three-necked flask,
there are added 100 cm³ of distilled water and, with
vigorous stirring, 3 cm³ of a 50% (w/v) solution of
sodium bisulphite and then a saturated sodium

002280" 267E4960
09643197-082200

bicarbonate solution up to pH 6. After decantation, the aqueous phase is washed with twice 100 cm³ of dichloromethane. The organic phases are combined, dried over sodium sulphate, filtered and concentrated to dryness at 40°C under reduced pressure (2.7 kPa) to give 15.3 g of a solid which is purified by flash chromatography [eluent: dichloromethane/methanol 95/5 by volume]. 10.2 g of product are thus obtained in the form of a yellow solid, which solid may be used as it is.

An analytical sample may be obtained by purification by flash chromatography [eluent: dichloromethane/methanol 98/2 by volume] of 0.6 g of product. After concentration of the fractions at 40°C under reduced pressure (2.7 kPa), trituration in 5 cm³ of diethyl ether, filtration and drying at 50°C (90 Pa), 0.35 g of 2"-methylsulphonylpyrimido-[4,5-5 γ ,5 δ]pristinamycin I_E is obtained in the form of a pale-yellow solid melting at 214°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.25 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β - 1H of CH₂ at position 3 γ); 1.32 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.44 (dd, J = 17 and 5.5 Hz, 1H : 1H of CH₂ at position 5 β); from 1.55 to 1.85 (mt : the 3H corresponding to CH₂ at position 2 β and the other H of CH₂ at position 3 γ); 2.08 (mt, 1H : the other H of CH₂ at position 3 β); 2.86 (s, 6H : ArN(CH₃)₂); 2.95 (dd,

002280" 26FE4960

J = 12 and 4.5 Hz, 1H : 1H of CH₂ at position 4β); 3.11
 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5β);
 3.20 (t, J = 12 Hz, 1H : the other H of CH₂ at position
 4β); from 3.20 to 3.35 (mt, 1H : 1H of CH₂ at position
 5 3δ); 3.27 (s, 6H : NCH₃ and ArSO₂CH₃); 3.51 (mt, 1H :
 the other H of CH₂ at position 3δ); 3.87 (d, J = 17 Hz,
 1H : 1H of CH₂ at position 5ε); 4.61 (dd, J = 7.5 and
 6 Hz, 1H : CH at position 3α); 4.81 (mt, 1H : CH at
 position 2α); 4.91 (broad d, J = 10 Hz, 1H : CH at
 10 position 1α); 5.11 (dd, J = 12 and 4.5 Hz, 1H : CH at
 position 4α); 5.42 (broad d, J = 5.5 Hz, 1H : CH at
 position 5α); 5.54 (d, J = 17 Hz, 1H : the other H of
 CH₂ at position 5ε); 5.63 (d, J = 8.5 Hz, 1H : CH at
 position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at
 15 position 1β); 6.34 (d, J = 8 Hz, 2H : aromatic H at
 position 4ε); 6.56 (d, J = 10 Hz, 1H : CONH at position
 2); 6.87 (d, J = 8 Hz, 2H : aromatic H at position 4δ);
 from 7.20 to 7.40 (mt : the 5 aromatic H at position
 6α); 7.49 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.54 (dd,
 20 J = 8.5 and 4 Hz, 1H : 1' H₅); 7.98 (broad d, J = 4 Hz,
 1H : 1' H₆); 8.41 (d, J = 10 Hz, 1H : CONH at position
 1); 8.53 (s, 1H : CH=N); 8.84 (d, J = 8.5 Hz, 1H : CONH
 at position 6); 11.65 (s, 1H : OH).

Example 25

25 1.9 cm³ of pyrrolidine are introduced into a
 three-necked flask containing 25 cm³ of dioxane and 2 g
 of 2"-(4-methylbenzylsulphonyl)pyrimido[4,5-5γ,5δ]-
 pristinamycin I₂ and then the mixture is heated at 90°C

002280 263496

for 3 hours. After concentrating the reaction mixture to dryness at 40°C under reduced pressure (2.7 kPa), the residue obtained is chromatographed on 150 g of silica [eluent: dichloromethane/methanol 96/4 by volume] to give 0.46 g of a cream-coloured solid which is recrystallized from 10 cm³ of methanol. The crystals are filtered, rinsed with a minimum of methanol and then dried at 40°C under reduced pressure (90 Pa) to give 0.32 g of 2''-(1-pyrrolidinyl)pyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E in the form of white crystals melting at 255°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 3H : 1H of CH₂ at position 3 β - 1H of CH₂ at position 3 γ and 1H of CH₂ at position 5 β); 1.29 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.56 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.85 (mt: the 2H corresponding to CH₂ at position 2 β); 1.93 (mt, 4H : the 2 CH₂ of pyrrolidine); 2.03 (mt, 1H : the other H of CH₂ at position 3 β); 2.86 (s, 6H : ArN(CH₃)₂); 2.88 (d, J = 17.5 Hz, 1H : the other H of CH₂ at position 5 β); 2.94 (dd, J = 12 and 4.5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.23 (s, 3H : NCH₃); from 3.45 to 3.60 (mt, 1H : the other H of CH₂ at position 3 δ); 3.53 (mt, 4H : the 2 NCH₂ of pyrrolidine); 3.74 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.61 (dd, J = 8 and 7 Hz, 1H : CH at

002280 4643197 082200

position 3 α); 4.78 (mt, 1H : CH at position 2 α); 4.86 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.11 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4 α); 5.29 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.31 (mt, 1H : CH at position 5 α); 5.62 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.87 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.38 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.55 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.86 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6 α); 7.43 (limiting AB, 2H : 1' H₄ and 1' H₅); 7.91 (mt, 1H : 1' H₆); 7.99 (s, 1H : CH=N); 8.39 (d, J = 10 Hz, 1H : CONH at position 1); 8.62 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.64 (s, 1H : OH).

2"-(4-Methylbenzylsulphonyl)pyrimido-[4,5-5 γ ,5 δ]pristinamycin I_E may be prepared in the following manner:

1 litre of 1 N sulphuric acid is added to a three-necked flask containing 800 cm³ of methanol and 24.6 g of 2"-(4-methylbenzylthio)pyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E. The mixture is cooled to 0°C and then 28.4 g of Oxone[®] are added. The stirring is maintained for 18 hours at room temperature and then the mixture is neutralized by slow addition of sodium bicarbonate so as to obtain a pH of 8 and then extracted with 3 times 1 litre of dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered

002280" 46FE4960

and concentrated to dryness at 45°C under reduced pressure (2.7 kPa) to give 30 g of a solid which is chromatographed on 1.2 kg of silica [eluent: dichloromethane/methanol/acetic acid, 89/10/1 by volume]. After concentration to dryness at 45°C under reduced pressure (2.7 kPa) of the fractions, the product is triturated in 100 cm³ of diethyl ether, filtered and dried at 40°C under reduced pressure (90 Pa). 21.7 g of 2''-(4-methylbenzylsulphonyl)-pyrimido[4,5-5 γ ,5 δ](4 ζ -dimethylamino N oxide)-(4 ζ -dedimethylamino)pristinamycin I_E are thus obtained in the form of a pale-yellow solid melting at 247°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); 0.99 (dd, J = 17 and 5.5 Hz, 1H : 1H of CH₂ at position 5 β); 1.14 (mt, 1H : 1H of CH₂ at position 3 β); 1.44 (mt, 1H : 1H of CH₂ at 3 γ); 1.32 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); from 1.55 to 1.75 (mt, 3H : CH₂ at position 2 β and the other H of CH₂ at position 3 γ); 2.07 (mt, 1H : the other H of CH₂ at position 3 β); 2.28 (s, 3H : ArCH₃); 3.10 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4 β); 3.17 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 β); 3.24 (s, 3H : NCH₃); 3.27 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4 β); 3.47 and 3.58 (2 mts, 1H each: CH₂ at position 3 δ); 3.58 and 3.73 (2 s, 3H each : ArN(CH₃)₂); 3.81 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.55 (mt, 1H : CH at position 3 α); 4.58 and 4.79 (2 d, J = 14 Hz, 1H each : O₂SCH₂Ar);

002280" 2614960

4.84 (mt, 1H : CH at position 2 α); 4.92 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.31 (dd, J = 12 and 4 Hz, 1H : CH at position 4 α); 5.36 (broad d, J = 5.5 Hz, 1H : CH at position 5 α); 5.60 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.70 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.83 (d, J = 9 Hz, 1H : CONH at position 2); 7.08 (d, J = 8 Hz, 2H : aromatic H at the ortho position with respect to CH₃); 7.11 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); 7.19 (d, J = 8 Hz, 2H : aromatic H at the meta position with respect to CH₃); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6 α); 7.47 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.62 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 7.72 (dd, J = 8.5 and 4.5 Hz, 1H : 1' H₅); 7.85 (mt, 1H : 1' H₆); 8.41 (d, J = 10 Hz, 1H : CONH at position 1); 8.55 (s, 1H : CH=N); 8.75 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.65 (broad unresolved complex, 1H: OH).

4.8 g of 2"-(4-methylbenzylsulphonyl)-pyrimido[4,5-5 γ ,5 δ](4 ζ -dimethylamino N oxide)-(4 ζ -dedimethylamino)pristinamycin I_E and 0.4 g of iron powder are introduced into a three-necked flask containing 50 cm³ of glacial acetic acid. The mixture is heated for 2 minutes at 60°C, cooled, neutralized by addition of a 10% solution of sodium bicarbonate and then extracted with 100 cm³ of dichloromethane. The organic phases are combined, dried over sodium

002290" 26FE4960

sulphate, filtered and concentrated to dryness at 40°C under reduced pressure (2.7 kPa) to give 4.35 g of a chestnut-coloured solid which is recrystallized from 50 cm³ of hot isopropanol. After filtration, washing of the crystals with 10 cm³ of diisopropyl ether and drying at 40°C under reduced pressure (90 kPa), 2.06 g of 2''-(4-methylbenzylsulphonyl)pyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E are obtained in the form of a beige solid melting at 188°C.

- ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
- 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.45 (dd, J = 17 and 5.5 Hz, 1H : 1H of CH₂ at position 5 β); from 1.55 to 1.75 (mt: the 2H corresponding to 1H of CH₂ at position 2 β and the other H of CH₂ at position 3 γ); 1.74 (mt, 1H : the other H of CH₂ at position 2 β); 2.08 (mt, 1H : the other H of CH₂ at position 3 β); 2.30 (s, 3H : ArCH₃); 2.81 (s, 6H : ArN(CH₃)₂); 2.95 (dd, J = 12 and 4.5 Hz, 1H : 1H of CH₂ at position 4 β); 3.01 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 β); 3.19 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4 β); from 3.20 to 3.35 (mt, 1H : 1H of CH₂ at position 3 δ); 3.26 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of CH₂ at position 3 δ); 3.88 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.50 and 4.74 (2 d, J = 14 Hz, 1H each : O₂SCH₂Ar); 4.61 (dd, J = 7.5 and 6 Hz, 1H : CH at position 3 α); 4.80 (mt, 1H

002230 264496

: CH at position 2 α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.08 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4 α); 5.40 (broad d, J = 5.5 Hz, 1H : CH at position 5 α); 5.54 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.66 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.89 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.29 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.53 (d, J = 10 Hz, 1H : CONH at position 2); 6.84 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); 7.12 (d, J = 8 Hz, 2H : aromatic H at the ortho position with respect to CH₃); from 7.10 to 7.35 (mt : the 5 aromatic H at position 6 α); 7.20 (d, J = 8 Hz, 2H : aromatic H at the meta position with respect to CH₃); 7.48 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.53 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.96 (broad d, J = 4 Hz, 1H : 1' H₆); 8.39 (d, J = 10 Hz, 1H : CONH at position 1); 8.50 (s, 1H : CH=N); 8.80 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.64 (s, 1H: OH).

2"-(4-Methylbenzylthio)pyrimido[4,5-5 γ ,5 δ]-

pristinamycin I_E may be prepared in the following manner:

4.3 g of 5 δ -dimethylaminomethylene-pristinamycin I_A, 1 g of (4-methylbenzyl)isothiourea hydrochloride are introduced into a three-necked flask containing 35 cm³ of dimethylformamide and then 1.8 cm³ of N,N-diisopropylamine are added dropwise. The mixture is heated for 3 hours at 60°C, cooled and then diluted with 200 cm³ of distilled water. The precipitate formed

002280" 06E4960

is filtered to give 1 g of product which is purified by HPLC on 450 g of 10 μ m C₈ silica [eluent: water-acetonitrile 50/50 by volume containing 0.1% trifluoroacetic acid]. The fractions are combined, the
 5 acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the aqueous phase adjusted to pH 7-8 with water saturated with sodium bicarbonate. The mixture is extracted with 3 times 80 cm³ of dichloromethane, the organic phases are combined, dried over magnesium
 10 sulphate, filtered, concentrated to dryness and then dried at 40°C under reduced pressure (90 Pa) to give 1.09 g of 2''-(4-methylbenzylthio)pyrimido-[4,5- γ ,5 δ]pristinamycin I_E in the form of a cream-coloured solid melting at 222°C.

15 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 3H : 1H of CH₂ at position 3 β - 1H of CH₂ at position 3 γ and 1H of CH₂ at position 5 β); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); from 1.55 to 1.80
 20 (mt: the 2H corresponding to CH₂ at position 2 β); 1.59 (mt, 1H: the other H of CH₂ at position 3 γ); 2.05 (mt, 1H: the other H of CH₂ at position 3 β); 2.32 (s, 3H : ArCH₃); 2.86 (s, 6H : ArN(CH₃)₂); 2.91 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4 β); 2.94 (d,
 25 J = 17.5 Hz, 1H : the other H of CH₂ at position 5 β); from 3.15 to 3.30 (mt, 1H : 1H of CH₂ at position 3 δ); 3.21 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4 β); 3.25 (s, 3H, NCH₃); 3.50 (mt, 1H : the other H of

002280" 0643197 082200

CH₂ at position 3δ); 3.76 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.27 and 4.39 (2 d, J = 13.5 Hz, 1H each : ArSCH₂Ar); 4.61 (dd, J = 7.5 and 5.5 Hz, 1H : CH at position 3α); 4.79 (mt, 1H : CH at position 2α);

5 4.88 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.07 (dd, J = 12 and 4 Hz, 1H : CH at position 4α); 5.32 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.39 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.64 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.87 (broad q,

10 J = 7 Hz, 1H : CH at position 1β); 6.33 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.53 (d, J = 10 Hz, 1H : CONH at position 2); 6.84 (d, J = 8 Hz, 2H : aromatic H at position 4δ); 7.11 (d, J = 8 Hz, 2H : aromatic H at the ortho position with respect to CH₃); from 7.15 to

15 7.40 (mt : the 5 aromatic H at position 6α); 7.32 (d, J = 8 Hz, 2H : aromatic H at the meta position with respect to the CH₃); 7.44 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.48 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.93 (broad d, J = 4 Hz, 1H : 1' H₆); 8.19 (s, 1H : CH=N);

20 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.70 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.63 (s, 1H : OH).

Example 26

By carrying out the procedure as in Example

25 25 but starting with 40 cm³ of dioxane, 2 g of 2"- (4-methylbenzylsulphonyl)pyrimido[4,5-5γ,5δ]-pristinamycin I_E, 1.02 cm³ of azetidine and after heating for 45 minutes at 60°C, a precipitate is

0022280" 2674960

obtained after cooling which is filtered, washed with 10 cm³ of diisopropyl ether and then recrystallized from 15 cm³ of methanol to give after filtration, drying at 40°C under reduced pressure (90 Pa), 1.05 g of

- 5 2"-(1-azetidiny)pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E in the form of a white powder melting at 243°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

- 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 3H : 1H of CH₂ at position 3 β - 1H of CH₂ at position 3 γ and 1H of CH₂ at position 5 β); 1.29 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.56 (mt, 1H : the other H of CH₂ at position 3 γ); 1.65 and 1.72 (2 mts, 1H each : CH₂ at position 2 β); 2.05 (mt, 1H : the other H of CH₂ at position 3 β); 2.33 (mt, 2H : CH₂ of
15 azetidine); 2.86 (d, J = 17.5 Hz, 1H : the other H of CH₂ at position 5 β); 2.88 (s, 6H : ArN(CH₃)₂); 2.92 (dd, J = 12 and 4.5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.10 to 3.35 (mt, 2H : the other H of CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.22 (s, 3H : NCH₃); 3.48
20 (mt, 1H : the other H of CH₂ at position 3 δ); 3.72 Hz (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.09 (mt, 4H : the 2 NCH₂ of azetidine); 4.59 (dd, J = 8 and 6 Hz, 1H : CH at position 3 α); 4.78 (mt, 1H : CH at position 2 α); 4.88 (broad d, J = 10 Hz, 1H : CH at position 1 α);
25 5.12 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4 α); 5.29 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.31 (broad d, J = 6 Hz, 1H : CH at position 5 α); 5.62 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.87

002280 1643497 082200

(broad q, $J = 7$ Hz, 1H : CH at position 1 β); 6.40 (d, $J = 8$ Hz, 2H : aromatic H at position 4 ϵ); 6.55 (d, $J = 9.5$ Hz, 1H : CONH at position 2); 6.87 (d, $J = 8$ Hz, 2H : aromatic H at position 4 δ); from 7.15 to 7.35 (mt : the 5 aromatic H at position 6 α); 7.42 (limiting AB, 2H : 1' H₄ and 1' H₅); 7.90 (mt, 1H : 1' H₆); 7.97 (s, 1H : CH=N); 8.40 (d, $J = 10$ Hz, 1H : CONH at position 1); 8.63 (d, $J = 8.5$ Hz, 1H : CONH at position 6).

10 Example 27

By carrying out the procedure as in Example 22 but starting with 5 cm³ of dimethylformamide, 1.84 g of 5 δ -dimethylaminomethylenepristinamycin I_A, 0.41 g of 4-amidinopyridinium hydrochloride, 0.235 g of sodium bicarbonate and heating for 4 hours at 65°C, a solution is obtained after cooling which is diluted with 40 cm³ of ethyl acetate and 50 cm³ of distilled water. After decantation, the aqueous phase is washed with twice 40 cm³ of ethyl acetate, the organic phases are pooled and then washed with 200 cm³ of brine, dried over magnesium sulphate, filtered and concentrated at 40°C under reduced pressure (2.7 kPa) to give a residue which is chromatographed on 90 g of silica [eluent: dichloromethane/methanol 96/4 by volume]. 0.535 g of a product is obtained which is purified with 1.37 g of an identical product obtained by a similar preparation by HPLC on 450 g of 10 μ m C₈ silica [eluent: water-acetonitrile 35/65 by volume containing 0.1%

002220" 26E4960

trifluoroacetic acid]. The fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the aqueous phase adjusted to pH 7-8 with water saturated with sodium bicarbonate. The mixture is
 5 extracted with 3 times 100 cm³ of dichloromethane, the organic phases are combined, dried over magnesium sulphate, filtered, concentrated to dryness and then dried at 40°C under reduced pressure (90 Pa) to give 0.73 g of a white solid which is triturated in 10 cm³ of
 10 diisopropyl ether, filtered and dried at 40°C (90 Pa). 0.67 g of 2''-(4-pyridyl)pyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E is thus obtained in the form of a white solid melting at 277°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

15 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.41 (dd, J = 17 and 6 Hz, 1H : 1H of CH₂ at position 5 β); 1.60 (mt, 1H : the other H of CH₂ at
 20 position 3 γ); from 1.60 to 1.85 (mt : the 2H corresponding to CH₂ at position 2 β); 2.07 (mt, 1H : the other H of CH₂ at position 3 β); 2.63 (s, 6H : ArN(CH₃)₂); 2.92 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4 β); 3.10 (d, J = 17 Hz, 1H : the other H of
 25 CH₂ at position 5 β); from 3.20 to 3.35 (mt, 2H : 1H of CH₂ at position 3 δ and the other H of CH₂ at position 4 β); 3.27 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of CH₂ at position 3 δ); 3.88 (d, J = 17 Hz, 1H : 1H of CH₂

002280" 46TE4960

at position 5 ϵ); 4.61 (dd, $J = 7.5$ and 6 Hz, $1H$: CH at position 3 α); 4.80 (mt, $1H$: CH at position 2 α); 4.88 (broad d, $J = 10$ Hz, $1H$: CH at position 1 α); 5.06 (dd, $J = 12$ and 4 Hz, $1H$: CH at position 4 α); 5.41 (broad d, $J = 6$ Hz, $1H$: CH at position 5 α); 5.52 (d, $J = 17$ Hz : the other H of CH₂ at position 5 ϵ); 5.64 (d, $J = 8.5$ Hz, $1H$: CH at position 6 α); 5.88 (broad q, $J = 7$ Hz, $1H$: CH at position 1 β); 6.38 (d, $J = 8$ Hz, $2H$: aromatic H at position 4 ϵ); 6.54 (d, $J = 10$ Hz, $1H$: CONH at position 2); 6.86 (d, $J = 8$ Hz, $2H$: aromatic H at position 4 δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6 α); 7.49 (broad d, $J = 8.5$ Hz, $1H$: 1'H₄); 7.57 (dd, $J = 8.5$ and 4 Hz, $1H$: 1' H₅); 8.04 (broad d, $J = 4$ Hz, $1H$: 1' H₆); 8.27 (d, $J = 5$ Hz, $2H$: aromatic H at position β of pyridine); 8.38 (d, $J = 10$ Hz, $1H$: CONH at position 1); 8.48 (s, $1H$: CH=N; 8.72 (d, $J = 8.5$ Hz, $1H$: CONH at position 6); 8.75 (d, $J = 5$ Hz, $2H$: aromatic H at position α of pyridine; 11.66 (s, $1H$: OH).

20 Example 28

6 g of 5 δ -dimethylaminomethylenepristinamycin I_A, 1.33 g of 2-amidinopyridinium hydrochloride are introduced into a three-necked flask containing 35 cm³ of dimethylformamide and then 3.4 cm³ of N,N-diisopropylamine are added dropwise. The mixture is heated for 4 hours at 65°C, cooled and then diluted with 500 cm³ of distilled water saturated with sodium chloride. The precipitate formed is filtered and then

00643197 08200

taken up in 300 cm³ of dichloromethane. The solution obtained is dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure at 40°C (2.7 kPa) to give 4.36 g of a product which is purified
 5 by chromatography on 220 g of silica [eluent: dichloromethane/methanol 95/5 by volume]. After concentrating the fractions to dryness under reduced pressure at 40°C (2.7 kPa), 3.15 g of a solid are obtained, which solid is recrystallized from 20 cm³ of
 10 isopropanol. The crystals are filtered, washed with 20 cm³ of diisopropyl ether and then dried at 40°C (90 Pa) to give 1.08 g of 2''-(2-pyridyl)pyrimido[4,5-5 γ ,5 δ]pristinamycin IE in the form of a white powder melting at 214°C.

15 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.51 (dd, J = 17 and 6 Hz, 1H : 1H of CH₂ at
 20 position 5 β); from 1.55 to 1.80 (mt : the 2H corresponding to CH₂ at position 2 β); 1.59 (mt, 1H : the other H of CH₂ at position 3 γ); 2.06 (mt, 1H : the other H of CH₂ at position 3 β); 2.64 (s, 6H : ArN(CH₃)₂); 2.93 (dd, J = 12 and 4.5 Hz, 1H : 1H of CH₂ at position 4 β);
 25 3.13 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 β); from 3.15 to 3.30 (mt, 1H : 1H of CH₂ at position 3 δ); 3.22 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4 β); 3.26 (s, 3H : NCH₃); 3.51 (mt, 1H : the

002280" 4674960

other H of CH₂ at position 3δ); 3.89 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.60 (dd, J = 8 and 6 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1α);

5 5.12 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4α); 5.42 (broad d, J = 6 Hz, 1H : CH at position 5α); 5.52 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.87 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.28 (d,

10 J = 8 Hz, 2H : aromatic H at position 4ε); 6.56 (d, J = 10 Hz, 1H : CONH at position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.15 to 7.40 (mt : the 5 aromatic H at position 6α); 7.35 (mt, 1H : H at position 5 of pyridine); 7.46 (broad d, J = 8.5 Hz, 1H

15 : 1' H₄); 7.51 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.82 (split t, J = 8 and 1.5 Hz, 1H : H at position 4 of pyridine); 7.99 (broad d, J = 4 Hz, 1H : 1' H₆); 8.41 (d, J = 10 Hz, 1H : CONH at position 1); 8.47 (d, J = 8 Hz, H at position 3 of pyridine); 8.56 (s, 1H :

20 CH=N); 8.72 (d, J = 8.5 Hz, 1H : CONH at position 6); 8.82 (broad d, J = 5 Hz, 1H : H at position 6 of pyridine); 11.65 (s, 1H : OH).

Example 29

By carrying out the procedure as in Example

25 22 but starting with 4 cm³ of dimethylformamide, 0.92 g of 5δ-dimethylaminomethylenepristinamycin I_A, 0.22 g of benzamidine hydrochloride and 0.12 g of sodium bicarbonate and after 4 hours at 60°C, 1 g of a residue

0022280" 1674960

which is chromatographed on 170 g of silica [eluent: dichloromethane/methanol 96/4 by volume] is obtained after cooling, addition of 50 cm³ of distilled water and 20 cm³ of ethyl acetate to the reaction mixture, washing
 5 of the aqueous phase with twice 20 cm³ of ethyl acetate, decantation of the organic phase which is dried over magnesium sulphate, filtered and concentrated to dryness at 40°C under reduced pressure (2.7 kPa). After concentration to dryness at 40°C under reduced pressure
 10 (2.7 kPa) of the fractions, the product is triturated in 10 cm³ of diisopropyl ether, filtered and dried at 40°C under reduced pressure (90 Pa) to give 0.49 g of 2"-phenylpyrimido[4,5-5 γ ,5 δ]pristinamycin I₂ in the form of a white powder melting at 201°C.

15 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.40 (dd, J = 17 and 6 Hz, 1H : 1H of CH₂ at
 20 position 5 β); 1.59 (mt : 1H : the other H of CH₂ at position 3 γ); 1.65 (mt: 1H corresponding to 1H of CH₂ at position 2 β); 1.74 (mt, 1H : the other H of CH₂ at position 2 β); 2.06 (mt, 1H : the other H of CH₂ at position 3 β); 2.64 (s, 6H : ArN(CH₃)₂); 2.93 (dd, J = 12
 25 and 4 Hz, 1H : 1H of CH₂ at position 4 β); 3.09 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 β); from 3.15 to 3.30 (mt, 2H : 1H of CH₂ at position 3 δ and the other H of CH₂ at position 4 β); 3.27 (s, 3H : NCH₃);

09643197-082200

3.50 (mt, 1H : the other H of CH₂ at position 3δ); 3.87 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.61 (dd, J = 8 and 6 Hz, 1H : CH at position 3α); 4.81 (mt, 1H, CH at position 2α); 4.90 (dd, J = 10 and 1.5 Hz, 1H : 5 CH at position 1α); 5.10 (dd, J = 12 and 4 Hz, 1H : CH at position 4α); 5.41 (broad d, J = 6 Hz, 1H : CH at position 5α); 5.49 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.90 (split q, J = 7 and 1.5 Hz, 1H : CH at position 1β); 6.30 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.56 (d, J = 10 Hz, 1H : CONH at position 2); 6.87 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6α); from 7.40 to 7.50 (mt, 3H : aromatic H at the para and meta positions of the phenyl); 7.48 (dd, J = 8.5 and 1.5 Hz, 1H : 1' H₄); 7.56 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 8.03 (dd, J = 4 and 1.5 Hz, 1H : 1' H₆); from 8.35 to 8.45 (mt, 3H : aromatic H at the ortho position of the phenyl and CONH at position 1); 8.44 (s, 1H : CH=N); 8.70 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.66 (s, 1H : OH).

Example 30

By carrying out the procedure as in Example 22 but starting with 10 cm³ of dimethylformamide, 2 g of 5δ-dimethylaminomethylenepristinamycin I_A, 0.59 g of 3-aminobenzamidine hydrochloride and 0.47 g of sodium bicarbonate and after 4 hours at 60°C, a residue which is chromatographed on 200 g of silica [eluent:

dichloromethane/methanol 96/4 by volume] to give 1.06 g of a solid is obtained after cooling, addition of 50 cm³ of distilled water and 40 cm³ of ethyl acetate to the reaction mixture, washing of the aqueous phase with
 5 twice 40 cm³ of ethyl acetate, decantation of the organic phase which is dried over magnesium sulphate, filtered and concentrated to dryness at 40°C under reduced pressure (2.7 kPa). The solid is purified by HPLC on 450 g of 10 µm C₈ silica [eluent: water-
 10 acetonitrile 65/35 by volume containing 0.1% trifluoroacetic acid], the fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the aqueous phase adjusted to pH 7-8 with water saturated with sodium bicarbonate. The
 15 precipitate formed is filtered, washed with diisopropyl ether, dried at 40°C under reduced pressure (90 Pa) to give 0.31 g of 2''-(3-aminophenyl)pyrimido[4,5-5γ,5δ]pristinamycin I_E in the form of a pale-yellow solid melting at 212°C.

20 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.43 (dd, J = 17 and 6 Hz, 1H : 1H of CH₂ at
 25 position 5β); from 1.50 to 1.75 (mt : the 2H corresponding to the other H of CH₂ at position 3γ and to 1H of CH₂ at position 2β); 1.76 (mt, 1H : the other H of CH₂ at position 2β); 2.08 (mt, 1H : the other H of

CH₂ at position 3β); 2.69 (s, 6H : ArN(CH₃)₂); 2.94 (dd, J = 12.5 and 4.5 Hz, 1H : 1H of CH₂ at position 4β); 3.10 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5β); from 3.15 to 3.35 (mt, 2H : 1H of CH₂ at position 5 3δ and the other H of CH₂ at position 4β); 3.28 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of CH₂ at position 3δ); 3.76 (broad s, 2H : ArNH₂); 3.88 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.63 (dd, J = 8 and 6 Hz, 1H : CH at position 3α); 4.82 (mt, 1H : CH at position 10 2α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.11 (dd, J = 12.5 and 4.5 Hz, 1H : CH at position 4α); 5.41 (broad d, J = 6 Hz, 1H : CH at position 5α); 5.49 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.66 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.90 15 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.31 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.55 (d, J = 10 Hz, 1H : CONH at position 2); 6.80 (dd, J = 8 and 1.5 Hz, 1H : aromatic H at position 4 of 3-aminophenyl); 6.85 (d, J = 8 Hz, 2H : aromatic H at 20 position 4δ); from 7.20 to 7.40 (mt : the 6H corresponding to the 5 aromatic H at position 6α and to the aromatic H at position 5 of 3-aminophenyl); 7.49 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.55 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.75 (broad s, 1H : aromatic H at 25 position 2 of 3-aminophenyl); 7.82 (broad d, 1H : aromatic H at position 6 of 3-aminophenyl); 8.03 (dd, J = 4 and 1.5 Hz, 1H : 1' H₆); 8.40 (d, J = 10 Hz, 1H : CONH at position 1); 8.42 (s, 1H : CH=N); 8.70 (d, J =

8.5 Hz, 1H : CONH at position 6); 11.66 (s, 1H : OH).

Example 31

By carrying out the procedure as in Example 22 but starting with 45 cm³ of dimethylformamide, 5 g of 5 5δ-dimethylaminomethylenepristinamycin I_B, 0.64 g of S-methylisothiouronium sulphate and 0.77 g of sodium bicarbonate and after 18 hours at 60°C, 3.16 g of a residue which is chromatographed on 250 g of silica [eluent: dichloromethane/methanol 95/5 by volume] to 10 give 1.2 g of a solid are obtained after cooling, addition of 200 cm³ of distilled water and 150 cm³ of ethyl acetate to the reaction mixture, washing of the aqueous phase with twice 150 cm³ of ethyl acetate, decantation of the organic phase which is washed with 15 250 cm³ of distilled water, dried over magnesium sulphate, filtered and concentrated to dryness at 40°C under reduced pressure (2.7 kPa). The solid is purified by HPLC on 450 g of 10 μm C₈ silica [eluent: water-acetonitrile 65/35 by volume containing 0.1% 20 trifluoroacetic acid], the fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa), the aqueous phase adjusted to pH 7-8 with water saturated with sodium bicarbonate and extracted with twice 100 cm³ of dichloromethane. The organic phase 25 is decanted off, dried over magnesium sulphate, filtered and then concentrated to dryness and then dried at 40°C under reduced pressure (90 Pa) to give 0.45 g of 2"-methylthioprimido[4,5-5γ,5δ] (4ζ-

methylamino) (4ζ-dedimethylamino)pristinamycin I_E in the form of a pale-yellow solid melting at 282°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.20
 5 to 1.40 (mt, 3H : 1H of CH₂ at position 3β - 1H of CH₂
 at position 3γ and 1H of CH₂ at position 5β); 1.32 (d,
 J = 7 Hz, 3H : CH₃ at position 1γ); 1.58 (mt, 1H : the
 other H of CH₂ at position 3γ); from 1.60 to 1.85 (mt :
 the 2H corresponding to CH₂ at position 2β); Hz2.06 (mt,
 10 1H : the other H of CH₂ at position 3β); 2.64 (s, 3H :
 ArSCH₃); 2.77 (s, 3H : ArNCH₃); 2.89 (dd, J = 12 and
 4.5 Hz, 1H : 1H of CH₂ at position 4β); 2.97 (d, J =
 17.5 Hz, 1H : the other H of CH₂ at position 5β); 3.20
 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β);
 15 from 3.20 to 3.35 (mt, 1H : 1H of CH₂ at position 3δ);
 3.25 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂
 at position 3δ); from 3.65 to 3.85 (broad unresolved
 complex, 1H : ArNH); 3.75 (d, J = 17 Hz, 1H : 1H of CH₂
 at position 5ε); 4.61 (dd, J = 8 and 5.5 Hz, 1H : CH at
 20 position 3α); 4.80 (mt, 1H : CH at position 2α); 4.88
 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.03 (dd,
 J = 12 and 4.5 Hz, 1H : CH at position 4α); 5.32 (broad
 d, J = 6 Hz, 1H : CH at position 5α); 5.39 (d, J =
 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.65 (d,
 25 J = 8.5 Hz, 1H : CH at position 6α); 5.88 (broad q, J =
 7 Hz, 1H : CH at position 1β); 6.18 (d, J = 8 Hz, 2H :
 aromatic H at position 4ε); 6.51 (d, J = 10 Hz, 1H :
 CONH at position 2); 6.78 (d, J = 8 Hz, 2H : aromatic H

09643197-082200

at position 4δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6α); 7.46 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.50 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.94 (broad d, J = 4 Hz, 1H : 1' H₆); 8.17 (s, 1H : CH=N);
 5 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.67 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.62 (s, 1H : OH).

Example 32

97 mg of 2"-(1-pyrrolidinylpyrimido[4,5-
 10 5γ,5δ]pristinamycin I_E, 5.4 mg of ethylene glycol, 65 mg of acetic acid and 20 mg of tetra-n-butylammonium periodate are introduced into a round-bottomed flask containing 0.4 cm³ of dichloromethane. The mixture is stirred for 4 hours at room temperature and then the
 15 reaction mixture is taken up in 8 cm³ of water and 4 cm³ of dichloromethane. The organic phase is decanted off, washed with 4 times 8 cm³ of distilled water, decanted off, dried and then concentrated to dryness at 40°C under reduced pressure (2.7 kPa) to give 70 mg of a
 20 solid which is purified by flash chromatography with 210 mg of an identical product obtained from a similar preparation on 15 g of silica [eluent: dichloromethane/methanol 97/3 by volume] to give after concentration to dryness of the fractions, trituration
 25 in 4 cm³ of diethyl ether, filtration and drying at 20°C under reduced pressure (90 Pa), 98 mg of 2"-(1-pyrrolidinyl)pyrimido[4,5-5γ,5δ](4ζ-methylamino)-(4ζ-dedimethylamino)pristinamycin I_E in the form of a

002280" 26 FEB 1960

cream-coloured powder melting at 222°C.

^1H NMR spectrum (400 MHz, CDCl_3 , δ in ppm):

0.92 (t, $J = 7.5$ Hz, 3H : CH_3 at position 2γ); from 1.20 to 1.40 (mt, 2H : 1H of CH_2 at position 3β and 1H of CH_2 at position 3γ); 1.31 (d, $J = 7$ Hz, 3H : CH_3 at position 1γ); 1.48 (dd, $J = 17$ and 6 Hz, 1H : 1H of CH_2 at position 5β); from 1.50 to 1.85 (mt : the 3H corresponding to the other H of CH_2 at position 3γ and to CH_2 at position 2β); 1.95 (mt, 4H : the 2 CH_2 of pyrrolidine); 2.04 (mt, 1H : the other H of CH_2 at position 3β); 2.62 (s, 3H : ArNCH_3); 2.91 (dd, $J = 12.5$ and 4.5 Hz, 1H : 1H of CH_2 at position 4β); 2.92 (d, $J = 17.5$ Hz, 1H : the other H of CH_2 at position 5β); from 3.15 to 3.35 (mt, 2H : the other H of CH_2 at position 4β and 1H of CH_2 at position 3δ); 3.22 (s, 3H : NCH_3); from 3.45 to 3.65 (mt, 5H : the other H of CH_2 at position 3δ and the 2 NCH_2 of pyrrolidine); 3.73 (d, $J = 17$ Hz, 1H : 1H of CH_2 at position 5ϵ); 4.60 (dd, $J = 6.5$ and 5.5 Hz, 1H : CH at position 3α); 4.78 (mt, 1H : CH at position 2α); 4.88 (broad d, $J = 10$ Hz, 1H : CH at position 1α); 5.14 (dd, $J = 12$ and 4.5 Hz, 1H : CH at position 4α); 5.29 (d, $J = 17$ Hz, 1H : the other H of CH_2 at position 5ϵ); 5.31 (unresolved complex, 1H : CH at position 5α); 5.64 (d, $J = 8.5$ Hz, 1H : CH at position 6α); 5.87 (broad q, $J = 7$ Hz, 1H : CH at position 1β); 6.28 (d, $J = 8$ Hz, 2H : aromatic H at position 4ϵ); 6.56 (d, $J = 9.5$ Hz, 1H : CONH at position 2); 6.82 (d, $J = 8$ Hz, 2H : aromatic H at

09643197-082200

position 4 δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6 α); 7.42 (limiting AB, 2H : 1' H₄ and 1' H₅); 7.90 (mt, 1H : 1' H₆); 7.98 (s, 1H : CH=N); 8.42 (d, J = 10 Hz, 1H : CONH at position 1); 8.62 (d, J = 5 8.5 Hz, 1H : CONH at position 6); 11.65 (s, 1H : OH).

Example 33

30 g of pristinamycin I_A, 2.42 g of 3-aminoacrolein and then 25.8 g of ammonium acetate are introduced into a three-necked flask containing 400 cm³ of methanol. The mixture is refluxed for 3 days and then diluted with 1 litre of distilled water. The precipitate obtained is filtered, dried and then chromatographed on 1 kg of silica (eluent: dichloromethane/methanol 98/2 by volume). The solid 15 obtained is purified by HPLC on 10 μ m C₈ silica (eluent: water-acetonitrile 70/30 containing 0.1% trifluoroacetic acid. The fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the aqueous phase adjusted to pH 8 with 20 3 cm³ of water saturated with sodium bicarbonate. The precipitate obtained is filtered, rinsed with 10 cm³ of distilled water and then 10 cm³ of diethyl ether to give after drying at 40°C under reduced pressure (90 Pa), 0.45 g of pyrido[2,3-5 γ ,5 δ]pristinamycin I_E in the form 25 of a white solid melting at around 170-180°C (dec.).

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm): 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂

at position 3 γ); 1.34 (d, $J = 7$ Hz, 3H : CH₃ at position 1 γ); from 1.55 to 1.85 (mt, 4H : the other H of CH₂ at position 3 γ - CH₂ at position 2 β and 1H of CH₂ at position 5 β); 2.04 (mt, 1H : the other H of CH₂ at position 3 β); 2.91 (s, 6H : ArN(CH₃)₂); 2.95 (dd, $J = 12$ and 5 Hz, 1H : 1H of CH₂ at position 4 β); 3.17 (t, $J = 12$ Hz, 1H : the other H of CH₂ at position 4 β); 3.24 (s, 3H : NCH₃); 3.30 (mt, 1H : 1H of CH₂ at position 3 δ); 3.43 (broad d, $J = 17$ Hz, 1H : the other H of CH₂ at position 5 β); 3.52 (mt, 1H : the other H of CH₂ at position 3 δ); 3.91 (d, $J = 17$ Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.58 (dd, $J = 7$ and 5.5 Hz, 1H : CH at position 3 α); 4.81 (mt, 1H : CH at position 2 α); 4.87 (dd, $J = 10$ and 1.5 Hz, 1H : CH at position 1 α); 5.13 (dd, $J = 12$ and 5 Hz, 1H : CH at position 4 α); 5.43 (mt, 1H : CH at position 5 α); 5.46 (d, $J = 17$ Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.65 (d, $J = 8.5$ Hz, 1H : CH at position 6 α); 5.87 (dq, $J = 7$ and 1.5 Hz, 1H : CH at position 1 β); 6.40 (d, $J = 8$ Hz, 2H : aromatic H at position 4 ϵ); 6.58 (d, $J = 9.5$ Hz, 1H : CONH at position 2); 6.85 (d, $J = 8$ Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.40 (mt : the 5 aromatic H at position 6 α); from 7.30 to 7.45 (mt, 1H : aromatic H at position β of N); 7.43 (d, $J = 8$ Hz, 1H : 1' H₄); 7.56 (dd, $J = 8$ and 4 Hz, 1H : 1' H₅); 7.61 (mt, 1H : aromatic H at position γ of N); 8.13 (mt, 1H : 1' H₆); 8.38 (d, $J = 4$ Hz, 1H : aromatic H at position α of N); 8.42 (d, $J = 10$ Hz, 1H : CONH at position 1); 8.69 (d,

002280" 16TEH960

J = 8.5 Hz, 1H : CONH at position 6); 11.59 (s, 1H : OH).

3-Aminoacrolein may be prepared according to R.P. Thummel & D.K. Kohli, J. Org. Chem., 42, 2742-2747 (1977).

Example 34

By carrying out the procedure as in Example 6 but starting with 11.4 g of 5 δ -methylenepristinamycin I_A in 200 cm³ of acetone, 3.8 g of 1-(2-oxopentyl)-pyridinium bromide, 10 g of ammonium acetate and heating for 3 hours under reflux, a solid is obtained which is chromatographed on 100 g of silica (eluent: acetonitrile) and then by HPLC on 450 g of 10 μ m C₈ silica (eluent: water-acetonitrile 70/30 by volume, containing 0.1% trifluoroacetic acid). The fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the pH of the aqueous phase adjusted to 8 by addition of water saturated with sodium bicarbonate. The precipitate is filtered, washed with 20 cm³ of distilled water and dried at 40°C under reduced pressure (90 Pa) to give 0.8 g of 2"-propylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E in the form of a white solid melting at 172°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); 0.98 (t, J = 7.5 Hz, 3H : CH₃ of propyl); from 1.20 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.58 (mt,

1H : the other H of CH₂ at position 3 γ); from 1.50 to
 1.90 (mt : the 3H corresponding to CH₂ at position 2 β
 and to 1H of CH₂ at position 5 β); 1.70 (mt, 2H : central
 CH₂ of propyl); 2.03 (mt, 1H : the other H of CH₂ at
 5 position 3 β); 2.68 (t, J = 8 Hz, 2H : ArCH₂ of propyl);
 2.84 (s, 6H : ArN(CH₃)₂); 2.97 (dd, J = 13 and 5.5 Hz,
 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.35 (mt,
 3H : the other H of CH₂ at position 5 β - the other H of
 CH₂ at position 4 β and 1H of CH₂ at position 3 δ); 3.21
 10 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at
 position 3 δ); 3.92 (d, J = 17 Hz, 1H : 1H of CH₂ at
 position 5 ϵ); 4.60 (dd, J = 8 and 5.5 Hz, 1H : CH at
 position 3 α); 4.79 (mt, 1H : CH at position 2 α); 4.87
 (dd, J = 10 and 1 Hz, 1H : CH at position 1 α); 5.28
 15 (dd, J = 10 and 5.5 Hz, 1H : CH at position 4 α); from
 5.35 to 5.50 (mt, 2H : CH at position 5 α and the other
 H of CH₂ at position 5 ϵ); 5.63 (d, J = 8 Hz, 1H : CH at
 position 6 α); 5.88 (split q, J = 7 and 1 Hz, 1H : CH at
 position 1 β); 6.36 (d, J = 8 Hz, 2H : aromatic H at
 20 position 4 ϵ); 6.58 (d, J = 9.5 Hz, 1H : CONH at
 position 2); 6.84 (d, J = 8 Hz, 2H : aromatic H at
 position 4 δ); 6.94 (d, J = 8 Hz, 1H : aromatic H at
 position β with respect to N); from 7.20 to 7.45 (mt :
 the 8H corresponding to the 5 aromatic H at position 6 α
 25 - to the aromatic H at position γ with respect to N -
 to 1' H₅ and to 1' H₄); 7.86 (dd, J = 4 and 1 Hz, 1H :
 1' H₆); 8.43 (d, J = 10 Hz, 1H : CONH at position 1);
 8.66 (d, J = 8 Hz, 1H : CONH at position 6); 11.64 (s,

1H : OH).

1-(2-Oxopentyl)pyridinium bromide may be prepared by analogy with 1-(2-oxopentyl)pyridinium iodide as described by R.P. SONI, J.P. SAXENA, J.

5 Indian Chem. Soc., 58, 885-887 (1981).

3.8 g of 1-bromo-2-pentanone and 9.2 cm³ of pyridine are introduced into a three-necked flask containing 25 cm³ of ethanol and then the mixture is heated for 3 hours under reflux. After concentrating to dryness at 40°C under reduced pressure (2.7 kPa), the residue is taken up in 200 cm³ of diisopropyl ether. After filtration, washing with 50 cm³ of diethyl ether, the precipitate is dried to give 3.8 g of a pale-yellow solid of 80% purity melting at 72°C and which is used as it is.

1-bromo-2-pentanone may be prepared according to H.J. HA, Synth. Commun., 24, 2557, (1994).

Example 35

By carrying out the procedure as in Example 6 but starting with 30 g of 5 δ -methylenepristinamycin I_A in 200 cm³ of acetone, 10 g of 1-(3-methyl-2-oxobutyl)-pyridinium bromide, 26.3 g of ammonium acetate and heating for 3 hours under reflux, 34 g of a solid are obtained, which solid is purified by 2 successive chromatographies on 1 kg of silica (eluent: methylene chloride-acetonitrile-water: 96/2/2 by volume) and then 700 g of silica (eluent: methylene chloride and then methylene chloride-methanol-acetonitrile gradient:

99/0.5/0.5 to 98/1/1 by volume). After 2
 recrystallizations from the methanol, 4.3 g of product
 are obtained of which 2 g are purified by HPLC on 450 g
 of 10 μ m C₈ silica (eluent: water-acetonitrile 70/30 by
 5 volume, containing 0.1% trifluoroacetic acid). The
 fractions are combined, the acetonitrile removed at
 40°C under reduced pressure (2.7 kPa) and the pH of the
 aqueous phase adjusted to 8 by addition of water
 saturated with sodium bicarbonate. The precipitate is
 10 filtered, washed with 20 cm³ of water and then with
 20 cm³ of diisopropyl ether. After recrystallization
 from 15 cm³ of methanol, filtration, washing with 10 cm³
 of methanol and 10 cm³ of diisopropyl ether and then
 drying at 40°C under reduced pressure (90 Pa), 0.75 g
 15 of 2"-isopropylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E is
 obtained in the form of white needles melting at 263°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.92 (t,
 J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.35
 (mt, 11H : 1H of CH₂ at position 3 β - 1H of CH₂ at
 20 position 3 γ - CH₃ at position 1 γ and the 2 CH₃ of
 isopropyl); 1.58 (mt, 1H : the other H of CH₂ at
 position 3 γ); 1.66 and 1.75 (2 mts, 1H each : CH₂ at
 position 2 β); 1.89 (mt : 1H corresponding to 1H of CH₂
 at position 5 β); 2.03 (mt, 1H : the other H of CH₂ at
 25 position 3 β); 2.85 (s, 6H : ArN(CH₃)₂); from 2.95 to
 3.05 (mt, 1H : ArCH of isopropyl); 2.99 (dd, J = 14 and
 6.5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to
 3.30 (mt, 3H : the other H of CH₂ at position 5 β - the

09643497-082200

other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.20 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at position 3δ); 3.93 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.60 (dd, J = 7.5 and 6 Hz, 1H : CH at position 3α); 4.79 (mt, 1H : CH at position 2α); 4.88 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.32 (dd, J = 9 and 6.5 Hz, 1H : CH at position 4α); from 5.40 to 5.50 (mt, 2H : CH at position 5α and the other H of CH₂ at position 5ε); 5.64 (d, J = 8 Hz, 1H : CH at position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.39 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.60 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4δ); 6.99 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.20 to 7.40 (mt : the 8H corresponding to the 5 aromatic H at position 6α - to the aromatic H at position γ with respect to N - to 1' H₅ and to 1' H₄); 7.85 (broad d, J = 4 Hz, 1H : 1' H₆); 8.44 (d, J = 10 Hz, 1H : CONH at position 1); 8.69 (d, J = 8 Hz, 1H : CONH at position 6); 11.66 (s, 1H : OH).

1-(3-Methyl-2-oxobutyl)pyridinium bromide may be prepared as described by J.P. SAXENA, J. Indian Chem. Soc., 68, 99-100 (1991).

Example 36

By carrying out the process as in Example 5 but starting with 1.5 litres of acetonitrile, 100 g of 5δ-methylenepristinamycin I_A, 27.1 g of 1-(3-chloro-2-oxopropyl)pyridinium chloride, 88 g of ammonium

acetate and 5 hours reflux, a solid is obtained which is purified by two successive chromatographies on 1.5 kg and 100 g of silica (eluent: methylene chloride-methanol 97/3 by volume). The fractions containing the expected product are concentrated to give a solid which is purified by HPLC on 450 g of 10 μ m C₈ silica (eluent: water-acetonitrile 70/30 by volume, containing 0.1% trifluoroacetic acid). The fractions are combined, the acetonitrile removed at 40°C under reduced pressure (2.7 kPa) and the pH of the aqueous phase adjusted to 8 by addition of water saturated with sodium bicarbonate. The aqueous phase is extracted with twice 50 cm³ of methylene chloride. The organic phases are pooled, dried over sodium sulphate, filtered, concentrated under reduced pressure (45°C, 2.7 kPa) and the solid obtained is taken up in 20 cm³ of diethyl ether. After filtration and then drying at 40°C under reduced pressure (90 Pa), 0.5 g of 2"-acetoxymethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E is obtained in the form of a cream-coloured solid melting at 206°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); 1.25 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.58 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.85 (mts : the 3H corresponding to the CH₂ at position 2 β and to 1H of CH₂ at position 5 β); 2.03 (mt, 1H : the other H of CH₂ at position 3 β); 2.14 (s, 3H :

OCOCH₃); Hz2.84 (s, 6H : ArN(CH₃)₂); 2.96 (dd, J = 13
 and 5.5 Hz, 1H : 1H of CH₂ at position 4β); 3.14 (d, J =
 16.5 Hz, 1H : the other H of CH₂ at position 5β); from
 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4β
 5 and 1H of CH₂ at position 3δ); 3.22 (s, 3H : NCH₃); 3.49
 (mt, 1H : the other H of CH₂ at position 3δ); 3.93 (d, J
 = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.60 (dd, J = 8
 and 5.5 Hz, 1H : CH at position 3α); 4.79 (mt, 1H : CH
 at position 2α); 4.88 (dd, J = 10 and 1 Hz, 1H : CH at
 10 position 1α); 5.07 and 5.18 (2d, J = 13 Hz, 1H each :
 ArCH₂OCO); from 5.15 to 5.25 (mt, 1H : CH at position
 4α); 5.40 (broad d, J = 5.5 Hz, 1H : CH at position
 5α); 5.45 (d, J = 17 Hz, 1H : the other H of CH₂ at
 position 5ε); 5.60 (d, J = 8 Hz, 1H : CH at position
 15 6α); 5.88 (split q, J Hz= 7 and 1 Hz, 1H : CH at
 position 1β); 6.34 (d, J = 8 Hz, 2H : aromatic H at
 position 4ε); 6.56 (d, J = 9.5 Hz, 1H : CONH at
 position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at
 position 4δ); 7.15 (d, J = 8 Hz, 1H : aromatic H at
 20 position β with respect to N); from 7.20 to 7.35 (mt :
 the 5H corresponding to aromatic H at position 6α);
 7.36 (d, J = 8 Hz, 1H : aromatic H at position γ with
 respect to N); 7.40 (mt, 2H : 1' H₅ and 1' H₄); 7.89
 (mt, 1H : 1' H₆); 8.40 (d, J = 10 Hz, 1H : CONH at
 25 position 1); 8.68 (d, J = 8 Hz, 1H : CONH at position
 6); 11.65 (s, 1H : OH).

Example 37

When carrying out the procedure as in Example

20 but starting with 40 cm³ of acetonitrile, 2 g of 2"-chloromethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E, 1.5 cm³ of cyclopropylamine and 0.34 g of potassium iodide, after refluxing for 24 hours 2.2 g of a foam are obtained, which foam is purified by two successive chromatographies on 60 g of silica (eluent: methylene chloride-methanol 95/5 by volume). The fractions are combined, dried over sodium sulphate, filtered and concentrated at 40°C under reduced pressure (2.7 kPa); the foam obtained is disintegrated in 30 cm³ of diethyl ether. After filtration and drying at 40°C under reduced pressure (90 Pa), 0.55 g of 2"-cyclopropylaminomethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E is obtained in the form of a yellow solid melting at 184°C.

¹H NMR spectrum (400 MHz, CDCl₃): from 0.35 to 0.50 (mt, 4H : CH₂CH₂ of cyclopropane); 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); 1.26 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.58 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.85 (mt : the 2H corresponding to the CH₂ at position 2 β); 1.78 (dd, J = 16 and 6.5 Hz, 1H : 1H of CH₂ at position 5 β); 2.03 (mt, 1H : the other H of CH₂ at position 3 β); 2.16 (mt, 1H : CH of cyclopropane); 2.86 (s, 6H : ArN(CH₃)₂); 2.97 (dd, J = 13.5 and 6 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4 β - the other H of CH₂ at position

002230 " 67 082200

5 β and 1H of CH₂ at position 3 δ); 3.22 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at position 3 δ); 3.88 (s, 2H : ArCH₂N); 3.94 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.60 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3 α); 4.79 (mt, 1H : CH at position 2 α); 4.88 (dd, J = 10 and 1 Hz, 1H : CH at position 1 α); 5.26 (dd, J = 10 and 6 Hz, 1H : CH at position 4 α); from 5.40 to 5.50 (mt, 2H : CH at position 5 α and the other H of CH₂ at position 5 ϵ); 5.62 (d, J = 8 Hz, 1H : CH at position 6 α); 5.88 (split q, J = 7 and 1 Hz, 1H : CH at position 1 β); 6.36 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.57 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); 7.10 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.20 to 7.35 (mt : the 6H corresponding to the 5 aromatic H at position 6 α and to the aromatic H at position γ with respect to N); 7.39 (limiting AB, 2H : 1' H₅ and 1' H₄); 7.87 (dd, J = 4 and 2 Hz, 1H : 1' H₆); 8.42 (d, J = 10 Hz, 1H : CONH at position 1); 8.67 (d, J = 8 Hz, 1H : CONH at position 6); 11.65 (unresolved complex 1H : OH).

Example 38

By carrying out the procedure as in Example 20 but starting with 1.5 g of 2"-chloromethyl-pyrido[2,3-5 γ ,5 δ]pristinamycin I_E in 30 cm³ of acetonitrile, 0.5 cm³ of diethylamine, 0.26 g of potassium iodide and after refluxing for 6 hours at 45°C, 1.35 g of product are obtained, which product is

002280-082200 09643197

purified by HPLC on 450 g of 10 μ m C₈ silica (eluent: water-acetonitrile 60/40 by volume, containing 0.1% trifluoroacetic acid). The fractions are combined and the acetonitrile removed at 40°C under reduced pressure (2.7 kPa). The aqueous phase is adjusted to pH 8 by addition of water saturated with sodium bicarbonate and then extracted with 300 cm³ of ethyl acetate. The organic phase is decanted off, dried over sodium sulphate, filtered and then concentrated under reduced pressure (45°C, 2.7 kPa) to give a solid which is crystallized from 30 cm³ of methanol. After filtration, washing with 50 cm³ of diisopropyl ether and drying at 40°C under reduced pressure (90 Pa), 0.4 g of 2"-N-diethylaminomethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E is obtained in the form of a cottony white solid melting at 264°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); 1.04 (t, J = 7 Hz, 6H : CH₃ of diethylamino); from 1.20 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.58 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.80 (mt : the 2H corresponding to CH₂ at position 2 β); 1.85 (dd, J = 16.5 and 5.5 Hz, 1H : 1H of CH₂ at position 5 β); 2.03 (mt, 1H : the other H of CH₂ at position 3 β); 2.55 (q, J = 7 Hz, 4H : the 2 NCH₂ of diethylamino); 2.85 (s, 6H : ArN(CH₃)₂); 2.98 (dd, J = 14 and 6 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15

05643197-082200

to 3.30 (mt, 3H : the other H of CH₂ at position 4β - the other H of CH₂ at position 5β and 1H of CH₂ at position 3δ); 3.21 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3δ); 3.66 (s, 2H : ArCH₂N);

5 3.94 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.60 (dd, J = 7.5 and 5.5 Hz, 1H : CH at position 3α); 4.79 (mt, 1H : CH at position 2α); 4.88 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.30 (dd, J = 9 and 6 Hz, 1H : CH at position 4α); 5.42 (broad d, J = 5.5 Hz, 1H : CH

10 at position 5α); 5.43 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.64 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.37 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.58 (d, J = 9.5 Hz, 1H : CONH at

15 position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt : the 9H corresponding to the 5 aromatic H at position 6α - to the aromatic H at position β with respect to N - to the aromatic H at position γ with respect to N - to 1' H₄

20 and to 1' H₅); 7.85 (broad d, J = 4 Hz, 1H : 1' H₆); 8.43 (d, J = 10 Hz, 1H : CONH at position 1); 8.68 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.65 (broad s, 1H : OH).

2"-Chloromethylpyrido[2,3-5γ,5δ]pristinamycin

25 I_E may be obtained as described in Example 10.

Example 39

By carrying out the procedure as in Example 6 but starting with 5.6 g of 5δ-methylenevirginiamycin S

002220 09643197

in 100 cm³ of acetonitrile, 1.15 g of 1-acetonyl-pyridinium chloride, 5.17 g of ammonium acetate and heating for 4 hours under reflux, a red oil is obtained which is chromatographed on 500 g of silica (eluent: 5 methylene chloride-methanol 98/2 by volume) to give 2.1 g of yellow foam. The latter is purified by HPLC on 450 g of 10 µm C₈ silica (eluent: water-acetonitrile 65/35 by volume, containing 0.1% trifluoroacetic acid). The fractions are combined, the acetonitrile removed at 10 40°C under reduced pressure (2.7 kPa), the pH of the aqueous phase adjusted to 7 by addition of water saturated with sodium bicarbonate; the precipitate obtained is filtered, washed with 20 cm³ of water and then 20 cm³ of diethyl ether. After filtration and 15 drying at 40°C under reduced pressure (90 Pa), 0.39 g of 2"-methylpyrido[2,3-5γ,5δ]-5γ-deoxyvirginiamycin S is obtained in the form of a white solid melting at 176°C.

5δ-methylenevirginiamycin S may be obtained 20 as described.

¹H NMR spectrum (400 MHz, CDCl₃): 0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); 1.27 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1γ); from 1.50 to 25 1.85 (mt : the 4H corresponding to the other H of CH₂ at position 3γ - to the CH₂ at position 2β and 1H of CH₂ at position 5β); 2.04 (mt, 1H : the other H of CH₂ at position 3β); 2.50 (s, 3H : ArCH₃); 3.07 (dd, J = 13 and

002280" 267E960

6 Hz, 1H : 1H of CH₂ at position 4β); from 3.15 to 3.35 (mt, 3H : the other H of CH₂ at position 4β - the other H of CH₂ at position 5β and 1H of CH₂ at position 3δ); 3.22 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of CH₂ at position 3δ); 3.92 (d, J = 17.5 Hz, 1H : 1H of CH₂ at position 5ε); 4.58 (dd, J = 8 and 6.5 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.87 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.34 (dd, J = 10 and 6 Hz, 1H : CH at position 4α); from 5.35 to 5.45 (mt, 2H : the other H of CH₂ at position 5ε and CH at position 5α); 5.64 (d, J = 8 Hz, 1H : CH at position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.56 (d, J = 9.5 Hz, 1H : CONH at position 2); from 6.95 to 7.40 (mt : the 13H corresponding to the 5 aromatic H at position 6α - to the 5 aromatic H at position 4β - to the aromatic H at position γ with respect to N - to 1' H₄ and to 1' H₅); 6.96 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); 7.81 (broad d, J = 4 Hz, 1H : 1' H₆); 8.42 (d, J = 10 Hz, 1H : CONH at position 1); 8.64 (d, J = 8 Hz, 1H : CONH at position 6); 11.65 (s, 1H : OH).

Example 40

By carrying out the procedure by analogy with Example 15 but starting with 4ε-chloro-5δ-methylene-pristinamycin I_A, 4ε-chloro-2''-(2-pyridyl)pyrido[2,3-5γ,5δ]pristinamycin I_E is obtained in the form of a white solid melting at 194°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.93 (t, J =

002280" 46FE4960

7.5 Hz, 3H : CH₃ at position 2γ); from 1.20 to 1.35 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.58 (mt, 1H : the other H of CH₂ at position 3γ); from 1.60 to 1.85 (mt, the 3H corresponding to the CH₂ at position 2β and to 1H of CH₂ at position 5β); 2.04 (mt, 1H : the other H of CH₂ at position 3β); 2.56 (s, 6H : ArN(CH₃)₂); 2.99 (dd, J = 13 and 5.5 Hz, 1H : 1H of CH₂ at position 4β); from 3.20 to 3.35 (mt, 2H : the other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.23 (s, 3H : NCH₃); 3.36 (d, J = 16.5 Hz, 1H : the other H of CH₂ at position 5β); 3.51 (mt, 1H : the other H₂H of CH₂ at position 3δ); 4.01 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.60 (dd, J = 7.5 and 6 Hz, 1H : CH at position 3α); 4.81 (mt, 1H : CH at position 2α); 4.91 (dd, J = 10 and 1 Hz, 1H : CH at position 1α); 5.26 (dd, J = 10 and 5.5 Hz, 1H : CH at position 4α); 5.46 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.53 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.63 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.89 (split q, J = 7 and 1 Hz, 1H : CH at position 1β); 6.47 (d, J = 8 Hz, 1H : aromatic H at position 4ε); 6.57 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.77 (dd, J = 8 and 2 Hz, 1H : aromatic H at position 4δ at the para position with respect to the Cl); 7.13 (d, J = 2 Hz, 1H : aromatic H at position 4δ at the ortho position with respect to the Cl); from 7.20 to 7.40 (mt : the 6H corresponding to the 5 aromatic H at

002280" 4674960

position 6 α and to H₅ of pyridine); 7.41 (broad d, J = 8 Hz, 1H : 1' H₄); 7.50 (d, J = 8 Hz, 1H : aromatic H at position γ with respect to N); 7.53 (dd, J = 8 and 4.5 Hz, 1H : 1' H₅); 7.74 (split t, J = 8 and 1.5 Hz, 1H : H₄ of pyridine); 7.90 (broad d, J = 4.5 Hz, 1H : 1' H₆); 8.24 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); 8.37 (d, J = 8 Hz, 1H : H₃ of pyridine); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.64 (d, J = 8.5 Hz, 1H : CONH at position 6); 8.67 (broad d, J = 4.5 Hz, 1H : H₆ of pyridine); 11.67 (s, 1H : OH).

Example 41

By carrying out the procedure by analogy with Example 18 but starting with 4 ϵ -chloro-5 δ -methylene-pristinamycin I_A, 4 ϵ -chloro-2''-(2-pyridyl)pyrido[2,3-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E is obtained in the form of a white solid melting at 204°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); 1.27 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.59 (mt, 1H : the other H of CH₂ at position 3 γ); 1.67 and 1.75 (2 mts, 1H each : CH₂ at position 2 β); 1.84 (dd, J = 16.5 and 6 Hz, 1H : 1H of CH₂ at position 5 β); 2.04 (mt, 1H : the other H of CH₂ at position 3 β); 2.53 (s, 3H : ArNCH₃); 2.94 (dd, J = 13.5 and 6 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.30 (mt, 2H : the other H

of CH₂ at position 4β and 1H of CH₂ at position 3δ);
 3.22 (s, 3H : NCH₃); 3.35 (d, J = 16.5 Hz, 1H : the
 other H of CH₂ at position 5β); 3.49 (mt, 1H : the other
 H of CH₂ at position 3δ); 4.00 (d, J = 17 Hz, 1H : 1H of
 5 CH₂ at position 5ε); 4.60 (dd, J = 8 and 7 Hz, 1H : CH
 at position 3α); 4.79 (mt, 1H : CH at position 2α);
 4.89 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.19
 (dd, J = 10 and 6 Hz, 1H : CH at position 4α); from
 5.45 to 5.55 (mt, 2H : CH at position 5α and the other
 10 H of CH₂ at position 5ε); 5.64 (d, J = 8.5 Hz, 1H : CH
 at position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at
 position 1β); 6.09 (d, J = 8 Hz, 1H : aromatic H at
 position 4ε); 6.57 (d, J = 9.5 Hz, 1H : CONH at
 position 2); 6.75 (broad d, J = 8 Hz, 1H : aromatic H
 15 at position 4δ at the para position with respect to the
 Cl); 6.95 (broad s, 1H : aromatic H at position 4δ at
 the ortho position with respect to the Cl); from 7.20
 to 7.40 (mt : the 6H corresponding to the 5 aromatic H
 at position 6α and to H₅ of pyridine); 7.41 (broad d,
 20 J = 8 Hz, 1H : 1' H₄); 7.48 (d, J = 8 Hz, 1H : aromatic
 H at position γ with respect to N); 7.51 (dd, J = 8 and
 4 Hz, 1H : 1' H₅); 7.77 (broad t, J = 8 Hz, 1H : H₄ of
 pyridine); 7.97 (broad d, J = 4 Hz, 1H : 1' H₆); 8.19
 (d, J = 8 Hz, 1H : aromatic H at position β with
 25 respect to N); from 8.35 to 8.45 (mt, 2H : H₃ of
 pyridine and CONH at position 1); 8.63 (d, J = 8.5 Hz,
 1H : CONH at position 6); 8.67 (broad d, J = 4.5 Hz, 1H
 : H₆ of pyridine); 11.67 (s, 1H : OH).

09643197-082200

Example 42

By carrying out the procedure by analogy with Example 7 but starting with 4 ϵ -chloro-5 δ -methylene-pristinamycin I_A, 4 ϵ -chloro-2"-ethylpyrido[2,3-

- 5 5 γ ,5 δ]pristinamycin I_E is obtained in the form of a white solid melting at 184°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.27 (t, J = 7.5 Hz, 3H : CH₃ of ethyl); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.59 (mt, 1H : the other H of CH₂ at position 3 γ); 1.67 and 1.75 (2 mts, 1H each : CH₂ at position 2 β); 1.90 (dd, J = 16 and 5.5 Hz, 1H : 1H of CH₂ at position 5 β); 2.04 (mt, 1H : the other H of CH₂ at position 3 β); 2.72 (s, 6H : ArN(CH₃)₂); 2.77 (mt, 2H : ArCH₂ of ethyl); 3.01 (dd, J = 14 and 7 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.25 (mt, 2H : the other H of CH₂ at position 4 β); 3.19 (s, 3H : NCH₃); from 3.25 to 3.35 (mt, 1H : 1H of CH₂ at position 3 δ); 3.33 (d, J = 16 Hz, 1H : the other H of CH₂ at position 5 β); 3.51 (mt, 1H : the other H of CH₂ at position 3 δ); 3.95 (d, J = 17.5 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.57 (broad t, J = 6.5 Hz, 1H : CH at position 3 α); 4.78 (mt, 1H : CH at position 2 α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.34 (mt, 1H : CH at position 4 α); 5.41 (d, J = 17.5 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.47 (broad d, J = 5.5 Hz, 1H : CH at position 5 α); 5.61 (d, J = 8.5 Hz,

002280" 46TE4960

1H : CH at position 6 α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.59 (mt, 2H : aromatic H at position 4 ϵ and CONH at position 2); 6.79 (broad d, J = 8 Hz, 1H : aromatic H at position 4 δ at the para position with respect to the Cl); 6.98 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); 7.06 (broad s, 1H : aromatic H at position 4 δ at the ortho position with respect to the Cl); from 7.20 to 7.40 (mt : the 8H corresponding to the 5 aromatic H at position 6 α - to the aromatic H at position γ with respect to N - to 1' H₄ and to 1' H₅); 7.82 (broad d, J = 4 Hz, 1H : 1' H₆); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.64 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.67 (s, 1H : OH).

15 Example 43

By carrying out the procedure by analogy with Example 17 but starting with 4 ϵ -chloro-5 δ -methylene-pristinamycin I_A, 4 ϵ -chloro-2"-ethylpyrido[2,3-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E is obtained in the form of a white solid melting at 186°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.28 (t, J = 7.5 Hz, 3H : CH₃ of ethyl); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.58 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.85 (mt : the 2H corresponding to the CH₂ at position 2 β); 1.93

(dd, $J = 16$ and 6 Hz, $1H : 1H$ of CH_2 at position 5β);
 2.03 (mt, $1H : the other H$ of CH_2 at position 3β); 2.76
 (mt, $2H : ArCH_2$ of ethyl); 2.77 (s, $3H : ArNCH_3$); 2.96
 (dd, $J = 14$ and 6.5 Hz, $1H : 1H$ of CH_2 at position 4β);
 5 from 3.10 to 3.30 (mt, $2H : the other H$ of CH_2 at
 position 4β and $1H$ of CH_2 at position 3δ); 3.19 (s, $3H : NCH_3$); 3.30 (d, $J = 16$ Hz, $1H : the other H$ of CH_2 at
 position 5β); 3.50 (mt, $1H : the other H$ of CH_2 at
 position 3δ); 3.95 (d, $J = 17$ Hz, $1H : 1H$ of CH_2 at
 10 position 5ϵ); 4.21 (unresolved complex, $1H : ArNH$);
 4.60 (dd, $J = 7.5$ and 5.5 Hz, $1H : CH$ at position 3α);
 4.79 (mt, $1H : CH$ at position 2α); 4.88 (dd, $J = 10$ and
 1 Hz, $1H : CH$ at position 1α); 5.28 (dd, $J = 9$ and
 6.5 Hz, $1H : CH$ at position 4α); 5.42 (d, $J = 17$ Hz, $1H$
 15 : the other H of CH_2 at position 5ϵ); 5.46 (broad d, $J =$
 6 Hz, $1H : CH$ at position 5α); 5.63 (d, $J = 8$ Hz, $1H :$
 CH at position 6α); 5.89 (split q, $J = 7$ and 1 Hz, $1H :$
 CH at position 1β); 6.19 (d, $J = 8$ Hz, $1H : aromatic H$
 at position 4ϵ); 6.57 (d, $J = 9.5$ Hz, $1H : CONH$ at
 20 position 2); 6.77 (dd, $J = 8$ and 1.5 Hz, $1H : aromatic$
 H at position 4δ at the para position with respect to
 the Cl); 6.94 (d, $J = 1.5$ Hz, $1H : aromatic H$ at
 position 4δ at the para position with respect to the
 Cl); 6.98 (d, $J = 8$ Hz, $1H : aromatic H$ at position β
 25 with respect to N); from 7.20 to 7.45 (mt : the 6H
 corresponding to the 5 aromatic H at position 6α and to
 the aromatic H at position γ with respect to N); 7.37
 (limiting AB, $2H : 1' H_4$ and $1' H_5$); 7.84 (dd, $J = 4$ and

002230" 4574960

1.5 Hz, 1H : 1' H₆); 8.40 (d, J = 10 Hz, 1H : CONH at position 1); 8.67 (d, J = 8 Hz, 1H : CONH at position 6); 11.66 (s, 1H : OH).

Example 44

5 By carrying out the procedure by analogy with Example 6 but starting with 4ε-chloro-5δ-methylene-pristinamycin I_A, 4ε-chloro-2"-methylpyrido[2,3-5γ,5δ]pristinamycin I_E is obtained in the form of a yellow powder melting at 210°C.

10 ¹H NMR spectrum (400 MHz, CDCl₃): 0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.20 to 1.40 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.29 (d, J = 7 Hz, 3H : CH₃ at position 1γ); from 1.50 to 1.80 (mt : the 3H corresponding to the other H
15 of CH₂ at position 3γ and to CH₂ at position 2β); 1.81 (dd, J = 16 and 5.5 Hz, 1H : 1H of CH₂ at position 5β); 2.04 (mt, 1H : the other H of CH₂ at position 3β); 2.48 (s, 3H : ArCH₃); 2.74 (s, 6H : ArN(CH₃)₂); 3.02 (dd, J = 14 and 6.5 Hz, 1H : 1H of CH₂ at position 4β); from 3.15
20 to 3.30 (mt, 2H : the other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.20 (s, 3H : NCH₃); 3.28 (d, J = 16 Hz, 1H : the other H of CH₂ at position 5β); 3.51 (mt, 1H : the other H of CH₂ at position 3δ); 3.96 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.59 (dd, J =
25 7.5 and 7 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.90 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.31 (dd, J = 9 and 6.5 Hz, 1H : CH at position 4α); 5.40 (d, J = 17 Hz, 1H : the other H of

09643497-082200

CH₂ at position 5ε); 5.47 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.61 (d, J = 8 Hz, 1H : CH at position 6α); 5.89 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.45 (d, J = 8 Hz, 1H : aromatic H at position 4ε);

5 6.59 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.80 (broad d, J = 8 Hz, 1H : aromatic H at position 4δ at the para position with respect to the Cl); 6.97 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); 7.10 (broad s, 1H : aromatic H at position 4δ at the

10 ortho position with respect to the Cl); from 7.20 to 7.35 (mt : the 6H corresponding to the 5 aromatic H at position 6α and to the aromatic H at position γ with respect to N); 7.37 (broad d, J = 8 Hz, 1H : 1' H₄); 7.42 (dd, J = 8 and 4.5 Hz, 1H : 1' H₅); 7.84 (broad d, J = 4.5 Hz, 1H : 1' H₆);

15 8.37 (d, J = 10 Hz, 1H : CONH at position 1); 8.61 (d, J = 8 Hz, 1H : CONH at position 6); 11.68 (s, 1H : OH).

Example 45

4 g of 2"-hydroxymethylpyrido[2,3-

20 5γ,5δ]pristinamycin I_E and 0.48 g of selenium oxide are introduced into a three-necked flask containing 70 cm³ of dioxane and the mixture is refluxed for 1 hour. The reaction mixture is filtered on Celite® and the filtrate concentrated under reduced pressure at 45°C

25 (2.7 kPa) to give 5.7 g of a chestnut-coloured foam which is purified by 2 successive chromatographies on 60 g of silica (eluent: methylene chloride-methanol 97/3 by volume). The fractions are combined and

concentrated under reduced pressure at 45°C (2.7 kPa).
 The solid obtained is stirred in 30 cm³ of diethyl
 ether, filtered and dried at 40°C under reduced
 pressure (90 Pa) to give 0.76 g of 2"-formylpyrido[2,3-
 5 5 γ ,5 δ]pristinamycin I_E in the form of a white solid
 melting at 202°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.92 (t, J =
 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.35 (mt,
 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position
 10 3 γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); from
 1.50 to 1.75 (mt : the 3H corresponding to the other H
 of CH₂ at position 3 γ - to 1H of CH₂ at position 2 β and
 to 1H of CH₂ at position 5 β); 1.74 (mt, 1H : the other H
 of CH₂ at position 2 β); 2.05 (mt, 1H : the other H of
 15 CH₂ at position 3 β); 2.79 (s, 6H : ArN(CH₃)₂); 2.95 (dd,
 J = 13 and 5 Hz, 1H : 1H of CH₂ at position 4 β); from
 3.15 to 3.30 (mt, 3H : the other H of CH₂ at position 4 β
 - the other H of CH₂ at position 5 β and 1H of CH₂ at
 position 3 δ); 3.26 (s, 3H : NCH₃); 3.50 (mt, 1H : the
 20 other H of CH₂ at position 3 δ); 3.97 (d, J = 18 Hz, 1H :
 1H of CH₂ at position 5 ϵ); 4.62 (dd, J = 7.5 and 6 Hz,
 1H : CH at position 3 α); 4.81 (mt, 1H : CH at position
 2 α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1 α);
 5.14 (dd, J = 11 and 5 Hz, 1H : CH at position 4 α);
 25 5.44 (broad d, J = 5.5 Hz, 1H : CH at position 5 α);
 5.52 (d, J = 18 Hz, 1H : the other H of CH₂ at position
 5 ϵ); 5.62 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.88
 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.29 (d, J

002230" 2674960

= 8 Hz, 2H : aromatic H at position 4ε); 6.56 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.86 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt : the 5H corresponding to the aromatic H at position 6α);
 5 7.45 (broad d, J = 8 Hz, 1H : 1' H₄); from 7.45 to 7.55 (mt, 2H : 1' H₅ and aromatic H at position γ with respect to N); 7.77 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); 8.00 (broad d, J = 4 Hz, 1H : 1' H₆); 8.40 (d, J = 10 Hz, 1H : CONH at position
 10 1); 8.69 (d, J = 8.5 Hz, 1H : CONH at position 6); 9.97 (s, 1H : COH); 11.65 (s, 1H : OH).

2"-hydroxymethylpyrido[2,3-5γ,5δ]-

pristinamycin I_E may be obtained as described in

Example 11.

15 **Example 46**

1.7 g of 2"-formylpyrido[2,3-5γ,5δ]-
 pristinamycin I_E and 1.4 g of ammonium acetate are
 introduced into a three-necked flask containing 100 cm³
 of dioxane and the mixture is refluxed for 1 hour. The
 20 reaction mixture is concentrated under reduced pressure
 and then taken up in 100 cm³ of water and 100 cm³ of
 methylene chloride. After decantation, drying of the
 organic phase over sodium sulphate, filtration and
 concentration to dryness, 1.5 g of a solid is obtained
 25 which is chromatographed on 60 g of silica (eluent:
 methylene chloride-methanol 97/3 by volume). The
 fractions are combined and then concentrated under
 reduced pressure at 45°C (2.7 kPa). The solid obtained

002230" 2674960

is taken up in 30 cm³ of diethyl ether and then filtered and dried at 40°C under reduced pressure (90 Pa) to give 0.32 g of 2"-carbamoypyrido[2,3-5γ,5δ]-pristinamycin I_E in the form of an orange-coloured solid
5 melting at 226°C.

¹H NMR spectrum (400 MHz, CDCl₃): 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); 1.26 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.43 (dd, J = 16.5 and 5.5 Hz, 1H : 1H of CH₂ at position 5β); from 1.50 to 1.70 (mt : the 2H corresponding to the other H of CH₂ at position 3γ and to 1H of CH₂ at position 2β); 1.75 (mt, 1H : the other H of CH₂ at position 2β); 2.06 (mt, 1H : the other H of CH₂ at position 3β); 2.79 (s, 6H : ArN(CH₃)₂); 2.93 (dd, J = 12.5 and 4.5 Hz, 1H : 1H of CH₂ at position 4β); 3.08 (d, J = 16.5 Hz, 1H : the other H of CH₂ at position 5β); from 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.26 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at position 3δ); 3.94 (d, J = 17.5 Hz, 1H : 1H of CH₂ at position 5ε); 4.62 (dd, J = 8 and 6.5 Hz, 1H : CH at position 3α); 4.81 (mt, 1H : CH at position 2α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.09 (dd, J = 11.5 and 4.5 Hz, 1H : CH at position 4α); 5.39 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.48 (d, J = 5 Hz, 1H : 1H of CONH₂); 5.51 (d, J = 17.5 Hz, 1H : the other H of CH₂ at position 5ε); 5.60 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.88 (broad q,

002280" 46TE460

J = 7 Hz, 1H : CH at position 1 β); 6.28 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.57 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.87 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.40 (mt : the 5 5H corresponding to the aromatic H at position 6 α); 7.46 (broad d, J = 8 Hz, 1H : 1' H₄); from 7.50 to 7.60 (mt, 2H : 1' H₅ and aromatic H at position γ with respect to N); 7.78 (d, J = 5 Hz, 1H : the other H of CONH₂); 7.99 (mt, 1H : 1' H₆); 8.00 (d, J = 8 Hz, 1H : 10 aromatic H at position β with respect to N); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.67 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.67 (s, 1H : OH).

2"-formylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E may be obtained as described in Example 45.

15 **Example 47**

By carrying out the procedure as in Example 22 but starting with 40 cm³ of acetonitrile, 4.6 g of 5 δ -dimethylaminomethylenepristinamycin I_A, 0.38 g of acetamidine and heating for 12 hours at 60°C, a solid 20 which is chromatographed on 400 g of silica (eluent: methylene chloride-methanol 97/3 by volume) is obtained after concentrating the reaction mixture to dryness at 45°C (2.7 kPa). The fractions are pooled, dried over sodium sulphate, filtered and concentrated at 45°C 25 under reduced pressure (2.7 kPa). The solid obtained is crystallized from 10 cm³ of methanol and then filtered and dried at 40°C (90 Pa) to give 0.4 g of 2"-methylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E in the form of

0022280" 26 FEB 1960

white crystals melting at 265°C.

¹H NMR spectrum (400 MHz, CDCl₃ with addition of (CD₃)₂SO d₆) : 0.79 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.05 to 1.20 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.14 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.24 (dd, J = 17 and 5.5 Hz, 1H : 1H of CH₂ at position 5β); 1.46 (mt, 1H : the other H of CH₂ at position 3γ); 1.52 and 1.62 (2 mts, 1H each : CH₂ at position 2β); 1.95 (mt, 1H : the other H of CH₂ at position 3β); 2.51 (s, 3H : ArCH₃); 2.74 (s, 6H : ArN(CH₃)₂); from 2.75 to 2.85 (mt, 1H : 1H of CH₂ at position 4β); 2.83 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5β); from 3.05 to 3.20 (mt, 2H : the other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.13 (s, 3H : NCH₃); 3.37 (mt, 1H : the other H of CH₂ at position 3δ); 3.70 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.48 (dd, J = 8 and 6 Hz, 1H : CH at position 3α); 4.65 (mt, 1H : CH at position 2α); 4.75 (broad d, J = 10 Hz, 1H : CH at position 1α); 4.94 (dd, J = 11.5 and 5 Hz, 1H : CH at position 4α); 5.24 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.30 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.45 (d, J = 8 Hz, 1H : CH at position 6α); 5.72 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.20 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.54 (d, J = 9.5 Hz, 1H : CONH at position 2); 6.72 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.05 to 7.30 (mt : the 5H corresponding to the aromatic H at position 6α);

002280 "082200" 09643197

7.32 (broad d, $J = 8$ Hz, 1H : 1' H₄); 7.37 (dd, $J = 8$
and 4 Hz, 1H : 1' H₅); 7.81 (broad d, $J = 4$ Hz, 1H : 1'
H₆); 8.17 (s, 1H : CH=N); 8.22 (d, $J = 10$ Hz, 1H : CONH
at position 1); 8.56 (d, $J = 8$ Hz, 1H : CONH at
5 position 6); 11.52 (s, 1H : OH).

Example 48

By carrying out the procedure as in Example
22 but starting with 40 cm³ of dimethylformamide, 1.84 g
of 5 δ -dimethylaminomethylenepristinamycin I_A, 0.41 g of
10 2-pyrazinecarboxamidine hydrochloride and 1 cm³ of
diisopropylamine, the reaction mixture is heated for
12 hours at 65°C. 0.16 g of 2-pyrazinecarboxamidine
hydrochloride is added and the heating is continued for
an additional 24 hours. After treating and
15 concentrating the reaction mixture to dryness at 45°C
(2.7 kPa), 2.1 g of solid are obtained, which solid is
chromatographed on 100 g of silica (eluent: methylene
chloride-methanol 97/3 by volume). The fractions are
pooled, dried over sodium sulphate, filtered and
20 concentrated at 45°C under reduced pressure (2.7 kPa).
The solid obtained is crystallized from 10 cm³ of
methanol, filtered, washed with twice 5 cm³ of
diisopropyl ether and then dried at 40°C (90 Pa) to
give 0.49 g of 2''-(2-pyrazinyl)pyrimido[4,5-
25 5 γ ,5 δ]pristinamycin I_E in the form of yellow crystals
melting at 254°C.

¹H NMR spectrum (400 MHz, CDCl₃) : 0.93 (t, J
= 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.25 to 1.40

002280" 082200

(mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.31 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.51 (dd, J = 17 and 6 Hz, 1H : 1H of CH₂ at position 5β); from 1.55 to 1.65 (mt, 1H corresponding to the other H of CH₂ at position 3γ); 1.67 and 1.75 (2 mts, 1H each : CH₂ at position 2β); 2.08 (mt, 1H : the other H of CH₂ at position 3β); 2.64 (s, 6H : ArN(CH₃)₂); 2.94 (dd, J = 12 and 5 Hz, 1H : 1H of CH₂ at position 4β); 3.18 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5β); from 3.20 to 3.35 (mt, 1H : 1H of CH₂ at position 3δ and the other H of CH₂ at position 4β); 3.26 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of CH₂ at position 3δ); 3.90 (d, J = 17.5 Hz, 1H : 1H of CH₂ at position 5ε); 4.61 (dd, J = 8 and 6 Hz, 1H : CH at position 3α); 4.81 (mt, 1H : CH at position 2α); 4.90 (dd, J = 10 and 1 Hz, 1H : CH at position 1α); 5.12 (dd, J = 12 and 5 Hz, 1H : CH at position 4α); 5.45 (broad d, J = 6 Hz, 1H : CH at position 5α); 5.53 (d, J = 17.5 Hz, 1H : the other H of CH₂ at position 5ε); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.89 (split q, J = 7 and 1 Hz, 1H : CH at position 1β); 6.29 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.55 (d, J = 10 Hz, 1H : CONH at position 2); 6.87 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt : the 5H corresponding to the aromatic H at position 6α); 7.48 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.53 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 8.02 (broad d, J = 4 Hz, 1H : 1' H₆); 8.41 (d, J = 10 Hz, 1H : CONH at position 1);

09643197-082200

8.58 (s, 1H : CH=N); 8.67 (d, $J = 2$ Hz, 1H : H at position 5 of pyrazine); 8.74 (d, $J = 8.5$ Hz, 1H : CONH at position 6); 8.77 (dd, $J = 2$ and 1.5 Hz, 1H : H at position 6 of pyrazine); 9.68 (d, $J = 1.5$ Hz, 1H : H at position 3 of pyrazine); 11.65 (s, 1H : OH).

Example 49

By carrying out the procedure as in Example 22 but starting with 40 cm³ of dimethylformamide, 3 g of 5 δ -dimethylaminomethylenepristinamycin I_A, 0.74 g of 1H-pyrozolecarboxamidine hydrochloride and 2 cm³ of diisopropylethylamine, the reaction mixture is heated for 4 hours at 65°C. After treating and concentrating the reaction mixture to dryness at 45°C (2.7 kPa), 2.4 g of a solid is obtained which is chromatographed on 160 g of silica (eluent: methylene chloride-methanol 96/4 by volume). The fractions are combined, dried over sodium sulphate, filtered and concentrated at 45°C under reduced pressure (2.7 kPa). The foam obtained is crystallized from 10 cm³ of isopropanol. After filtration, washing and drying at 40°C (90 Pa), 0.41 g of 2''-(1-pyrazolyl)pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E is obtained in the form of yellow crystals melting at 197°C.

¹H NMR spectrum (400 MHz, CDCl₃) : 0.93 (t, $J = 7.5$ Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.35 (mt, 2H : 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ); 1.31 (d, $J = 7$ Hz, 3H : CH₃ at position 1 γ); 1.45 (dd, $J = 17$ and 6 Hz, 1H : 1H of CH₂ at

002280" 16Feb96

position 5 β); from 1.55 to 1.65 (mt, 1H corresponding to the other H of CH₂ at position 3 γ); 1.67 and 1.75 (2 mts, 1H each : CH₂ at position 2 β); 2.07 (mt, 1H : the other H of CH₂ at position 3 β); 2.67 (s, 6H :
 5 ArN(CH₃)₂); 2.93 (dd, J = 12 and 4.5 Hz, 1H : 1H of CH₂ at position 4 β); 3.10 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 β); from 3.15 to 3.30 (mt, 1H : 1H of CH₂ at position 3 δ and the other H of CH₂ at position 4 β); 3.27 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of
 10 CH₂ at position 3 δ); 3.84 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.62 (dd, J = 8 and 6 Hz, 1H : CH at position 3 α); 4.81 (mt, 1H : CH at position 2 α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1 α); 5.07 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4 α); 5.41 (broad
 15 d, J = 6 Hz, 1H : CH at position 5 α); 5.48 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.67 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.89 (broad q, J = 7 Hz, 1H : CH at position 1 β); 6.29 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.48 (broad d, J = 2 Hz, 1H
 20 : H at position 4 of pyrazole); 6.53 (d, J = 10 Hz, CONH at position 2); 6.87 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.40 (mt : the 5H corresponding to the aromatic H at position 6 α); 7.48 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.53 (dd, J = 8.5 and
 25 4 Hz, 1H : 1' H₅); 7.80 (broad s, 1H : H at position 3 of pyrazole); 8.00 (broad d, J = 4 Hz, 1H : 1' H₆); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.38 (s, 1H : CH=N); 8.54 (d, J = 2 Hz, 1H : H at position 5 of

002280" 6F4960

pyrazole); 8.71 (d, $J = 8.5$ Hz, 1H : CONH at position 6); 11.65 (s, 1H : OH).

Example 50

By carrying out the procedure as in Example 22 but starting with 40 cm³ of dimethylformamide, 1.84 g of 5 δ -dimethylaminomethylenepristinamycin I_A, 0.60 g of S-(2-morpholinoethyl)isothiuronium hydrochloride, 1 cm³ of diisopropylamine and heating overnight at 65°C, 1.5 g of a yellow solid which is purified by two successive chromatographies with 100 g and 200 g of silica respectively (eluent: methylene chloride-methanol 97/3 by volume) are obtained after treating and concentrating the reaction mixture to dryness at 45°C (2.7 kPa). The fractions are pooled, dried over sodium sulphate, filtered and concentrated at 45°C under reduced pressure (2.7 kPa). The solid obtained is taken up in 10 cm³ of diisopropyl ether. After filtration, washing and drying at 40°C (90 Pa), 0.51 g of 2''-(2-morpholinoethylthio)pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E is obtained in the form of an off-white solid melting at 187°C.

¹H NMR spectrum (400 MHz, CDCl₃) : 0.92 (t, $J = 7.5$ Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.40 (mt, 3H : 1H of CH₂ at position 3 β - 1H of CH₂ at position 3 γ and 1H of CH₂ at position 5 β); 1.31 (d, $J = 7$ Hz, 3H : CH₃ at position 1 γ); from 1.50 to 1.70 (mt : the 2H corresponding to the other H of CH₂ at position 3 γ and to 1H of CH₂ at position 2 β); 1.75 (mt, 1H : the

002290" 032000 09643197

other H of CH₂ at position 2β); 2.04 (mt, 1H : the other H of CH₂ at position 3β); 2.53 (unresolved complex, 4H : the 2 NCH₂ of morpholine); 2.69 (t, J = 7.5 Hz, 2H : NCH₂); from 2.80 to 2.95 (mt, 2H : H₂the other H of CH₂ at position 5β and 1H of CH₂ at position 4β); 2.90 (s, 6H : ArN(CH₃)₂); from 3.15 to 3.35 (mt, 4H : ArSCH₂ - the other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.27 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3δ); from 3.65 to 3.80 (mt, 5H : the 2 OCH₂ of morpholine and 1H of CH₂ at position 5ε); 4.60 (dd, J = 8 and 6 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.89 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.08 (dd, J = 11.5 and 5 Hz, 1H : CH at position 4α); 5.33 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.40 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.35 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.52 (d, J = 10 Hz, 1H : CONH at position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.15 to 7.40 (mt : the 5H corresponding to the aromatic H at position 6α); 7.45 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.49 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.92 (broad d, J = 4 Hz, 1H : H₂1' H₆); 8.16 (s, 1H : CH=N); 8.37 (d, J = 10 Hz, 1H : CONH at position 1); 8.70 (d, J = 8.5 Hz, 1H : CONH at position 6); 11.64 (s, 1H : OH).

S-(2-morpholinoethyl)isothiouronium

0064319-082200

dihydrochloride may be prepared according to DOHERTY Chem. Soc., 79, 5667-70, (1957) or CLINTON J. Am. Chem. Soc., 70, 950, (1948).

Example 51

5 By carrying out the procedure as in Example
22 but starting with 50 cm³ of dimethylformamide, 2 g of
5δ-dimethylaminomethylenepristinamycin I_A, 0.67 g of
S-(4-pyridylmethyl)isothiuronium hydrochloride, 1.5 cm³
of diisopropylamine and heating at 65°C for 48 hours, a
10 solid which is chromatographed on 40 g of silica
(eluent: methylene chloride-methanol 98/2 by volume)
and then HPLC on 450 g of 10 μm C₈ silica (eluent:
water-acetonitrile 72.5/27.5 by volume, containing 0.1%
trifluoroacetic acid) is obtained after treating and
15 concentrating the reaction mixture to dryness at 45°C
(2.7 kPa). The fractions are combined, the acetonitrile
removed at 40°C under reduced pressure (2.7 kPa) and
then the pH of the aqueous phase is adjusted to 7-8 by
addition of water saturated with sodium bicarbonate.
20 The precipitate obtained is filtered, dried at 40°C
under 90 Pa to give 0.22 g of 2''-(4-pyridylmethylthio)-
pyrimido[4,5-5γ,5δ]pristinamycin I_E in the form of a
white solid melting at 195°C.

¹H NMR spectrum (400 MHz, CDCl₃) : 0.91 (t, J
25 = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.20 to 1.40
(mt, 3H : 1H of CH₂ at position 3β - 1H of CH₂ at
position 3γ and 1H of CH₂ at position 5β); 1.31 (d, J =
7 Hz, 3H : CH₃ at position 1γ); from 1.50 to 1.75 (mt :

002280" 26FEH960

the 2H corresponding to 1H of CH₂ at position 2β and the other H of CH₂ at position 3γ); 1.74 (mt, 1H : the other H of CH₂ at position 2β); 2.05 (mt, 1H : the other H of CH₂ at position 3β); 2.83 (s, 6H : ArN(CH₃)₂); from 2.90 to 3.00 (mt, 2H : 1H of CH₂ at position 4β and the other H of CH₂ at position 5β); from 3.15 to 3.30 (mt, 2H : 1H of CH₂ at position 3δ and the other H of CH₂ at position 4β); 3.26 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3δ); 3.76 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.27 and 4.39 (2 d, J = 15 Hz, 1H each : ArSCH₂Ar); 4.61 (dd, J = 7.5 and 5.5 Hz, 1H : CH at position 3α); 4.79 (mt, 1H : CH at position 2α); 4.87 (broad d, J = 10 Hz, 1H : CH at position 1α); 5.07 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4α); 5.33 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.39 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.64 (d, J = 8 Hz, 1H : CH at position 6α); 5.87 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.33 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.53 (d, J = 10 Hz, 1H : CONH at position 2); 6.84 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt : the 7H corresponding to aromatic H at position 6α and to H at position β of pyridine); 7.45 (broad d, J = 8.5 Hz, 1H : 1' H₄); 7.48 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.93 (broad d, J = 4 Hz, 1H : 1' H₆); 8.18 (s, 1H : CH=N); 8.36 (d, J = 10 Hz, 1H : CONH at position 1); 8.52 (d, J = 6 Hz, 2H : H at position α of pyridine); 8.72 (d, J = 8 Hz, 1H : CONH at position 6); 11.63 (s, 1H : OH).

Example 52

25 cm³ of water, 1.1 g of sodium metaperiodate and then 21 mg of ruthenium trichloride are introduced into a three-necked flask containing 100 cm³ of acetonitrile and 5 g of 2"-methylsulphonylpyrimido[4,5- γ ,5 δ]pristinamycin I_E and the mixture is kept stirring for 12 hours. An additional 0.55 g of sodium periodate is again added and the mixture is kept stirring for 4 hours. 25 cm³ of water, 1.25 g of sodium thiosulphate and then 250 cm³ of methylene chloride and 150 cm³ of water are added to the reaction mixture. The organic phase is decanted off, dried over magnesium sulphate, filtered and concentrated to dryness at 40°C under reduced pressure (2.7 kPa). The solid obtained is disintegrated in diethyl ether to give 3.57 g of a solid which is purified by 2 flash chromatographies on 250 g and 70 g of silica respectively (eluent: methylene chloride-methanol 95/5 and then 97/3 by volume). The fractions are pooled, dried over magnesium sulphate, filtered and concentrated at 45°C under reduced pressure (2.7 kPa) to give after drying at 40°C (90 Pa) 0.60 g of 2"-methylsulphonylpyrimido[4,5- γ ,5 δ](4 ζ -methylamino)-(4 ζ -dedimethylamino)pristinamycin I_E.

25 ¹H NMR spectrum (400 MHz, CDCl₃) : 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.20 to 1.40 (mt, 3H : 1H of CH₂ at position 3 β - 1H of CH₂ at position 3 γ and 1H of CH₂ at position 5 β); 1.31 (d, J =

7 Hz, 3H : CH₃ at position 1γ); from 1.50 to 1.70 (mt : the 2H corresponding to 1H of CH₂ at position 2β and the other H of CH₂ at position 3γ); 1.74 (mt, 1H : the other H of CH₂ at position 2β); 2.07 (mt, 1H : the other H of CH₂ at position 3β); 2.82 (s, 3H : ArNCH₃); 2.88 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.10 (d, J = 18 Hz, 1H : the other H of CH₂ at position 5β); 3.16 (t, J = 12 Hz, 1H : the other H of CH₂ at position Hz4β); from 3.20 to 3.30 (mt, 1H : 1H of CH₂ at position 3δ); 3.25 (s, 3H : NCH₃); 3.33 (s, 3H : SO₂CH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3γ); 3.82 (d, J = 17.5 Hz, 1H : 1H of CH₂ at position 5ε); 4.12 (unresolved complex, 1H : ARNH); 4.60 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.90 (dd, J = 10 and 1 Hz, 1H : CH at position 1α); 4.97 (dd, J = 12 and 4 Hz, 1H : CH at position Hz4α); 5.41 (broad d, J = 6.5 Hz, 1H : CH at position 5α); 5.55 (d, J = 17.5 Hz, 1H : the other H of CH₂ at position Hz5ε); 5.65 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.87 (split q, J = 7 and 1 Hz, 1H : CH at position 1β); 6.05 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.53 (d, J = 10 Hz, 1H : CONH at position 2); 6.72 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.15 to 7.40 (mt : the 5H corresponding to the aromatic H at position 6α); 7.49 (dd, J = 8.5 and 1.5 Hz, 1H : 1' H₄); 7.56 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 8.00 (dd, J = 4 and 1.5 Hz, 1H : 1' H₆); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.50 (s, 1H : CH=N);

002280" 1644960

8.73 (d, $J = 8.5$ Hz, 1H : CONH at position 6); 11.63 (s, 1H : OH).

2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E may be obtained as described in

5 Example 24.

Example 53

0.146 ml of 2-diethylaminoethanethiol and 47 mg of sodium hydride are added to a three-necked flask containing 10 cm³ of dimethylformamide followed,
10 dropwise, by 1 g of potassium salt of 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E in 10 cm³ of dimethylformamide. The mixture is kept stirring for one hour at 20°C. The reaction mixture is poured over 100 cm³ of water and 10 cm³ of 0.1 N hydrochloric acid
15 are added to pH 7 and then 40 cm³ of methylene chloride. The aqueous phase is decanted off and extracted with 4 times 40 cm³ of methylene chloride. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated under reduced pressure. The solid
20 obtained is disintegrated in ether to give, after filtration, 0.64 g of a solid which is purified by flash chromatography (eluent: methylene chloride-methanol 97/3 by volume). The fractions are pooled, dried over magnesium sulphate, filtered and
25 concentrated at 45°C under reduced pressure (2.7 kPa) to give after drying at 40°C (90 Pa) 0.23 g of 2"-diethylaminoethylthiopyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E.

002280 46TE4960 09643197 082200

¹H NMR spectrum (400 MHz, CDCl₃) : 0.90 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); 1.06 (unresolved complex, 6H : the 2 CH₃ of diethylamine); from 1.20 to 1.35 (mt, 3H : 1H of CH₂ at position 3β - 1H of CH₂ at position 3γ and 1H of CH₂ at position 5β); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1γ); from 1.50 to 1.65 (mt : the 1H corresponding to the other H of CH₂ at position 3γ); 1.65 and 1.74 (2 mts, 1H each : CH₂ at position 2β); 2.05 (mt, 1H : the other H of CH₂ at position 3β); 2.58 (unresolved complex, 4H : the 2 NCH₂ of diethylamine); 2.79 (mt, 2H : NCH₂); from 2.85 to 3.00 (mt, 2H : 1H of CH₂ at position 4β and the other H of CH₂ at position 5β); 2.88 (s, 6H : ArN(CH₃)₂); from 3.10 to 3.30 (mt, 4H : the other H of CH₂ at position 4β - 1H of CH₂ at position 3δ and ArSCH₂); 3.26 (s, 3H : NCH₃); 3.50 (mt, 1H : the other H of CH₂ at position 3δ); 3.76 (d, J = 17.5 Hz, 1H : 1H of CH₂ at position 5ε); 4.60 (dd, J = 7.5 and 5.5 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); 4.89 (dd, J = 10 and 1 Hz, 1H : CH at position 1α); 5.07 (dd, J = 12 and 4.5 Hz, 1H : CH at position 4α); 5.33 (broad d, J = 5.5 Hz, 1H : CH at position 5α); 5.38 (d, J = 17.5 Hz, 1H : the other H of CH₂ at position 5ε); 5.65 (d, J = 8 Hz, 1H : CH at position 6α); 5.88 (split q, J = 7 and 1 Hz, 1H : CH at position 1β); 6.34 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.53 (d, J = 10 Hz, 1H : CONH at position 2); 6.85 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.20 to 7.40 (mt :

00643197 082200

the 5H corresponding to the aromatic H at position 6 α); 7.46 (dd, J = 8.5 and 1.5 Hz, 1H : 1' H₄); 7.49 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.92 (dd, J = 4 and 1.5 Hz, 1H : 1' H₆); 8.15 (s, 1H : CH=N); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.68 (d, J = 8 Hz, 1H : CONH at position 6); 11.64 (unresolved complex, 1H : OH).

The potassium salt of 2"-methylsulphonyl-pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E may be prepared in the following manner:

10 1.4 g of potassium bicarbonate are added to a round-bottomed flask placed under argon containing 150 cm³ of acetone and 10 g of 2"-methylsulphonyl-pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E and the mixture is kept stirring overnight. The cream-coloured precipitate
15 is filtered, washed several times with acetone and with diethyl ether and then filtered, dried under reduced pressure to give 7.4 g of potassium salt of 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E which is used as it is.

20 The 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E may be obtained as described in Example 24.

Example 54

 3.7 g of potassium salt of 2"-methyl-
25 sulphonylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E and 2.2 cm³ of an 8 M solution of methylamine in ethanol are added to an autoclave containing 37 cm³ of dimethylformamide and the mixture is heated for 8 hours at 80°C. The

09643197-082200

reaction mixture is concentrated to dryness at 50°C under reduced pressure (2.7 kPa) to give 4.1 g of an orange-coloured residue which is taken up in 20 cm³ of water and 15 cm³ of ethyl acetate. The organic phase is decanted off, washed with twice 10 cm³ of water, dried over magnesium sulphate, filtered and concentrated to dryness at 35°C under reduced pressure (2.7 kPa). 0.4 g of a beige solid is thus obtained which is purified by flash chromatography on 40 g of silica (eluent: methylene chloride-methanol 96/4 by volume). The fractions are combined, dried over magnesium sulphate, filtered and concentrated at 45°C under reduced pressure (2.7 kPa) to give 0.16 g of a solid which is crystallized from 3.2 cm³ of an acetonitrile-water mixture (50/50 by volume). After filtration and then drying at 40°C (90 Pa), 0.13 g of 2"-methylamino-pyrimido[4,5-5γ,5δ]pristinamycin I_E is obtained in the form of beige crystals melting at 210-220°C.

¹H NMR spectrum (400 MHz, CDCl₃) : 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.15 to 1.35 (mt, 3H: 1H of CH₂ at position 3β - 1H of CH₂ at position 3γ and 1H of CH₂ at position 5β); 1.30 (d, J = 7 Hz, 3H : CH₃ at position 1γ); from 1.50 to 1.70 (mt : the 2H corresponding to the other H of CH₂ at position 3γ and to 1H of CH₂ at position 2β); 1.74 (mt, 1H : the other H of CH₂ at position 2β); 2.04 (mt, 1H : the other H of CH₂ at position 3β); from 2.80 to 3.00 (mt, 2H : 1H of CH₂ at position 4β and the other H of CH₂ at position

00643197 082200

5β); 2.88 (s, 6H : ArN(CH₃)₂); 2.97 (d, J = 5 Hz, 3H : ArNCH₃); from 3.15 to 3.30 (mt, 2H : the other H of CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.25 (s, 3H : NCH₃); 3.48 (mt, 1H : the other H of CH₂ at position 3δ); 3.72 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5ε); 4.60 (dd, J = 8 and 7 Hz, 1H : CH at position 3α); 4.80 (mt, 1H : CH at position 2α); from 4.85 to 4.95 (mt, 2H : CH at position 1α and ArNH); 5.10 (dd, J = 10.5 and 4 Hz, 1H : CH at position 4α); 5.30 (mt, 1H : CH at position 5α); 5.31 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε); 5.64 (d, J = 8 Hz, 1H : CH at position 6α); 5.88 (broad q, J = 7 Hz, 1H : CH at position H_z1β); 6.40 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.54 (d, J = 10 Hz, 1H : CONH at position 2); 6.87 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.15 to 7.40 (mt : the 5H corresponding to the aromatic H at position 6α); 7.44 (limiting AB, 2H : 1' H₄ and 1' H₅); 7.91 (broad d, J = 4 Hz, 1H : 1' H₆); 7.97 (s, 1H : CH=N); 8.38 (d, J = 10 Hz, 1H : CONH at position 1); 8.64 (d, J = 8 Hz, 1H : CONH at position 6); 11.65 (s, 1H : OH).

The potassium salt of 2"-methylsulphonyl-pyrimido[4,5-5γ,5δ]pristinamycin I₂ may be prepared according to Example 53.

25 Example 55

By carrying out the procedure by analogy with Example 32 but starting with 20 cm³ of methylene chloride, 2.3 g of 2"-(2-pyridyl)pyrimido[4,5-

002280" 2644560

5γ,5δ]pristinamycin I_E, 0.2 g of ethylene glycol, 2.35 g of acetic acid, 0.48 g of tetra-n-butylammonium periodate and stirring for 12 hours, 3.4 g of a crude product are obtained, which product is dissolved in 70 cm³ of 0.5 N sulphuric acid. The mixture is extracted with 3 times 50 cm³ of ethyl acetate. After treatment and concentration, 1.58 g of yellow solid are obtained, which solid is purified by two successive chromatographies, on 100 g and 30 g of silica respectively (eluent: methylene chloride-methanol 95/5 and then methylene chloride-acetonitrile-methanol: 86/8/6 by volume). The fractions are pooled, dried over magnesium sulphate, filtered and then concentrated at 45°C under reduced pressure (2.7 kPa). The solid obtained is taken up in 10 cm³ of diisopropyl ether, filtered, washed with 10 cm³ of diisopropyl ether and then dried at 40°C under reduced pressure (90 Pa) to give 0.52 g of 2''-(2-pyridyl)pyrimido[4,5-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E in the form of a pale-yellow solid melting at 209°C.

¹H NMR spectrum (400 MHz, CDCl₃) : 0.93 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.25 to 1.40 (mt, 2H: 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.32 (d, J = 7 Hz, 3H : CH₃ at position 1γ); 1.52 (dd, J = 18 and 6, 1H : 1H of CH₂ at position 5β); 1.62 (mt, 1H : the other H of CH₂ at position 3γ); from 1.60 to 1.85 (mt : the 2H corresponding to CH₂ at position 2β); 2.08 (mt, 1H : the other H of CH₂ at

position 3 β); 2.58 (s, 3H : ArNCH₃); 2.92 (dd, J = 12 and 4.5 Hz, 1H : 1H of CH₂ at position 4 β); from 3.15 to 3.30 (mt, 3H : the other H of CH₂ at position 5 β - 1H of CH₂ at position 3 δ and the other H of CH₂ at position 4 β); 3.27 (s, 3H : NCH₃); 3.51 (mt, 1H : the other H of CH₂ at position 3 δ); 3.89 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.63 (dd, J = 8 and 6 Hz, 1H : CH at position 3 α); 4.82 (mt, 1H : CH at position 2 α); 4.90 (dd, J = 10 and 1 Hz, 1H : CH at position 1 α); 5.10 (dd, J = 11 and 4.5 Hz, 1H : CH at position 4 α); 5.42 (broad d, J = 6 Hz, 1H : CH at position 5 α); 5.53 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5 ϵ); 5.69 (d, J = 8.5 Hz, 1H : CH at position 6 α); 5.89 (split q, J = 7 and 1 Hz, 1H : CH at position 1 β); 6.16 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.56 (d, J = 10 Hz, 1H : CONH at position 2); 6.79 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); from 7.20 to 7.40 (mt : the 5H corresponding to the aromatic H at position 6 α); 7.40 (broad dd, J = 8 and 5 Hz, 1H : H at position 5 of pyridine); 7.48 (dd, J = 8.5 and 1 Hz, 1H : 1' H₄); 7.53 (dd, J = 8.5 and 4 Hz, 1H : 1' H₅); 7.85 (split t, J = 8 and 2 Hz, 1H : H at position 4 of pyridine); 8.01 (dd, J = 4 and 1 Hz, 1H : 1' H₆); 8.43 (d, J = 10 Hz, 1H : CONH at position 1); 8.46 (broad d, J = 8 Hz, H at position 3 of pyridine); 8.56 (s, 1H : CH=N); 8.71 (d, J = 8.5 Hz, 1H : CONH at position 6); 8.84 (broad d, J = 5 Hz, 1H : H at position 6 of pyridine); 11.64 (s, 1H : OH).

00643197 032200

2"-(2-pyridyl)pyrimido[4,5-5 γ ,5 δ]-
pristinamycin I_E may be obtained as described in Example
28.

Example 56

- 5 3.9 g of 2"-azidopyrimido[4,5-5 γ ,5 δ]-
pristinamycin I_E and 2.16 g of triphenylphosphine are
added to a three-necked flask containing 70 cm³ of
tetrahydrofuran and 100 cm³ of 0.1 N hydrochloric acid
and the mixture is kept stirring overnight. The
10 reaction mixture is concentrated to dryness at 40°C
under reduced pressure (2.7 kPa); the gummy residue is
taken up in 50 cm³ of water and 100 cm³ of 0.1 N
hydrochloric acid and extracted with 3 times 80 cm³ of
methylene chloride. After decantation, the aqueous
15 phase is neutralized by addition of water saturated
with sodium bicarbonate and extracted with 3 times
100 cm³ of methylene chloride. The organic phases are
pooled, dried over magnesium sulphate, filtered and
concentrated at 45°C under reduced pressure to give
20 3.5 g of a yellow solid which is purified by
chromatography on 300 g of silica (eluent: methylene
chloride-methanol : 96/4 by volume). The fractions are
pooled, dried over magnesium sulphate, filtered and
concentrated at 45°C under reduced pressure (2.7 kPa)
25 to give a yellow solid which is recrystallized from
40 cm³ of isopropanol. After filtration, washing with
10 cm³ of isopropanol and drying at 40°C under reduced
pressure, 0.97 g of 2"-aminopyrimido[4,5-5 γ ,5 δ]-

002280 " 082200 09643197

pristinamycin I_E is obtained in the form of a pale-yellow powder melting at 214°C.

2"-azidopyrimido[4,5-5 γ ,5 δ]pristinamycin I_E may be prepared as in Example 25 but starting with 5 250 cm³ of dimethylformamide, 10 g of 2"-(4-methyl-benzenesulphonyl)pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E, 2.42 g of sodium azide and heating at 65°C for three days. After concentrating the reaction mixture to dryness, 400 cm³ of water saturated with sodium chloride 10 are added. The orange-yellow precipitate which appeared is filtered and then taken up in 200 cm³ of methylene chloride. After decantation, drying over magnesium sulphate, filtration and concentration to dryness at 40°C under reduced pressure (2.7 kPa), a solid is 15 obtained which is purified by chromatography on 150 g of silica (eluent: methylene chloride-methanol 96/4 by volume) to give after concentrating the fractions 3.9 g of 2"-azidopyrimido[4,5-5 γ ,5 δ]pristinamycin I_E in the form of an orange-coloured solid which is used as it 20 is.

¹H NMR spectrum (400 MHz, CDCl₃) : 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); from 1.15 to 1.35 (mt, 3H: 1H of CH₂ at position 3 β - 1H of CH₂ at position 3 γ and 1H of CH₂ at position 5 β); 1.30 (d, J = 25 7 Hz, 3H : CH₃ at position 1 γ); 1.56 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.80 (mt : the 2H corresponding to CH₂ at position 2 β); 2.04 (mt, 1H : the other H of CH₂ at position 3 β); 2.81 (d, J = 17.5 Hz, 1H

002280" 46 FEB 98 09643197 082200

: the other H of CH₂ at position 5β); from 2.85 to 2.95
 (mt, 1H : 1H of CH₂ at position 4β); 2.89 (s, 6H :
 ArN(CH₃)₂; from 3.15 to 3.30 (mt, 2H : the other H of
 CH₂ at position 4β and 1H of CH₂ at position 3δ); 3.25
 5 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at
 position 3δ); 3.71 (d, J = 17 Hz, 1H : 1H of CH₂ at
 position 5ε); 4.60 (dd, J = 8 and 6 Hz, 1H : CH at
 position 3α); 4.80 (mt, 1H : CH at position 2α); 4.86
 (s, 2H : ArNH₂); 4.88 (broad d, J = 10 Hz, 1H : CH at
 10 position 1α); 5.08 (dd, J = 11.5 and 5 Hz, 1H : CH at
 position 4α); 5.31 (mt, 1H : CH at position 5α); 5.33
 (d, J = 17 Hz, 1H : the other H of CH₂ at position 5ε);
 5.64 (d, J = 8.5 Hz, 1H : CH at position 6α); 5.88
 (broad q, J = 7 Hz, 1H : CH at position 1β); 6.40 (d, J
 15 = 8 Hz, 2H : aromatic H at position 4ε); 6.54 (d, J =
 10 Hz, 1H : CONH at position 2); 6.86 (d, J = 8 Hz, 2H
 : aromatic H at position 4δ); from 7.20 to 7.35 (mt :
 the 5H corresponding to the aromatic H at position 6α);
 7.42 (dd, J = 8 and 1.5 Hz, 1H : 1' H₄); 7.45 (dd, J = 8
 20 and 4 Hz, 1H : 1' H₅); 7.89 (dd, J = 4 and 1.5 Hz, 1H :
 1' H₆); 7.97 (s, 1H : CH=N); 8.36 (d, J = 10 Hz, 1H :
 CONH at position 1); 8.64 (d, J = 8.5 Hz, 1H : CONH
 at position 6); 11.65 (s, 1H : OH).

2"-(4-methylbenzenesulphonyl)pyrimido[4,5-
 25 5γ,5δ]pristinamycin I_E may be obtained as described in
 Example 25.

Example 57

1 g of 2"-hydroxymethylpyrido[2,3-5γ,5δ]-

09643197-082200

pristinamycin I_E and 0.155 cm³ of thionyl chloride are added to a three-necked flask placed under a nitrogen stream and containing 10 cm³ of acetonitrile. The mixture is kept stirring for 30 minutes and 0.9 cm³ of triethylamine is added. After filtering the triethylamine hydrochloride formed, a solution of the sodium salt of 2-diethylaminoethanethiol (obtained after stirring for 30 minutes from 0.324 cm³ of diethylaminoethanethiol and 102 mg of sodium hydride in 20 cm³ of acetonitrile) are added. After heating at 50°C for 3 hours, the insoluble matter is removed by filtration and then washed with 20 cm³ of acetonitrile. The filtrate is concentrated to dryness under reduced pressure (45°C - 2.7 kPa) and then the residue is taken up in 50 cm³ of methylene chloride and 50 cm³ of water. The organic phase is decanted off, washed with 25 cm³ of water, dried over sodium sulphate and then filtered to give, after concentration to dryness, 1.1 g of a residue which is chromatographed on 50 g of silica (eluent: methylene chloride-methanol gradient 98/2 to 90/10 by volume) to give 150 mg of product which is purified by HPLC on 450 g of 10 µm C₈ silica (eluent: water-acetonitrile 70/30 by volume, containing 0.1% trifluoroacetic acid). The fractions are combined and then the acetonitrile removed at 40°C under reduced pressure (2.7 kPa). The aqueous phase is adjusted to pH 7-8 by addition of water saturated with sodium bicarbonate and then extracted with twice 25 cm³ of

09643197 082200

methylene chloride. The organic phase is dried over sodium sulphate, filtered and then concentrated to dryness to give 30 mg of 2"-diethylaminoethylthio-methylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E in the form of a
5 yellow solid melting at 132°C.

¹H NMR spectrum (400 MHz, CDCl₃) : 0.92 (t, J = 7.5 Hz, 3H : CH₃ at position 2 γ); 1.02 (t, J = 7 Hz, 6H : CH₃ of diethylamino); from 1.20 to 1.35 (mt, 2H: 1H of CH₂ at position 3 β and 1H of CH₂ at position 3 γ);
10 1.29 (d, J = 7 Hz, 3H : CH₃ at position 1 γ); 1.57 (mt, 1H : the other H of CH₂ at position 3 γ); from 1.60 to 1.80 (mt : the 2H corresponding to the CH₂ at position 2 β); 1.88 (very broad d, J = 16.5 Hz, 1H : 1H of CH₂ at position 5 β); 2.03 (mt, 1H : the other H of CH₂ at
15 position 3 β); from 2.45 to 2.65 (unresolved complex, 4H : NCH₂ of diethylamino); from 2.60 to 2.75 (mt, 4H : SCH₂CH₂N); 2.84 (s, 6H : ArN(CH₃)₂); 2.98 (dd, J = 13.5 and 6 Hz, 1H : 1H of CH₂ at position 4 β); from 3.10 to 3.30 (mt, 3H : the other H of CH₂ at position 4 β - the
20 other H of CH₂ at position 5 β and 1H of CH₂ at position 3 δ); 3.20 (s, 3H : NCH₃); 3.49 (mt, 1H : the other H of CH₂ at position 3 δ); 3.79 (s, 2H : ArCH₂S); 3.94 (d, J = 17 Hz, 1H : 1H of CH₂ at position 5 ϵ); 4.60 (dd, J = 8 and 5.5 Hz, 1H : CH at position 3 α); 4.79 (mt, 1H : CH
25 at position 2 α); 4.87 (dd, J = 10 and 1 Hz, 1H : CH at position 1 α); 5.28 (dd, J = 9 and 6 Hz, 1H : CH at position 4 α); 5.44 (broad d, J = 5.5 Hz, 1H : CH at position 5 α); 5.44 (d, J = 17 Hz, 1H : the other H of

002280 261E4960

CH₂ at position 5ε); 5.60 (d, J = 8 Hz, 1H : CH at position 6α); 5.87 (split q, J = 7 and 1 Hz, 1H : CH at position 1β); 6.36 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 6.57 (d, J = 10 Hz, 1H : CONH at position 2); 6.84 (d, J = 8 Hz, 2H : aromatic H at position 4δ); 7.20 (d, J = 8 Hz, 1H : aromatic H at position β with respect to N); from 7.20 to 7.40 (mt : the 8H corresponding to the 5 aromatic H at position 6α - to the aromatic H at position γ with respect to N - to 1' H₄ and to 1' H₅); 7.83 (dd, J = 4 and 1 Hz, 1H : 1' H₆); 8.40 (d, J = 10 Hz, 1H : CONH at position 1); 8.67 (d, J = 8 Hz, 1H : CONH at position 6); 11.65 (broad unresolved complex, 1H : OH).

2"-hydroxymethylpyrido[2,3-5γ,5δ]-

15 pristinamycin I_E may be obtained as described in Example 11.

Example 58

- 4ε-Chloro-2"-tert-butylpyrido[2,3-5γ,5δ]-pristinamycin I_E
- 20 • 2"-tert-Butylpyrido[2,3-5γ,5δ] (4ζ-methylamino) - (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-tert-butylpyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-aminopyrido[2,3-5γ,5δ]pristinamycin I_E
- 25 • 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-methylamino) - (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-aminopyrido[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

002280 " 082000 09643197

- 4ε-Chloro-3"-methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ]pristinamycin I_E
- 4ε-Chloro-2"-phenylpyrido[2,3-5γ,5δ]pristinamycin I_E
- 5 • 2"-Phenylpyrido[2,3-5γ,5δ] (4ζ-methylamino) - (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-phenylpyrido[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"- (4-aminophenyl)pyrido-
- 10 [2,3-5γ,5δ]pristinamycin I_E
- 2"- (4-Aminophenyl)pyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"- (4-aminophenyl)pyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 15 • 4ε-Chloro-2"- (4-diethylaminophenyl)pyrido[2,3-5γ,5δ]pristinamycin I_E
- 2"- (4-Diethylaminophenyl)pyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"- (4-diethylaminophenyl)pyrido-
- 20 [2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloropyrido[2,3-5γ,5δ]pristinamycin I_E
- Pyrido[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 25 • 4ε-Chloropyrido[2,3-5γ,5δ] (4ζ-methylamino) - (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-chloromethylpyrido[2,3-5γ,5δ] - pristinamycin I_E

002280 " 082200 09643197

- 2"-Chloromethylpyrido[2,3-5 γ ,5 δ] (4 ζ -methylamino) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Chloro-2"-chloromethylpyrido[2,3-5 γ ,5 δ] (4 ζ -
methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 5 · 4 ϵ -Chloro-3"-methoxycarbonyl-2"-methylpyrido-
[2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 4 ϵ -Chloro-2"-(2-pyridyl)pyrido[2,3-5 γ ,5 δ] -
pristinamycin I_E
- 10 · 4 ϵ -Chloro-2"-morpholinomethylpyrido[2,3-5 γ ,5 δ] -
pristinamycin I_E
- 2"-Morpholinomethylpyrido[2,3-5 γ ,5 δ] (4 ζ -
methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Chloro-2"-morpholinomethylpyrido[2,3-5 γ ,5 δ] -
- 15 (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Chloro-2"-(3-pyridyl)pyrido[2,3-5 γ ,5 δ] -
pristinamycin I_E
- 2"-(3-Pyridyl)pyrido[2,3-5 γ ,5 δ] (4 ζ -methylamino) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 20 · 4 ϵ -Chloro-2"-(3-pyridyl)pyrido[2,3-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Chloro-2"-(4-methyl-1-piperazinylmethyl)pyrido-
[2,3-5 γ ,5 δ]pristinamycin I_E
- 2"-(4-Methyl-1-piperazinylmethyl)pyrido-
- 25 [2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 4 ϵ -Chloro-2"-(4-methyl-1-piperazinylmethyl)pyrido-
[2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -

002290" 46TFE960

pristinamycin I_E

· 4ε-Chloro-2"-methylpyrido[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Chloro-2"-cyclopropylpyrido[2,3-5γ,5δ]-

5 pristinamycin I_E

· 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-methylamino) - (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Chloro-2"-cyclopropylpyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

10 · 4ε-Chloro-2"-hydroxymethylpyrido[2,3-5γ,5δ] - pristinamycin I_E

· 2"-Hydroxymethylpyrido[2,3-5γ,5δ] (4ζ-methylamino) - (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Chloro-2"-hydroxymethylpyrido[2,3-5γ,5δ] -

15 (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Chloro-2"-propylpyrido[2,3-5γ,5δ]pristinamycin I_E

· 2"-Propylpyrido[2,3-5γ,5δ] (4ζ-methylamino) - (4ζ-dedimethylamino)pristinamycin I_E

20 · 4ε-Chloro-2"-propylpyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Chloro-2"-isopropylpyrido[2,3-5γ,5δ] - pristinamycin I_E

· 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-methylamino) -

25 (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Chloro-2"-isopropylpyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Chloro-2"-acetoxymethylpyrido[2,3-5γ,5δ] -

0022280" 261E4960

pristinamycin I_E

- 2"-Acetoxymethylpyrido[2,3-5γ,5δ] (4ζ-methylamino) -
(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-acetoxymethylpyrido[2,3-5γ,5δ] -
- 5 (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-cyclopropylaminomethylpyrido-
[2,3-5γ,5δ]pristinamycin I_E
- 2"-Cyclopropylaminomethylpyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 10 · 4ε-Chloro-2",3"-dimethylpyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-ethoxycarbonylpyrido[2,3-5γ,5δ] -
pristinamycin I_E
- 2"-Ethoxycarbonylpyrido[2,3-5γ,5δ] -
- 15 (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Chloro-2"-ethoxycarbonylpyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- PIA Cl: 4ε-chloro-2"-(N-diethylaminomethyl)pyrido-
[2,3-5γ,5δ]pristinamycin I_E
- 20 · PIB: 2"-(N-diethylaminomethyl)pyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- PIB Cl: 4ε-chloro-2"-(N-diethylaminomethyl)pyrido-
[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -
pristinamycin I_E
- 25 · PIA Cl: 4ε-chloro-2"-carbamoylpyrido[2,3-5γ,5δ] -
pristinamycin I_E
- PIB: 2"-carbamoylpyrido[2,3-5γ,5δ] (4ζ-methyl-
amino) (4ζ-dedimethylamino)pristinamycin I_E

002280" 264966

- PIB Cl: 4ε-chloro-2"-carbamoylpyrido[2,3-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- PIA Cl: 4ε-chloro-2"-diethylaminoethylthiomethylpyrido[2,3-5γ,5δ]pristinamycin I_E
- 5 · PIB: 2"-diethylaminoethylthiomethylpyrido[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
 - PIB Cl: 4ε-chloro-2"-diethylaminoethylthiomethylpyrido[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-
- 10 pristinamycin I_E
 - PIA Cl: 4ε-chloro-2"-(morpholinoethylthiomethyl)pyrido[2,3-5γ,5δ]pristinamycin I_E
 - PIB: 2"-(morpholinoethylthiomethyl)pyrido[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-
- 15 pristinamycin I_E
 - 4ε-Chloro-2"-(morpholinoethylthiomethyl)pyrido[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
 - 4ε-Chloro-2"-(1-pyrrolidinoethylthiomethyl)pyrido-
- 20 [2,3-5γ,5δ]pristinamycin I_E
 - 2"-(1-Pyrrolidinoethylthiomethyl)pyrido[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
 - 4ε-Chloro-2"-(1-pyrrolidinoethylthiomethyl)pyrido-
- 25 [2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
 - 4ε-Chloro-2"-(piperidinoethylthiomethyl)pyrido[2,3-5γ,5δ]pristinamycin I_E

002230 " 082200 09643497

- 2"-(Piperidinoethylthiomethyl)pyrido[2,3-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Chloro-2"-(piperidinoethylthiomethyl)pyrido-
[2,3-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)-
5 pristinamycin I_E
- 4 ϵ -Bromo-2"-tert-butylpyrido[2,3-5 γ ,5 δ]-
pristinamycin I_E
- 4 ϵ -Bromo-2"-tert-butylpyrido[2,3-5 γ ,5 δ](4 ζ -
methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 10 · 4 ϵ -Allyl-2"-tert-butylpyrido[2,3-5 γ ,5 δ]-
pristinamycin I_E
- 4 ϵ -Allyl-2"-tert-butylpyrido[2,3-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-tert-butylpyrido-
15 [2,3-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-tert-butylpyrido-
[2,3-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-tert-Butylpyrido[2,3-5 γ ,5 δ](4 ζ -diethylamino)-
20 (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-tert-Butylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
allylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-tert-Butylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
ethylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 25 · 2"-tert-Butylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
propylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-tert-Butylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
(4-pyridylmethyl)amino)(4 ζ -dedimethylamino)-

00643197 032200

pristinamycin I_E

· 2"-tert-Butylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino) -

pristinamycin I_E

5 · 2"-tert-Butylpyrido[2,3-5γ,5δ] (4ζ-methyl) -
(4ζ-dedimethylamino)pristinamycin I_E

· 2"-tert-Butylpyrido[2,3-5γ,5δ] (4ζ-tert-butyl) -
(4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Bromo-2"-aminopyrido[2,3-5γ,5δ]pristinamycin I_E

10 · 4ε-Bromo-2"-aminopyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Allyl-2"-aminopyrido[2,3-5γ,5δ]pristinamycin I_E

· 4ε-Allyl-2"-aminopyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

15 · 4ε-(2-Methylpropen-1-yl)2"-aminopyrido[2,3-5γ,5δ] -
pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)2"-aminopyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-diethylamino) -

20 (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-allylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-ethylamino) (4ζ-dedimethylamino)pristinamycin I_E

25 · 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-propylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(4-pyridylmethyl)amino) (4ζ-dedimethylamino) -

002280 1674960

pristinamycin I_E

· 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino) -

pristinamycin I_E

5 · 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-methyl) -

(4ζ-dedimethylamino)pristinamycin I_E

· 2"-Aminopyrido[2,3-5γ,5δ] (4ζ-tert-butyl) -

(4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Bromo-3"-methoxycarbonyl-2"-methylpyrido-

10 [2,3-5γ,5δ]pristinamycin I_E

· 4ε-Bromo-3"-methoxycarbonyl-2"-methylpyrido-

[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -

pristinamycin I_E

· 4ε-Allyl-3"-methoxycarbonyl-2"-methylpyrido-

15 [2,3-5γ,5δ]pristinamycin I_E

· 4ε-Allyl-3"-methoxycarbonyl-2"-methylpyrido-

[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -

pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-3"-methoxycarbonyl-2"-

20 methylpyrido[2,3-5γ,5δ]pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-3"-methoxycarbonyl-2"-

methylpyrido[2,3-5γ,5δ] (4ζ-methylamino) -

(4ζ-dedimethylamino)pristinamycin I_E

· 3"-Methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ] -

25 (4ζ-diethylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 3"-Methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ] -

(4ζ-N-methyl-N-allylamino) (4ζ-dedimethylamino) -

pristinamycin I_E

002280 082200 09643197 064960

- 3"-Methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ]-
(4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 3"-Methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ]-
5 (4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 3"-Methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ]-
(4ζ-N-methyl-N-(4-pyridylmethyl)amino)(4ζ-dedimethyl-
amino)pristinamycin I_E
- 10 · 3"-Methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ]-
(4ζ-N-methyl-N-(3-pyridylmethyl)amino)(4ζ-dedimethyl-
amino)pristinamycin I_E
- 3"-Methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ]-
(4ζ-methyl)(4ζ-dedimethylamino)pristinamycin I_E
- 15 · 3"-Methoxycarbonyl-2"-methylpyrido[2,3-5γ,5δ]-
(4ζ-tert-butyl)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"-phenylpyrido[2,3-5γ,5δ]pristinamycin I_E
- 4ε-Bromo-2"-phenylpyrido[2,3-5γ,5δ]-
(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 20 · 4ε-Allyl-2"-phenylpyrido[2,3-5γ,5δ]pristinamycin I_E
- 4ε-Allyl-2"-phenylpyrido[2,3-5γ,5δ]-
(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-phenylpyrido-
[2,3-5γ,5δ]pristinamycin I_E
- 25 · 4ε-(2-Methylpropen-1-yl)-2"-phenylpyrido-
[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 2"-Phenylpyrido[2,3-5γ,5δ](4ζ-diethylamino)-

002280" 08200 09643197

- (4ζ-dedimethylamino)pristinamycin I_E
- 2"-Phenylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-allylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Phenylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Phenylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-propylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Phenylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(4-pyridylmethyl)amino) (4ζ-dedimethylamino)pristinamycin I_E
 - 10 • 2"-Phenylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Phenylpyrido[2,3-5γ,5δ] (4ζ-methyl)-(4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Phenylpyrido[2,3-5γ,5δ] (4ζ-tert-butyl)-(4ζ-dedimethylamino)pristinamycin I_E
 - 15 • 4ε-Bromo-2"-(4-aminophenyl)pyrido[2,3-5γ,5δ]-pristinamycin I_E
 - 4ε-Bromo-2"-(4-aminophenyl)pyrido[2,3-5γ,5δ]-(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 20 • 4ε-Allyl-2"-(4-aminophenyl)pyrido[2,3-5γ,5δ]-pristinamycin I_E
 - 4ε-Allyl-2"-(4-aminophenyl)pyrido[2,3-5γ,5δ]-(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-(2-Methylpropen-1-yl)-2"-(4-aminophenyl)-pyrido[2,3-5γ,5δ]pristinamycin I_E
 - 25 • 4ε-(2-Methylpropen-1-yl)-2"-(4-aminophenyl)-pyrido[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)-pristinamycin I_E

002280 " 032200 09643197

- 2"-(4-Aminophenyl)pyrido[2,3-5 γ ,5 δ]-
(4 ζ -diethylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(4-Aminophenyl)pyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-allylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 5 · 2"-(4-Aminophenyl)pyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-ethylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(4-Aminophenyl)pyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-propylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(4-Aminophenyl)pyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
10 (4-pyridylmethyl)amino)(4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-(4-Aminophenyl)pyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-(3-pyridylmethyl)amino)(4 ζ -dedimethylamino)-
pristinamycin I_E
- 15 · 2"-(4-Aminophenyl)pyrido[2,3-5 γ ,5 δ](4 ζ -methyl)-
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(4-Aminophenyl)pyrido[2,3-5 γ ,5 δ](4 ζ -tert-butyl)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-(4-diethylaminophenyl)pyrido-
20 [2,3-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -Bromo-2"-(4-diethylaminophenyl)pyrido-
[2,3-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)-
pristinamycin I_E
- 4 ϵ -Allyl-2"-(4-diethylaminophenyl)pyrido-
25 [2,3-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -Allyl-2"-(4-diethylaminophenyl)pyrido-
[2,3-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)-
pristinamycin I_E

002280" 46T4960

- 4ε-(2-Methylpropen-1-yl)-2"-(4-diethylamino-phenyl)pyrido[2,3-5γ,5δ]pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-(4-diethylamino-phenyl)pyrido[2,3-5γ,5δ](4ζ-methylamino)-
- 5 (4ζ-dedimethylamino)pristinamycin I_E
- 2"-(4-Diethylaminophenyl)pyrido[2,3-5γ,5δ]-(4ζ-diethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(4-Diethylaminophenyl)pyrido[2,3-5γ,5δ](4ζ-N-methyl-N-allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 10 · 2"-(4-Diethylaminophenyl)pyrido[2,3-5γ,5δ](4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(4-Diethylaminophenyl)pyrido[2,3-5γ,5δ](4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 15 · 2"-(4-Diethylaminophenyl)pyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(4-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-(4-Diethylaminophenyl)pyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-
- 20 pristinamycin I_E
- 2"-(4-Diethylaminophenyl)pyrido[2,3-5γ,5δ]-(4ζ-methyl)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(4-Diethylaminophenyl)pyrido[2,3-5γ,5δ]-(4ζ-tert-butyl)(4ζ-dedimethylamino)pristinamycin I_E
- 25 · 4ε-Bromopyrido[2,3-5γ,5δ]pristinamycin I_E
- 4ε-Bromopyrido[2,3-5γ,5δ](4ζ-methylamino)-(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Allylpyrido[2,3-5γ,5δ]pristinamycin I_E

002280" 4643197 082200

- 4ε-Allylpyrido[2,3-5γ,5δ] (4ζ-methylamino) -
(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)pyrido[2,3-5γ,5δ] -
pristinamycin I_E
- 5 · 4ε-(2-Methylpropen-1-yl)pyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- Pyrido[2,3-5γ,5δ] (4ζ-diethylamino) -
(4ζ-dedimethylamino)pristinamycin I_E
- Pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-allylamino) -
10 (4ζ-dedimethylamino)pristinamycin I_E
- Pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-ethylamino) -
(4ζ-dedimethylamino)pristinamycin I_E
- Pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-propylamino) -
(4ζ-dedimethylamino)pristinamycin I_E
- 15 · Pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(4-pyridylmethyl) -
amino) (4ζ-dedimethylamino)pristinamycin I_E
- Pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl) -
amino) (4ζ-dedimethylamino)pristinamycin I_E
- Pyrido[2,3-5γ,5δ] (4ζ-methyl) (4ζ-dedimethylamino) -
20 pristinamycin I_E
- Pyrido[2,3-5γ,5δ] (4ζ-tert-butyl) (4ζ-dedimethyl-
amino)pristinamycin I_E
- 4ε-Bromo-2"-chloromethylpyrido[2,3-5γ,5δ] -
pristinamycin I_E
- 25 · 4ε-Bromo-2"-chloromethylpyrido[2,3-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Allyl-2"-chloromethylpyrido[2,3-5γ,5δ] -
pristinamycin I_E

002280 767E4960

- 4ε-Allyl-2"-chloromethylpyrido[2,3-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-chloromethylpyrido-[2,3-5γ,5δ]pristinamycin I_E
- 5 · 4ε-(2-Methylpropen-1-yl)-2"-chloromethylpyrido-[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-Chloromethylpyrido[2,3-5γ,5δ](4ζ-diethylamino)-(4ζ-dedimethylamino)pristinamycin I_E
- 10 · 2"-Chloromethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Chloromethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Chloromethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 15 · 2"-Chloromethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(4-pyridylmethyl)amino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Chloromethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(3-pyridylmethyl)amino)(4ζ-dedimethylamino)pristinamycin I_E
- 20 · 2"-Chloromethylpyrido[2,3-5γ,5δ](4ζ-methyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Chloromethylpyrido[2,3-5γ,5δ](4ζ-tert-butyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"-(2-pyridyl)pyrido[2,3-5γ,5δ]-pristinamycin I_E
- 25 · 4ε-Bromo-2"-(2-pyridyl)pyrido[2,3-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Allyl-2"-(2-pyridyl)pyrido[2,3-5γ,5δ]-

002280" 67E4660

pristinamycin I_E

· 4ε-Allyl-2"-(2-pyridyl)pyrido[2,3-5γ,5δ]-
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-2"-(2-pyridyl)pyrido-
5 [2,3-5γ,5δ]pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-2"-(2-pyridyl)pyrido-
[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)-
pristinamycin I_E

· 2"-(2-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-diethylamino)-
10 (4ζ-dedimethylamino)pristinamycin I_E

· 2"-(2-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
allylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-(2-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
ethylamino) (4ζ-dedimethylamino)pristinamycin I_E

15 · 2"-(2-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
propylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-(2-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
(4-pyridylmethyl)amino) (4ζ-dedimethylamino)-
pristinamycin I_E

20 · 2"-(2-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
(3-pyridylmethyl)amino) (4ζ-dedimethylamino)-
pristinamycin I_E

· 2"-(2-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-methyl)-
(4ζ-dedimethylamino)pristinamycin I_E

25 · 2"-(2-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-tert-butyl)-
(4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Bromo-2"-morpholinomethylpyrido[2,3-5γ,5δ]-
pristinamycin I_E

002280 1674960

- 4ε-Bromo-2"-morpholinomethylpyrido[2,3-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Allyl-2"-morpholinomethylpyrido[2,3-5γ,5δ]-pristinamycin I_E
- 5 · 4ε-Allyl-2"-morpholinomethylpyrido[2,3-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-morpholinomethylpyrido[2,3-5γ,5δ]pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-morpholinomethylpyrido[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 10 · 2"-Morpholinomethylpyrido[2,3-5γ,5δ]-(4ζ-diethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Morpholinomethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 15 · 2"-Morpholinomethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Morpholinomethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 20 · 2"-Morpholinomethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(4-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-Morpholinomethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E
- 25 · 2"-Morpholinomethylpyrido[2,3-5γ,5δ](4ζ-methyl)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Morpholinomethylpyrido[2,3-5γ,5δ](4ζ-tert-

002280 16TE86 09643197 082200

- butyl) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"- (3-pyridyl)pyrido[2,3-5γ,5δ]-
pristinamycin I_E
 - 4ε-Bromo-2"- (3-pyridyl)pyrido[2,3-5γ,5δ]-
 - 5 (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-Allyl-2"- (3-pyridyl)pyrido[2,3-5γ,5δ]-
pristinamycin I_E
 - 4ε-Allyl-2"- (3-pyridyl)pyrido[2,3-5γ,5δ]-
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 10 · 4ε-(2-Methylpropen-1-yl)-2"- (3-pyridyl)pyrido-
[2,3-5γ,5δ]pristinamycin I_E
 - 4ε-(2-Methylpropen-1-yl)-2"- (3-pyridyl)pyrido-
[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -
pristinamycin I_E
 - 15 · 2"- (3-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-diethylamino) -
(4ζ-dedimethylamino)pristinamycin I_E
 - 2"- (3-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
allylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"- (3-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
 - 20 ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"- (3-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
propylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"- (3-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
(4-pyridylmethyl) amino) (4ζ-dedimethylamino) -
 - 25 pristinamycin I_E
 - 2"- (3-Pyridyl)pyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
(3-pyridylmethyl) amino) (4ζ-dedimethylamino) -
pristinamycin I_E

00220" 082200 09643497

- 2"-(3-Pyridyl)pyrido[2,3-5γ,5δ](4-methyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(3-Pyridyl)pyrido[2,3-5γ,5δ](4-tert-butyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 5 · 4ε-Bromo-2"-(4-methyl-1-piperazinylmethyl)pyrido-[2,3-5γ,5δ]pristinamycin I_E
- 4ε-Bromo-2"-(4-methyl-1-piperazinylmethyl)pyrido-[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 10 · 4ε-Allyl-2"-(4-methyl-1-piperazinylmethyl)pyrido-[2,3-5γ,5δ]pristinamycin I_E
- 4ε-Allyl-2"-(4-methyl-1-piperazinylmethyl)pyrido-[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 15 · 4ε-(2-Methylpropen-1-yl)-2"-(4-methyl-1-piperazinylmethyl)pyrido[2,3-5γ,5δ]pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-(4-methyl-1-piperazinylmethyl)pyrido[2,3-5γ,5δ](4ζ-methylamino)-(4ζ-dedimethylamino)pristinamycin I_E
- 20 · 2"-(4-Methyl-1-piperazinylmethyl)pyrido-[2,3-5γ,5δ](4ζ-diethylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-(4-Methyl-1-piperazinylmethyl)pyrido-[2,3-5γ,5δ](4ζ-N-methyl-N-allylamino)(4ζ-dedimethyl-
- 25 amino)pristinamycin I_E
- 2"-(4-Methyl-1-piperazinylmethyl)pyrido-[2,3-5γ,5δ](4ζ-N-methyl-N-ethylamino)(4ζ-dedimethyl-amino)pristinamycin I_E

002200 "032200" 43197

- 2"-(4-Methyl-1-piperazinylmethyl)pyrido-
[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-propylamino) (4 ζ -dedimethyl-
amino)pristinamycin I_E
- 2"-(4-Methyl-1-piperazinylmethyl)pyrido-
5 [2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-(4-pyridylmethyl) amino) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(4-Methyl-1-piperazinylmethyl)pyrido-
[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl) amino) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 10 · 2"-(4-Methyl-1-piperazinylmethyl)pyrido-
[2,3-5 γ ,5 δ] (4 ζ -methyl) (4 ζ -dedimethylamino)pristinamycin
I_E
- 2"-(4-Methyl-1-piperazinylmethyl)pyrido-
[2,3-5 γ ,5 δ] (4 ζ -tert-butyl) (4 ζ -dedimethylamino) -
15 pristinamycin I_E
- 4 ϵ -Bromo-2"-ethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -Bromo-2"-ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -
methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-ethylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E
- 20 · 4 ϵ -Allyl-2"-ethylpyrido[2,3-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-ethylpyrido-
[2,3-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-ethylpyrido-
25 [2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 2"-Ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -diethylamino) -
(4 ζ -dedimethylamino)pristinamycin I_E

002220" 46TEH950

- 2"-Ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 5 · 2"-Ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-propylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-(4-pyridylmethyl)amino) (4 ζ -dedimethylamino) - pristinamycin I_E
- 10 · 2"-Ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl)amino) (4 ζ -dedimethylamino) - pristinamycin I_E
- 2"-Ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -methyl) - (4 ζ -dedimethylamino)pristinamycin I_E
- 15 · 2"-Ethylpyrido[2,3-5 γ ,5 δ] (4 ζ -tert-butyl) - (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-cyclopropylpyrido[2,3-5 γ ,5 δ] - pristinamycin I_E
- 4 ϵ -Bromo-2"-cyclopropylpyrido[2,3-5 γ ,5 δ] - (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 20 · 4 ϵ -Allyl-2"-cyclopropylpyrido[2,3-5 γ ,5 δ] - pristinamycin I_E
- 4 ϵ -Allyl-2"-cyclopropylpyrido[2,3-5 γ ,5 δ] - (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 25 · 4 ϵ -(2-Methylpropen-1-yl)-2"-cyclopropylpyrido-[2,3-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-cyclopropylpyrido-[2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -

09643197 082200

- pristinamycin I_E
- 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-diethylamino) - (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-allylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-propylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 10 • 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(4-pyridylmethyl)amino) (4ζ-dedimethylamino) - pristinamycin I_E
 - 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino) - pristinamycin I_E
 - 15 • 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-methyl) - (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Cyclopropylpyrido[2,3-5γ,5δ] (4ζ-tert-butyl) - (4ζ-dedimethylamino)pristinamycin I_E
 - 20 • 4ε-Bromo-2"-hydroxymethylpyrido[2,3-5γ,5δ] - pristinamycin I_E
 - 4ε-Bromo-2"-hydroxymethylpyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-Allyl-2"-hydroxymethylpyrido[2,3-5γ,5δ] - pristinamycin I_E
 - 25 • 4ε-Allyl-2"-hydroxymethylpyrido[2,3-5γ,5δ] - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-(2-Methylpropen-1-yl)-2"-hydroxymethylpyrido-

09643197 082200

[2,3-5 γ ,5 δ]pristinamycin I_E

· 4 ϵ -(2-Methylpropen-1-yl)-2"-hydroxymethylpyrido-
[2,3-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)-
pristinamycin I_E

5 · 2"-Hydroxymethylpyrido[2,3-5 γ ,5 δ](4 ζ -
diethylamino)(4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Hydroxymethylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
allylamino)(4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Hydroxymethylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
10 ethylamino)(4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Hydroxymethylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
propylamino)(4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Hydroxymethylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
(4-pyridylmethyl)amino)(4 ζ -dedimethylamino)-
15 pristinamycin I_E

· 2"-Hydroxymethylpyrido[2,3-5 γ ,5 δ](4 ζ -N-methyl-N-
(3-pyridylmethyl)amino)(4 ζ -dedimethylamino)-
pristinamycin I_E

· 2"-Hydroxymethylpyrido[2,3-5 γ ,5 δ](4 ζ -methyl)-
20 (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Hydroxymethylpyrido[2,3-5 γ ,5 δ](4 ζ -tert-butyl)-
(4 ζ -dedimethylamino)pristinamycin I_E

· 4 ϵ -Bromo-2"-propylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E

· 4 ϵ -Bromo-2"-propylpyrido[2,3-5 γ ,5 δ]-
25 (4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E

· 4 ϵ -Allyl-2"-propylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E

· 4 ϵ -Allyl-2"-propylpyrido[2,3-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E

002280-062200

- 4ε-(2-Methylpropen-1-yl)-2"-propylpyrido-[2,3-5γ,5δ]pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-propylpyrido-[2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-
- 5 pristinamycin I_E
- 2"-Propylpyrido[2,3-5γ,5δ](4ζ-diethylamino)-(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Propylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 10 · 2"-Propylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Propylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Propylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-
- 15 (4-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-Propylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E
- 20 · 2"-Propylpyrido[2,3-5γ,5δ](4ζ-methyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Propylpyrido[2,3-5γ,5δ](4ζ-tert-butyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"-isopropylpyrido[2,3-5γ,5δ]-
- 25 pristinamycin I_E
- 4ε-Bromo-2"-isopropylpyrido[2,3-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Allyl-2"-isopropylpyrido[2,3-5γ,5δ]-

002280" 46TE4360

pristinamycin I_E

· 4ε-Allyl-2"-isopropylpyrido[2,3-5γ,5δ]-
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-2"-isopropylpyrido-
5 [2,3-5γ,5δ]pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-2"-isopropylpyrido-
[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)-
pristinamycin I_E

· 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-diethylamino)-
10 (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
allylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
ethylamino) (4ζ-dedimethylamino)pristinamycin I_E

15 · 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
propylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
(4-pyridylmethyl) amino) (4ζ-dedimethylamino)-
pristinamycin I_E

20 · 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-
(3-pyridylmethyl) amino) (4ζ-dedimethylamino)-
pristinamycin I_E

· 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-methyl)-
(4ζ-dedimethylamino)pristinamycin I_E

25 · 2"-Isopropylpyrido[2,3-5γ,5δ] (4ζ-tert-butyl)-
(4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Bromo-2"-acetoxymethylmethylpyrido[2,3-5γ,5δ]-
pristinamycin I_E

002280 161E4960

- 4ε-Bromo-2"-acetoxymethylmethylpyrido[2,3-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Allyl-2"-acetoxymethylmethylpyrido[2,3-5γ,5δ]-pristinamycin I_E
- 5 · 4ε-Allyl-2"-acetoxymethylmethylpyrido[2,3-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-acetoxymethylpyrido-[2,3-5γ,5δ]pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-acetoxymethylpyrido-
- 10 [2,3-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-Acetoxymethylpyrido[2,3-5γ,5δ](4ζ-diethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Acetoxymethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-
- 15 allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Acetoxymethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Acetoxymethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 20 · 2"-Acetoxymethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(4-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-Acetoxymethylpyrido[2,3-5γ,5δ](4ζ-N-methyl-N-(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-
- 25 pristinamycin I_E
- 2"-Acetoxymethylpyrido[2,3-5γ,5δ](4ζ-methyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Acetoxymethylpyrido[2,3-5γ,5δ](4ζ-tert-butyl)-

002280 082200 09643197

- (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"-cyclopropylaminomethylpyrido-[2,3-5γ,5δ]pristinamycin I_E
 - 4ε-Bromo-2"-cyclopropylaminomethylpyrido-
 - 5 [2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -
pristinamycin I_E
 - 4ε-Allyl-2"-cyclopropylaminomethylpyrido-[2,3-5γ,5δ]pristinamycin I_E
 - 4ε-Allyl-2"-cyclopropylaminomethylpyrido-
 - 10 [2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -
pristinamycin I_E
 - 4ε-(2-Methylpropen-1-yl)-2"-cyclopropylamino-
methylpyrido[2,3-5γ,5δ]pristinamycin I_E
 - 4ε-(2-Methylpropen-1-yl)-2"-cyclopropylamino-
 - 15 methylpyrido[2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethyl-
amino)pristinamycin I_E
 - 2"-Cyclopropylaminomethylpyrido[2,3-5γ,5δ] (4ζ-
diethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Cyclopropylaminomethylpyrido[2,3-5γ,5δ] (4ζ-N-
 - 20 methyl-N-allylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Cyclopropylaminomethylpyrido[2,3-5γ,5δ] (4ζ-N-
methyl-N-ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Cyclopropylaminomethylpyrido[2,3-5γ,5δ] (4ζ-N-
methyl-N-propylamino) (4ζ-dedimethylamino)pristinamycin
 - 25 I_E
 - 2"-Cyclopropylaminomethylpyrido[2,3-5γ,5δ] (4ζ-N-
methyl-N-(4-pyridylmethyl)amino) (4ζ-dedimethylamino) -
pristinamycin I_E

002280" 467E4950

- 2"-Cyclopropylaminomethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl)amino) (4 ζ -dedimethylamino)-pristinamycin I_E
- 2"-Cyclopropylaminomethylpyrido[2,3-5 γ ,5 δ] (4 ζ -methyl) (4 ζ -dedimethylamino)pristinamycin I_E
- 5 methyl) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Cyclopropylaminomethylpyrido[2,3-5 γ ,5 δ] (4 ζ -tert-butyl) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2",3"-dimethylpyrido[2,3-5 γ ,5 δ]-pristinamycin I_E
- 10 · 4 ϵ -Bromo-2",3"-dimethylpyrido[2,3-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2",3"-dimethylpyrido[2,3-5 γ ,5 δ]-pristinamycin I_E
- 4 ϵ -Allyl-2",3"-dimethylpyrido[2,3-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 15 (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2",3"-dimethylpyrido-[2,3-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2",3"-dimethylpyrido-[2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino)-
- 20 pristinamycin I_E
- 2",3"-Dimethylpyrido[2,3-5 γ ,5 δ] (4 ζ -diethylamino)- (4 ζ -dedimethylamino)pristinamycin I_E
- 2",3"-Dimethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 25 · 2",3"-Dimethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2",3"-Dimethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-propylamino) (4 ζ -dedimethylamino)pristinamycin I_E

002280" 26 FEB 1960

- 2",3"-Dimethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-(4-pyridylmethyl)amino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2",3"-Dimethylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl)amino) (4 ζ -dedimethylamino)pristinamycin I_E
- 5 · 2",3"-Dimethylpyrido[2,3-5 γ ,5 δ] (4 ζ -methyl)-(4 ζ -dedimethylamino)pristinamycin I_E
- 2",3"-Dimethylpyrido[2,3-5 γ ,5 δ] (4 ζ -tert-butyl)-(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-ethoxycarbonylpyrido[2,3-5 γ ,5 δ]-
- 10 pristinamycin I_E
- 4 ϵ -Bromo-2"-ethoxycarbonylpyrido[2,3-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-ethoxycarbonylpyrido[2,3-5 γ ,5 δ]- pristinamycin I_E
- 15 · 4 ϵ -Allyl-2"-ethoxycarbonylpyrido[2,3-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-ethoxycarbonylpyrido-[2,3-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-ethoxycarbonylpyrido-
- 20 [2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino)- pristinamycin I_E
- 2"-Ethoxycarbonylpyrido[2,3-5 γ ,5 δ] (4 ζ -diethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethoxycarbonylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-
- 25 allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethoxycarbonylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethoxycarbonylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-

002280" 26 FEB 1960

propylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Ethoxycarbonylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(4-pyridylmethyl)amino) (4ζ-dedimethylamino) -
pristinamycin I_E

5 · 2"-Ethoxycarbonylpyrido[2,3-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino) -
pristinamycin I_E

· 2"-Ethoxycarbonylpyrido[2,3-5γ,5δ] (4ζ-methyl) -
(4ζ-dedimethylamino)pristinamycin I_E

10 · 2"-Ethoxycarbonylpyrido[2,3-5γ,5δ] (4ζ-tert-butyl) -
(4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Bromo-2"- (N-diethylaminomethyl)pyrido-
[2,3-5γ,5δ]pristinamycin I_E

· 4ε-Bromo-2"- (N-diethylaminomethyl)pyrido-
15 [2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -
pristinamycin I_E

· 4ε-Allyl-2"- (N-diethylaminomethyl)pyrido-
[2,3-5γ,5δ]pristinamycin I_E

· 4ε-Allyl-2"- (N-diethylaminomethyl)pyrido-
20 [2,3-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -
pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-2"- (N-diethylamino-
methyl)pyrido[2,3-5γ,5δ]pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-2"- (N-diethylamino-
25 methyl)pyrido[2,3-5γ,5δ] (4ζ-methylamino) -
(4ζ-dedimethylamino)pristinamycin I_E

· 2"- (N-Diethylaminomethyl)pyrido[2,3-5γ,5δ] -
(4ζ-diethylamino) (4ζ-dedimethylamino)pristinamycin I_E

09643197-082200

- 2"-(N-Diethylaminomethyl)pyrido[2,3-5 γ ,5 δ]-
(4 ζ -N-methyl-N-allylamino)(4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-(N-Diethylaminomethyl)pyrido[2,3-5 γ ,5 δ]-
5 (4 ζ -N-methyl-N-ethylamino)(4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-(N-Diethylaminomethyl)pyrido[2,3-5 γ ,5 δ]-
(4 ζ -N-methyl-N-propylamino)(4 ζ -dedimethylamino)-
pristinamycin I_E
- 10 • 2"-(N-Diethylaminomethyl)pyrido[2,3-5 γ ,5 δ]-
(4 ζ -N-methyl-N-(4-pyridylmethyl)amino)-
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(N-Diethylaminomethyl)pyrido[2,3-5 γ ,5 δ]-
(4 ζ -N-methyl-N-(3-pyridylmethyl)amino)-
15 (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(N-Diethylaminomethyl)pyrido[2,3-5 γ ,5 δ]-
(4 ζ -methyl)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(N-Diethylaminomethyl)pyrido[2,3-5 γ ,5 δ]-
(4 ζ -tert-butyl)(4 ζ -dedimethylamino)pristinamycin I_E
- 20 • 4 ϵ -Bromo-2"-carbamoylpyrido[2,3-5 γ ,5 δ]-
pristinamycin I_E
- 4 ϵ -Bromo-2"-carbamoylpyrido[2,3-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-carbamoylpyrido[2,3-5 γ ,5 δ]-
25 pristinamycin I_E
- 4 ϵ -Allyl-2"-carbamoylpyrido[2,3-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-methylpropen-1-yl)-2"-carbamoylpyrido-

002280" 46TE4660

[2,3-5 γ ,5 δ]pristinamycin I_E

· 4 ϵ -(2-methylpropen-1-yl)-2"-carbamoylpyrido-
[2,3-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -
pristinamycin I_E

5 · 2"-Carbamoylpyrido[2,3-5 γ ,5 δ] (4 ζ -diethylamino) (4 ζ -
dedimethylamino)pristinamycin I_E

· 2"-Carbamoylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-
allylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Carbamoylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-
10 ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Carbamoylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-
propylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Carbamoylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-
(4-pyridylmethyl) amino) (4 ζ -dedimethylamino) -
15 pristinamycin I_E

· 2"-Carbamoylpyrido[2,3-5 γ ,5 δ] (4 ζ -N-methyl-N-
(3-pyridylmethyl) amino) (4 ζ -dedimethylamino) -
pristinamycin I_E

· 2"-Carbamoylpyrido[2,3-5 γ ,5 δ] (4 ζ -methyl) -
20 (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Carbamoylpyrido[2,3-5 γ ,5 δ] (4 ζ -tert-butyl) -
(4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) -
(4 ζ -dedimethylamino)pristinamycin I_E

25 · 2"-Methoxypyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I_E

· 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) -
(4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E

002280" 267E4960

- 2"-(4-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(4-Pyridyl)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I_E
- 5 · 2"-(4-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl-
amino) (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 2"-Methylthiopyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5 γ ,5 δ]-
10 (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -
chloropristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl-
amino) (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 15 · 2"-Methylthiopyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) -
(4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 2"-(1-Pyrrolidinyl)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -
chloropristinamycin I_E
- 2"-(1-Azetidinyl)pyrimido[4,5-5 γ ,5 δ]-
20 (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(1-Azetidinyl)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -
chloropristinamycin I_E
- 2"-(1-Azetidinyl)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino) (4 ζ -dedimethylamino)-4 ϵ -chloro-
25 pristinamycin I_E
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) -
(4 ζ -dedimethylamino)pristinamycin I_E

002280" 4674960

- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I $_E$
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl-
amino) (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I $_E$
- 5 · 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I $_E$
- 2"-(1-Pyrrolidinyl)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino) (4 ζ -dedimethylamino)-4 ϵ -chloro-
pristinamycin I $_E$
- 10 · 2"-Methylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -
dedimethylamino)pristinamycin I $_E$
- 2"-Methylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I $_E$
- 2"-Methylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino)-
15 (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I $_E$
- 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino)-
(4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I $_E$
- 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I $_E$
- 20 · 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I $_E$
- 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino) (4 ζ -dedimethylamino)-4 ϵ -chloro-
pristinamycin I $_E$
- 25 · 2"-(2-Morpholinoethylthio)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I $_E$
- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -
chloropristinamycin I $_E$

00643197 082200

- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)-4 ϵ -chloro-
pristinamycin I_E
- 2"-Aminopyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -
5 dedimethylamino)pristinamycin I_E
- 2"-Aminopyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloropristinamycin
I_E
- 2"-Aminopyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-
(4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 10 · 2"-(1-Pyrazol)pyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(1-Pyrazol)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I_E
- 2"-(1-Pyrazol)pyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-
15 (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -
chloropristinamycin I_E
- 20 · 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)-4 ϵ -
chloropristinamycin I_E
- 2"-Methylaminopyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-
(4 ζ -dedimethylamino)pristinamycin I_E
- 25 · 2"-Methylaminopyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
pristinamycin I_E
- 2"-Methylaminopyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-
(4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E

09643197 082200

- 2"-Methylsulphonylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl-amino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methylsulphonylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloropristinamycin I_E
- 5 · 2"-Methylsulphonylpyrimido[4,5-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 2"-(4-Aminophenyl)pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 10 · 2"-(4-Aminophenyl)pyrimido[4,5-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(4-Aminophenyl)pyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloropristinamycin I_E
- 2"-(4-Aminophenyl)pyrimido[4,5-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 15 · 2"-Trifluoromethylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 2"-Trifluoromethylpyrimido[4,5-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 20 · 2"-Trifluoromethylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloropristinamycin I_E
- 2"-Trifluoromethylpyrimido[4,5-5 γ ,5 δ]- (4 ζ -methylamino) (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 25 · 2"-Cyclopropylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 2"-Cyclopropylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino)- (4 ζ -dedimethylamino)pristinamycin I_E

002280" 1574960

- 2"-Cyclopropylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloropristinamycin I_E
- 2"-Cyclopropylpyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-(4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 5 · 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E
- 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
- 10 pristinamycin I_E
- 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)-4 ϵ -chloro-pristinamycin I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 15 · 2"-Ethylpyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-(4 ζ -dedimethylamino)pristinamycin. I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloropristinamycin I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-(4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 20 · 2"-Propylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 2"-Propylpyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Propylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-
- 25 pristinamycin I_E
- 2"-Propylpyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)-(4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 2"-Isopropylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E

002280" 08E496

- 2"-Isopropylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methyamino) - (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Isopropylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloro-pristinamycin I_E
- 5 · 2"-Isopropylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methyamino) - (4 ζ -dedimethylamino)-4 ϵ -chloropristinamycin I_E
- 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E
- 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ]-
- 10 (4 ζ -methyamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ]-4 ϵ -chloropristinamycin I_E
- 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ]-
- (4 ζ -methyamino) (4 ζ -dedimethylamino)-4 ϵ -
- 15 chloropristinamycin I_E
- 4 ϵ -Bromo-2"-methoxypyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E
- 4 ϵ -Bromo-2"-methoxypyrimido[4,5-5 γ ,5 δ]-
- (4 ζ -methyamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 20 · 4 ϵ -Allyl-2"-methoxypyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E
- 4 ϵ -Allyl-2"-methoxypyrimido[4,5-5 γ ,5 δ]-
- (4 ζ -methyamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-methylpropen-1-yl)-2"-methoxypyrimido-
- 25 [4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-methylpropen-1-yl)-2"-methoxypyrimido-[4,5-5 γ ,5 δ] (4 ζ -methyamino) (4 ζ -dedimethylamino)-pristinamycin I_E

09643197 082200

- 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -diethylamino) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 5 · 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
propylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
10 (4-pyridylmethyl)amino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
(3-pyridylmethyl)amino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 15 · 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methoxypyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-(4-pyridyl)pyrimido[4,5-5 γ ,5 δ] -
20 pristinamycin I_E
- 4 ϵ -Bromo-2"-(4-pyridyl)pyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-(4-pyridyl)pyrimido[4,5-5 γ ,5 δ] -
pristinamycin I_E
- 25 · 4 ϵ -Allyl-2"-(4-pyridyl)pyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-(4-pyridyl)pyrimido-
[4,5-5 γ ,5 δ]pristinamycin I_E

0022280 2644960

- 4ε-(2-Methylpropen-1-yl)-2"-(4-pyridyl)pyrimido-
[4,5-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 2"-(4-Pyridyl)pyrimido[4,5-5γ,5δ]-
5 (4ζ-diethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(4-Pyridyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(4-Pyridyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 10 · 2"-(4-Pyridyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(4-Pyridyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
(4-pyridylmethyl)amino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 15 · 2"-(4-Pyridyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 2"-(4-Pyridyl)pyrimido[4,5-5γ,5δ](4ζ-methyl)-
(4ζ-dedimethylamino)pristinamycin I_E
- 20 · 2"-(4-Pyridyl)pyrimido[4,5-5γ,5δ](4ζ-tert-butyl)-
(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"-methylthiopyrimido[4,5-5γ,5δ]-
pristinamycin I_E
- 4ε-Bromo-2"-methylthiopyrimido[4,5-5γ,5δ]-
25 (4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Allyl-2"-methylthiopyrimido[4,5-5γ,5δ]-
pristinamycin I_E
- 4ε-Allyl-2"-methylthiopyrimido[4,5-5γ,5δ]-

002280 064E496

- (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-methylthiopyrimido-[4,5-5γ,5δ]pristinamycin I_E
 - 4ε-(2-Methylpropen-1-yl)-2"-methylthiopyrimido-
 - 5 [4,5-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino) -
pristinamycin I_E
 - 2"-Methylthiopyrimido[4,5-5γ,5δ] (4ζ-diethylamino) -
(4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Methylthiopyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-
 - 10 allylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Methylthiopyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-
ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Methylthiopyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-
propylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 15 · 2"-Methylthiopyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-
(4-pyridylmethyl)amino) (4ζ-dedimethylamino) -
pristinamycin I_E
 - 2"-Methylthiopyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-
(3-pyridylmethyl)amino) (4ζ-dedimethylamino) -
 - 20 pristinamycin I_E
 - 2"-Methylthiopyrimido[4,5-5γ,5δ] (4ζ-methyl) -
(4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Methylthiopyrimido[4,5-5γ,5δ] (4ζ-tert-butyl) -
(4ζ-dedimethylamino)pristinamycin I_E
 - 25 · 4ε-Bromo-2"- (3-aminophenyl)pyrimido[4,5-5γ,5δ] -
pristinamycin I_E
 - 4ε-Bromo-2"- (3-aminophenyl)pyrimido[4,5-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

002280" 26FE4960

- 4ε-Allyl-2"-(3-aminophenyl)pyrimido[4,5-5γ,5δ]-
pristinamycin I_E
- 4ε-Allyl-2"-(3-aminophenyl)pyrimido[4,5-5γ,5δ]-
(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 5 · 4ε-(2-Methylpropen-1-yl)-2"-(3-aminophenyl)-
pyrimido[4,5-5γ,5δ]pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-(3-aminophenyl)-
pyrimido[4,5-5γ,5δ](4ζ-methylamino)(4ζ-dedimethyl-
amino)pristinamycin I_E
- 10 · 2"-(3-Aminophenyl)pyrimido[4,5-5γ,5δ]-
(4ζ-diethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-
N-allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-
15 N-ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-
N-propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-
N-(4-pyridylmethyl)amino)(4ζ-dedimethylamino)-
20 pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-
N-(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5γ,5δ](4ζ-methyl)-
25 (4ζ-dedimethylamino)pristinamycin I_E
- 2"-(3-Aminophenyl)pyrimido[4,5-5γ,5δ](4ζ-tert-
butyl)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"-(1-pyrrolidinyl)pyrimido[4,5-5γ,5δ]-

002280" 267E4960

- (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 · 4ε-Allyl-2"-(1-pyrrolidinyl)pyrimido[4,5-5γ,5δ]-
 pristinamycin I_E
 · 4ε-Allyl-2"-(1-pyrrolidinyl)pyrimido[4,5-5γ,5δ]-
 5 (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 · 4ε-(2-Methylpropen-1-yl)-2"-(1-pyrrolidinyl)-
 pyrimido[4,5-5γ,5δ]pristinamycin I_E
 · 4ε-(2-Methylpropen-1-yl)-2"-(1-pyrrolidinyl)-
 pyrimido[4,5-5γ,5δ] (4ζ-methylamino)-
 10 (4ζ-dedimethylamino)pristinamycin I_E
 · 2"-(1-Pyrrolidinyl)pyrimido[4,5-5γ,5δ] (4ζ-
 diethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 · 2"-(1-Pyrrolidinyl)pyrimido[4,5-5γ,5δ] (4ζ-N-
 methyl-N-allylamino) (4ζ-dedimethylamino)pristinamycin I_E
 15 · 2"-(1-Pyrrolidinyl)pyrimido[4,5-5γ,5δ] (4ζ-N-
 methyl-N-ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 · 2"-(1-Pyrrolidinyl)pyrimido[4,5-5γ,5δ] (4ζ-N-
 methyl-N-propylamino) (4ζ-dedimethylamino)pristinamycin
 I_E
 20 · 2"-(1-Pyrrolidinyl)pyrimido[4,5-5γ,5δ] (4ζ-N-
 methyl-N-(4-pyridylmethyl)amino) (4ζ-dedimethylamino)-
 pristinamycin I_E
 · 2"-(1-Pyrrolidinyl)pyrimido[4,5-5γ,5δ] (4ζ-N-
 methyl-N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino)-
 25 pristinamycin I_E
 · 2"-(1-Pyrrolidinyl)pyrimido[4,5-5γ,5δ] (4ζ-methyl)-
 (4ζ-dedimethylamino)pristinamycin I_E
 · 2"-(1-Pyrrolidinyl)pyrimido[4,5-5γ,5δ] (4ζ-tert-

002280" 2674960

- butyl) (4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"-(1-azetidiny)pyrimido[4,5-5γ,5δ]-pristinamycin I_E
 - 4ε-Bromo-2"-(1-azetidiny)pyrimido[4,5-5γ,5δ]-
 - 5 (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-Allyl-2"-(1-azetidiny)pyrimido[4,5-5γ,5δ]-pristinamycin I_E
 - 4ε-Allyl-2"-(1-azetidiny)pyrimido[4,5-5γ,5δ]-
 - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 10 · 4ε-(2-Methylpropen-1-yl)-2"-(1-azetidiny)-pyrimido[4,5-5γ,5δ]pristinamycin I_E
 - 4ε-(2-Methylpropen-1-yl)-2"-(1-azetidiny)-pyrimido[4,5-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 15 · 2"-(1-Azetidiny)pyrimido[4,5-5γ,5δ]-
 - (4ζ-diethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-(1-Azetidiny)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-allylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-(1-Azetidiny)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-
 - 20 N-ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-(1-Azetidiny)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-propylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-(1-Azetidiny)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-(4-pyridylmethyl) amino) (4ζ-dedimethylamino)-
 - 25 pristinamycin I_E
 - 2"-(1-Azetidiny)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl) amino) (4ζ-dedimethylamino)-pristinamycin I_E

002220 167E4960

- 2"-(1-Azetidinyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -methyl)-(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(1-Azetidinyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -tert-butyl)(4 ζ -dedimethylamino)pristinamycin I_E
- 5 · 4 ϵ -Bromo-2"-(3-pyridyl)pyrimido[4,5-5 γ ,5 δ]-pristinamycin I_E
- 4 ϵ -Bromo-2"-(3-pyridyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-(3-pyridyl)pyrimido[4,5-5 γ ,5 δ]-
- 10 pristinamycin I_E
- 4 ϵ -Allyl-2"-(3-pyridyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-(3-pyridyl)pyrimido-[4,5-5 γ ,5 δ]pristinamycin I_E
- 15 · 4 ϵ -(2-Methylpropen-1-yl)-2"-(3-pyridyl)pyrimido-[4,5-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)-pristinamycin I_E
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -diethylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 20 · 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -N-methyl-N-allylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -N-methyl-N-ethylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -N-methyl-N-
- 25 propylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ](4 ζ -N-methyl-N-(4-pyridylmethyl)amino)(4 ζ -dedimethylamino)-pristinamycin I_E

00643197 082200

- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl)amino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl) -
5 (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(3-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-(2-pyridyl)pyrimido[4,5-5 γ ,5 δ] -
pristinamycin I_E
- 10 · 4 ϵ -Bromo-2"-(2-pyridyl)pyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-(2-pyridyl)pyrimido[4,5-5 γ ,5 δ] -
pristinamycin I_E
- 4 ϵ -Allyl-2"-(2-pyridyl)pyrimido[4,5-5 γ ,5 δ] -
15 (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-(2-pyridyl)pyrimido-
[4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-(2-pyridyl)pyrimido-
[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -
20 pristinamycin I_E
- 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] -
(4 ζ -diethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 25 · 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
propylamino) (4 ζ -dedimethylamino)pristinamycin I_E

002280" 2674960

- 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(4-pyridylmethyl)amino) (4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
5 (3-pyridylmethyl)amino) (4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl)-
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(2-Pyridyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl)-
10 (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-methylpyrimido[4,5-5 γ ,5 δ]pristinamycin
I_E
- 4 ϵ -Bromo-2"-methylpyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-methylpyrimido[4,5-5 γ ,5 δ]pristinamycin
15 I_E
- 4 ϵ -Allyl-2"-methylpyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-methylpyrimido-
20 [4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-methylpyrimido-
[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-Methylpyrimido[4,5-5 γ ,5 δ] (4 ζ -diethylamino)-
25 (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-

0022280" 267E4960

- ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 2"-Methylpyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-propylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Methylpyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-
 - 5 (4-pyridylmethyl)amino) (4ζ-dedimethylamino)-pristinamycin I_E
 - 2"-Methylpyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino)-pristinamycin I_E
 - 10 · 2"-Methylpyrimido[4,5-5γ,5δ] (4ζ-methyl)-(4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Methylpyrimido[4,5-5γ,5δ] (4ζ-tert-butyl)-(4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-Bromo-2"-(2-pyrazinyl)pyrimido[4,5-5γ,5δ]-
 - 15 pristinamycin I_E
 - 4ε-Bromo-2"-(2-pyrazinyl)pyrimido[4,5-5γ,5δ]-(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-Allyl-2"-(2-pyrazinyl)pyrimido[4,5-5γ,5δ]-pristinamycin I_E
 - 20 · 4ε-Allyl-2"-(2-pyrazinyl)pyrimido[4,5-5γ,5δ]-(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-(2-methylpropen-1-yl)-2"-(2-pyrazinyl)pyrimido-[4,5-5γ,5δ]pristinamycin I_E
 - 4ε-(2-methylpropen-1-yl)-2"-(2-pyrazinyl)pyrimido-
 - 25 [4,5-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethylamino)-pristinamycin I_E
 - 2"-(2-Pyrazinyl)pyrimido[4,5-5γ,5δ]-(4ζ-diethylamino) (4ζ-dedimethylamino)pristinamycin I_E

002200 "082200 2643197 05643197

- 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 5 · 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-propylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(4-pyridylmethyl)amino) (4 ζ -dedimethylamino) - pristinamycin I_E
- 10 · 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl)amino) (4 ζ -dedimethylamino) - pristinamycin I_E
- 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl) - (4 ζ -dedimethylamino)pristinamycin I_E
- 15 · 2"-(2-Pyrazinyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-(2-morpholinoethylthio)pyrimido-[4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -Bromo-2"-(2-morpholinoethylthio)pyrimido-
- 20 [4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) - pristinamycin I_E
- 4 ϵ -Allyl-2"-(2-morpholinoethylthio)pyrimido-[4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -Allyl-2"-(2-morpholinoethylthio)pyrimido-
- 25 [4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) - pristinamycin I_E
- 4 ϵ -(2-methylpropen-1-yl)-2"-(2-morpholinoethylthio)pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E

002280 2644360

- 4ε-(2-methylpropen-1-yl)-2"-(2-morpholino-ethylthio)pyrimido[4,5-5γ,5δ](4ζ-methylamino)-(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5γ,5δ]-
- 5 (4ζ-diethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5γ,5δ]-
- (4ζ-N-methyl-N-allylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5γ,5δ]-
- 10 (4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5γ,5δ]-
- (4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 15 · 2"-(2-Morpholinoethylthio)pyrimido[4,5-5γ,5δ]-
- (4ζ-N-methyl-N-(4-pyridylmethyl)amino)-(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5γ,5δ]-
- (4ζ-N-methyl-N-(3-pyridylmethyl)amino)-(4ζ-dedimethylamino)pristinamycin I_E
- 20 (4ζ-dedimethylamino)pristinamycin I_E
- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5γ,5δ]-
- (4ζ-methyl)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-(2-Morpholinoethylthio)pyrimido[4,5-5γ,5δ]-
- (4ζ-tert-butyl)(4ζ-dedimethylamino)pristinamycin I_E
- 25 · 4ε-Bromo-2"-aminopyrimido[4,5-5γ,5δ]pristinamycin I_E
- 4ε-Bromo-2"-aminopyrimido[4,5-5γ,5δ]-
- (4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E

002280" 2644960

- 4ε-Allyl-2"-aminopyrimido[4,5-5γ,5δ]pristinamycin
I_E
- 4ε-Allyl-2"-aminopyrimido[4,5-5γ,5δ]-
(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 5 · 4ε-(2-Methylpropen-1-yl)-2"-aminopyrimido-
[4,5-5γ,5δ]pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-aminopyrimido-
[4,5-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 10 · 2"-Aminopyrimido[4,5-5γ,5δ](4ζ-diethylamino)-
(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Aminopyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Aminopyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
15 ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Aminopyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-Aminopyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
(4-pyridylmethyl)amino)(4ζ-dedimethylamino)-
20 pristinamycin I_E
- 2"-Aminopyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-
(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-
pristinamycin I_E
- 2"-Aminopyrimido[4,5-5γ,5δ](4ζ-methyl)-
25 (4ζ-dedimethylamino)pristinamycin I_E
- 2"-Aminopyrimido[4,5-5γ,5δ](4ζ-tert-butyl)-
(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-Bromo-2"-(1-pyrazolyl)pyrimido[4,5-5γ,5δ]-

09643197 082200

pristinamycin I_E

· 4ε-Bromo-2"-(1-pyrazolyl)pyrimido[4,5-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E

· 4ε-Allyl-2"-(1-pyrazolyl)pyrimido[4,5-5γ,5δ]-

5 pristinamycin I_E

· 4ε-Allyl-2"-(1-pyrazolyl)pyrimido[4,5-5γ,5δ]-

(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E

· 4ε-(2-Methylpropen-1-yl)-2"-(1-pyrazolyl)pyrimido-[4,5-5γ,5δ]pristinamycin I_E

10 · 4ε-(2-Methylpropen-1-yl)-2"-(1-pyrazolyl)pyrimido-[4,5-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E

· 2"-(1-Pyrazolyl)pyrimido[4,5-5γ,5δ](4ζ-diethylamino)(4ζ-dedimethylamino)pristinamycin I_E

15 · 2"-(1-Pyrazolyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-allylamino)(4ζ-dedimethylamino)pristinamycin I_E

· 2"-(1-Pyrazolyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)pristinamycin I_E

· 2"-(1-Pyrazolyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)pristinamycin I_E

20 · 2"-(1-Pyrazolyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-(4-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E

· 2"-(1-Pyrazolyl)pyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E

25 · 2"-(1-Pyrazolyl)pyrimido[4,5-5γ,5δ](4ζ-methyl)-(4ζ-dedimethylamino)pristinamycin I_E

002280 08200 09643197

- 2"-(1-Pyrazolyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-(diethylaminoethylthio)pyrimido-[4,5-5 γ ,5 δ]pristinamycin I_E
- 5 • 4 ϵ -Bromo-2"-(diethylaminoethylthio)pyrimido-[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) - pristinamycin I_E
- 4 ϵ -Allyl-2"-(diethylaminoethylthio)pyrimido-[4,5-5 γ ,5 δ]pristinamycin I_E
- 10 • 4 ϵ -Allyl-2"-(diethylaminoethylthio)pyrimido-[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) - pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-(diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 15 • 4 ϵ -(2-Methylpropen-1-yl)-2"-(diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) - (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(1-Pyrazolyl)pyrimido[4,5-5 γ ,5 δ] (4 ζ -diethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 20 • 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 25 • 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-propylamino) (4 ζ -dedimethylamino) - pristinamycin I_E

002280 267E4960

- 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -N-methyl-N-(4-pyridylmethyl)amino)(4 ζ -dedimethyl-
amino)pristinamycin I_E
- 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ]-
5 (4 ζ -N-methyl-N-(3-pyridylmethyl)amino)(4 ζ -dedimethyl-
amino)pristinamycin I_E
- 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methyl)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-(Diethylaminoethylthio)pyrimido[4,5-5 γ ,5 δ]-
10 (4 ζ -tert-butyl)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-methylaminopyrimido[4,5-5 γ ,5 δ]-
pristinamycin I_E
- 4 ϵ -Bromo-2"-methylaminopyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 15 · 4 ϵ -Allyl-2"-methylaminopyrimido[4,5-5 γ ,5 δ]-
pristinamycin I_E
- 4 ϵ -Allyl-2"-methylaminopyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-methylaminopyrimido-
20 [4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-methylaminopyrimido-
[4,5-5 γ ,5 δ](4 ζ -methylamino)(4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-Methylaminopyrimido[4,5-5 γ ,5 δ]-
25 (4 ζ -diethylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methylaminopyrimido[4,5-5 γ ,5 δ](4 ζ -N-methyl-N-
allylamino)(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Methylaminopyrimido[4,5-5 γ ,5 δ](4 ζ -N-methyl-N-

002280" 267E4960

- ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
- 2"-Methylaminopyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-propylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Methylaminopyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-
 - 5 (4-pyridylmethyl)amino) (4ζ-dedimethylamino) -
pristinamycin I_E
 - 2"-Methylaminopyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino) -
pristinamycin I_E
 - 10 · 2"-Methylaminopyrimido[4,5-5γ,5δ] (4ζ-methyl) -
(4ζ-dedimethylamino)pristinamycin I_E
 - 2"-Methylaminopyrimido[4,5-5γ,5δ] (4ζ-tert-butyl) -
(4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-Bromo-2"-methylsulphonylpyrimido[4,5-5γ,5δ] -
 - 15 pristinamycin I_E
 - 4ε-Bromo-2"-methylsulphonylpyrimido[4,5-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-Allyl-2"-methylsulphonylpyrimido[4,5-5γ,5δ] -
pristinamycin I_E
 - 20 · 4ε-Allyl-2"-methylsulphonylpyrimido[4,5-5γ,5δ] -
(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-(2-methylpropen-1-yl)-2"-methylsulphonyl-
pyrimido[4,5-5γ,5δ]pristinamycin I_E
 - 4ε-(2-methylpropen-1-yl)-2"-methylsulphonyl-
 - 25 pyrimido[4,5-5γ,5δ] (4ζ-methylamino) (4ζ-
dedimethylamino)pristinamycin I_E
 - 2"-methylsulphonylpyrimido[4,5-5γ,5δ] -
(4ζ-diethylamino) (4ζ-dedimethylamino)pristinamycin I_E

09643197 " 082200

- 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 5 · 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-propylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(4-pyridylmethyl) amino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 10 · 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl) amino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methyl) (4 ζ -dedimethylamino)pristinamycin I_E
- 15 · 2"-methylsulphonylpyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-(4-aminophenyl)pyrimido[4,5-5 γ ,5 δ] -
pristinamycin I_E
- 4 ϵ -Bromo-2"-(4-aminophenyl)pyrimido[4,5-5 γ ,5 δ] -
20 (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-(4-aminophenyl)pyrimido[4,5-5 γ ,5 δ] -
pristinamycin I_E
- 4 ϵ -Allyl-2"-(4-aminophenyl)pyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 25 · 4 ϵ -(2-Methylpropen-1-yl)-2"-(4-aminophenyl) -
pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-(4-aminophenyl) -
pyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) -

002280" 2674960

- (4ζ-dedimethylamino)pristinamycin I_E
- 2"-(4-Aminophenyl)pyrimido[4,5-5γ,5δ]-
 - (4ζ-diethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-(4-Aminophenyl)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-
 - 5 N-allylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-(4-Aminophenyl)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-
 - N-ethylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-(4-Aminophenyl)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-
 - N-propylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 10 · 2"-(4-Aminophenyl)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-
 - N-(4-pyridylmethyl)amino) (4ζ-dedimethylamino) -
 - pristinamycin I_E
 - 2"-(4-Aminophenyl)pyrimido[4,5-5γ,5δ] (4ζ-N-methyl-
 - N-(3-pyridylmethyl)amino) (4ζ-dedimethylamino) -
 - 15 pristinamycin I_E
 - 2"-(4-Aminophenyl)pyrimido[4,5-5γ,5δ] (4ζ-methyl) -
 - (4ζ-dedimethylamino)pristinamycin I_E
 - 2"-(4-Aminophenyl)pyrimido[4,5-5γ,5δ] (4ζ-tert-
 - butyl) (4ζ-dedimethylamino)pristinamycin I_E
 - 20 · 4ε-Bromo-2"-trifluoromethylpyrimido[4,5-5γ,5δ] -
 - pristinamycin I_E
 - 4ε-Bromo-2"-trifluoromethylpyrimido[4,5-5γ,5δ] -
 - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-Allyl-2"-trifluoromethylpyrimido[4,5-5γ,5δ] -
 - 25 pristinamycin I_E
 - 4ε-Allyl-2"-trifluoromethylpyrimido[4,5-5γ,5δ] -
 - (4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E
 - 4ε-(2-Methylpropen-1-yl)-2"-trifluoromethyl-

00643197 082200

4ε-(2-Methylpropen-1-yl)-2"-trifluoromethyl-
pyrimido[4,5-5γ,5δ] (4ζ-methylamino) (4ζ-dedimethyl-
amino)pristinamycin I_E

2"-Trifluoromethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E

2"-Trifluoromethylpyrimido[4,5-5',5δ] (4ζ-N-methyl-N-ethylamino) (4ζ-dedimethylamino)pristinamycin I_E

2"-Trifluoromethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-propylamino) (4 ζ -dedimethylamino)pristinamycin I_E

2"-Trifluoromethylpyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-(4-pyridylmethyl) amino) (4ζ-dedimethylamino) -

2"-Trifluoromethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl) amino) (4 ζ -dedimethylamino) -
pristinamycin I₂

2"-Trifluoromethylpyrimido[4,5-5y,5δ] (4ζ-methyl)-

(4ζ-dedimethylamino)pristinamycin I_E

2"-Trifluoromethylpyrimido[4,5-5γ,5δ] (4ζ-tert-butyl) (4ζ-dedimethylamino)pristinamycin I_E

4ε-Bromo-2"-cyclopropylpyrimido[4,5-5γ,5δ]-
pristinamycin I_E

(4ζ-methylamino) (4ζ-dedimethylamino)pristinamycin I_E

4ε-Allyl-2"-cyclopropylpyrimido[4,5-5γ,5δ]-
pristinamycin I_E

- 4ε-Allyl-2"-cyclopropylpyrimido[4,5-5γ,5δ]-(4ζ-methylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 4ε-(2-Methylpropen-1-yl)-2"-cyclopropylpyrimido-[4,5-5γ,5δ]pristinamycin I_E
- 5 · 4ε-(2-Methylpropen-1-yl)-2"-cyclopropylpyrimido-[4,5-5γ,5δ](4ζ-methylamino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-cyclopropylpyrimido[4,5-5γ,5δ]-(4ζ-diethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 10 · 2"-cyclopropylpyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-allylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-cyclopropylpyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-ethylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 2"-cyclopropylpyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-propylamino)(4ζ-dedimethylamino)pristinamycin I_E
- 15 · 2"-cyclopropylpyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-(4-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E
- 2"-cyclopropylpyrimido[4,5-5γ,5δ](4ζ-N-methyl-N-(3-pyridylmethyl)amino)(4ζ-dedimethylamino)-pristinamycin I_E
- 20 · 2"-cyclopropylpyrimido[4,5-5γ,5δ](4ζ-methyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 2"-cyclopropylpyrimido[4,5-5γ,5δ](4ζ-tert-butyl)-(4ζ-dedimethylamino)pristinamycin I_E
- 25 · 4ε-Bromo-2"-morpholinomethylpyrimido[4,5-5γ,5δ]-pristinamycin I_E
- 4ε-Bromo-2"-morpholinomethylpyrimido-

002280" 082200 09643197

[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -
pristinamycin I_E

· 4 ϵ -Allyl-2"-morpholinomethylpyrimido[4,5-5 γ ,5 δ] -
pristinamycin I_E

5 · 4 ϵ -Allyl-2"-morpholinomethylpyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 4 ϵ -(2-Methylpropen-1-yl)-2"-morpholinomethyl-
pyrimido[4,5-5 γ ,5 δ]pristinamycin I_E

· 4 ϵ -(2-Methylpropen-1-yl)-2"-morpholinomethyl-
10 pyrimido[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethyl-
amino)pristinamycin I_E

· 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ] -
(4 ζ -diethylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-
15 methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-
methyl-N-ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-
methyl-N-propylamino) (4 ζ -dedimethylamino)pristinamycin

20 I_E

· 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-
methyl-N-(4-pyridylmethyl) amino) (4 ζ -dedimethylamino) -
pristinamycin I_E

· 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-
25 methyl-N-(3-pyridylmethyl) amino) (4 ζ -dedimethylamino) -
pristinamycin I_E

· 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl) -
(4 ζ -dedimethylamino)pristinamycin I_E

002230" 2614960

- 2"-Morpholinomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-ethylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 5 · 4 ϵ -Bromo-2"-ethylpyrimido[4,5-5 γ ,5 δ]-
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Allyl-2"-ethylpyrimido[4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -Allyl-2"-ethylpyrimido[4,5-5 γ ,5 δ]-
10 (4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-ethylpyrimido-
[4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-ethylpyrimido-
[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino)-
15 pristinamycin I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -diethylamino)-
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 20 · 2"-Ethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
propylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
25 (4-pyridylmethyl)amino) (4 ζ -dedimethylamino)-
pristinamycin I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
(3-pyridylmethyl)amino) (4 ζ -dedimethylamino)-

002230" 03E4960

pristinamycin I_E

- 2"-Ethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl) -
(4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Ethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl) -
5 (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -Bromo-2"-propylpyrimido[4,5-5 γ ,5 δ]pristinamycin
I_E
- 4 ϵ -Bromo-2"-propylpyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 10 · 4 ϵ -Allyl-2"-propylpyrimido[4,5-5 γ ,5 δ]pristinamycin
I_E
- 4 ϵ -Allyl-2"-propylpyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-propylpyrimido-
15 [4,5-5 γ ,5 δ]pristinamycin I_E
- 4 ϵ -(2-Methylpropen-1-yl)-2"-propylpyrimido-
[4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -
pristinamycin I_E
- 2"-Propylpyrimido[4,5-5 γ ,5 δ] (4 ζ -diethylamino) -
20 (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Propylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
allylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Propylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 25 · 2"-Propylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
propylamino) (4 ζ -dedimethylamino)pristinamycin I_E
- 2"-Propylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
(4-pyridylmethyl) amino) (4 ζ -dedimethylamino) -

002280 2614960

pristinamycin I_E

· 2"-Propylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl)amino) (4 ζ -dedimethylamino) -

pristinamycin I_E

5 · 2"-Propylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl) -
(4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Propylpyrimido[4,5-5 γ ,5 δ] (4 ζ -tert-butyl) -
(4 ζ -dedimethylamino)pristinamycin I_E

· 4 ϵ -Bromo-2"-isopropylpyrimido[4,5-5 γ ,5 δ] -

10 pristinamycin I_E

· 4 ϵ -Bromo-2"-isopropylpyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 4 ϵ -Allyl-2"-isopropylpyrimido[4,5-5 γ ,5 δ] -
pristinamycin I_E

15 · 4 ϵ -Allyl-2"-isopropylpyrimido[4,5-5 γ ,5 δ] -
(4 ζ -methylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 4 ϵ -(2-Methylpropen-1-yl)-2"-isopropylpyrimido-
[4,5-5 γ ,5 δ]pristinamycin I_E

· 4 ϵ -(2-Methylpropen-1-yl)-2"-isopropylpyrimido-

20 [4,5-5 γ ,5 δ] (4 ζ -methylamino) (4 ζ -dedimethylamino) -
pristinamycin I_E

· 2"-Isopropylpyrimido[4,5-5 γ ,5 δ] (4 ζ -diethylamino) -
(4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Isopropylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
25 allylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Isopropylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-
ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Isopropylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-

002280" 26 FEB 96

2"-Isopropylpyrimido[4,5-5γ,5δ] (4ζ-N-methyl-N-(4-pyridylmethyl)amino) (4ζ-dedimethylamino) -
pristinamycin I_E

2"-Isopropylpyrimido[4,5-5 γ ,5 δ] (4 ζ -methyl)-
(4 ζ -dedimethylamino)pristinamycin I_E

4ε-Bromo-2"-cyclopropylaminomethylpyrimido-
[4,5-5γ,5δ]pristinamycin I_E

4ε-Allyl-2"-cyclopropylaminomethylpyrimido-
[4,5-5γ,5δ]pristinamycin I_E

4ε-(2-Methylpropen-1-yl)-2"-cyclopropylamino-
methylpyrimido[4,5-5γ,5δ]pristinamycin I_E

2"-Cyclopropylaminomethylpyrimido[4,5-5γ,5δ] (4ζ-diethylamino) (4ζ-dedimethylamino)pristinamycin I_E

· 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-allylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-ethylamino) (4 ζ -dedimethylamino)pristinamycin I_E

5 · 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-propylamino) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(4-pyridylmethyl)amino) (4 ζ -dedimethylamino)-
10 pristinamycin I_E

· 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ] (4 ζ -N-methyl-N-(3-pyridylmethyl)amino) (4 ζ -dedimethylamino)-
pristinamycin I_E

· 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ]-
15 (4 ζ -methyl) (4 ζ -dedimethylamino)pristinamycin I_E

· 2"-Cyclopropylaminomethylpyrimido[4,5-5 γ ,5 δ]-
(4 ζ -tert-butyl) (4 ζ -dedimethylamino)pristinamycin I_E

PREPARATION OF THE INTERMEDIATES

Example A

20 Method a

170 mg of pristinamycin I_B dissolved in 0.5 cm³ of dry dimethylformamide are placed in a three-necked flask maintained under a nitrogen atmosphere, and then 0.026 cm³ of 3,3-dimethylallyl bromide
25 dissolved in 0.2 cm³ of dry dimethylformamide is added. After stirring for 3 hours at room temperature, the reaction mixture is diluted with 10 cm³ of distilled water and then washed with twice 20 cm³ of ethyl

002280 1674960

acetate. The organic phase is decanted off, washed with water, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give a solid which is taken up in ethyl ether and then dried.

- 5 The solid is purified by flash chromatography (eluent: dichloromethane-methanol 97/3) to give 57 mg of 4-N-(2-methyl-2-buten-4-yl)pristinamycin I_B in the form of a pale-yellow solid melting at 170°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

- 10 1.70 (s, 6H : CH₃); 2.85 (s, 3H : ArNCH₃); 2.87 (mt, 1H : 1H of CH₂ at position 4β); 3.23 (s, 3H : NCH₃); 3.30 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β); 3.82 and 3.91 (2 dd, J = 16.5 and 5 Hz, 1H each : ArNCH₂); 5.08 (mt, 1H : CH=); 5.18 (dd, J = 12 and 4 Hz, 15 1H : 4α); 6.62 (d, J = 8.5 Hz, 2H : aromatic H at position 4ε); 7.03 (d, J = 8.5 Hz, 2H : aromatic H at position 4δ).

Method b

- 660 mg of pristinamycin I_B dissolved in 20 3.3 cm³ of dry chloroform (over amylene) are placed in a three-necked flask maintained under a nitrogen atmosphere, and then 65 mg of NaHCO₃ powder are added. After stirring for one hour, 0.09 cm³ of 3,3-dimethylallyl bromide dissolved in 0.9 cm³ of dry 25 chloroform (over amylene) is added. After stirring for 18 hours at room temperature, the reaction mixture is diluted with 20 cm³ of chloroform and then washed with 3 times 5 cm³ of distilled water. The organic phase is

09643197 "082200

5 chromatography (eluent: dichloromethane-methanol 97/3) to give 360 mg of 4-N-(2-methyl-2-buten-4-yl)-pristinamycin I_B in the form of a pale-yellow solid melting at 170°C.

1.7 g of pristinamycin I_B in 5.1 cm³ of dry dimethylformamide are placed in a three-necked flask maintained under a nitrogen atmosphere, and then 310 mg of crotyl bromide are added. The mixture is stirred for 22 hours at room temperature. The reaction mixture is diluted with 50 cm³ of distilled water, with stirring, and then extracted with twice 20 cm³ of ethyl acetate. The aqueous phase is decanted off and the organic phase is washed with twice 10 cm³ of distilled water, decanted off, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 1.1 g of a yellow oil which is purified by flash chromatography (eluent: dichloromethane-methanol 97/3) to give 0.62 g of 4-N-(2-butenyl)pristinamycin I_B in the form of a white solid melting at 180°C.

25 ^1H NMR spectrum (400 MHz, CDCl_3 , δ in ppm):
1.70 (d, $J = 6$ Hz, 3H : CH_3); from 2.85 to 2.90 (mt,
1H : 1H of CH_2 at position 4 β); 2.90 (s, 3H : ArNCH_3);
3.28 (s, 3H : NCH_3); 3.32 (t, $J = 12$ Hz, 1H : the other

H of CH₂ at position 4β); 3.81 and 3.91 (2 broad d, J = 18 Hz, 1H each : ArNCH₂); 5.22 (dd, J = 12 and 4 Hz, 1H : 4α); 5.43 and 5.57 (d mt and dq respectively, J = 14 Hz and J = 14 and 6 Hz, 1H each : CH=CH); 6.62 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 7.05 (d, J = 8 Hz, 2H : aromatic H at position 4δ).

Example C

By carrying out the procedure as in Example A but starting with 2.5 g of pristinamycin I_B, 400 mg of
 10 bromoacetic acid in 8 cm³ of dry dimethylformamide, 2.1 g of a white solid are obtained after stirring for 48 hours at room temperature, which solid is purified by flash chromatography (successive eluents: dichloromethane-methanol 95/5 then 90/10 then 80/20) to
 15 give 1.1 g of an oil which is taken up in dichloromethane, acidified to pH 4 with acetic acid and then washed with distilled water.

The organic phase is decanted off, dried over magnesium sulphate, filtered and then concentrated
 20 under reduced pressure (2.7 kPa), and then taken up in diethyl ether to give 750 mg of 4-N-(carboxymethyl)-pristinamycin I_B in the form of a white solid melting at 230°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 25 2.85 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.03 (s, 3H : ArNCH₃); from 3.10 to 3.40 (mt, 1H : the other H of CH₂ at position 4β); 3.25 (s, 3H : NCH₃); 4.04 (limiting AB, J = 18 Hz, 2H : ArNCH₂); 5.25 (dd,

J = 12 and 4 Hz, 1H : 4 α); 6.62 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 7.07 (d, J = 8 Hz, 2H : aromatic H at position 4 δ).

Example D

5 By carrying out the procedure as in Example A but starting with 1 g of pristinamycin I_B, 0.1 ml of allyl bromide in 3 cm³ of dry dimethylformamide, 620 mg of a white solid are obtained after stirring for 72 hours at room temperature, which solid is purified
10 by flash chromatography (eluent: dichloromethane-methanol 97/3) to give 290 mg of 4-N-allylpristinamycin I_B in the form of a white-yellow solid melting at 208°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
2.88 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position
15 4 β); 2.90 (s, 3H : ArNCH₃); 3.21 (s, 3H : NCH₃); 3.29 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4 β); 3.85 and 3.95 (2 broad d, J = 18 Hz, 1H each : ArNCH₂); 5.10 and 5.17 (2 d respectively, J = 17 Hz and J = 11.5 Hz, 1H each : =CH₂); 5.20 (dd, J = 12 and 4 Hz,
20 1H : 4 α); 5.78 (mt, 1H : CH=); 6.60 (d, J = 8 Hz, 2H : aromatic H at position 4 ϵ); 7.02 (d, J = 8 Hz, 2H : aromatic H at position 4 δ).

Example E

By carrying out the procedure as in Example A
25 but starting with 1 g of pristinamycin I_B in 3 cm³ of dry dimethylformamide and 230 mg of cinnamyl bromide, 0.8 g of a white solid is obtained after 72 hours at room temperature, which solid is purified by flash

05643197-082200

chromatography (eluent: dichloromethane-methanol 97/3) to give 0.31 g of 4-N-cinnamylpristinamycin I_B in the form of a white solid melting at 204°C.

¹H NMR spectrum (600 MHz, CDCl₃, δ in ppm):

- 5 2.90 (dd, J = 12.5 and 4 Hz, 1H : 1H of CH₂ at position 4β); 2.97 (s, 3H : ArNCH₃); 3.24 (s, 3H : NCH₃); 3.33 (t, J = 12.5 Hz, 1H : the other H of CH₂ at position 4β); 4.70 (limiting AB, J = 18 and 5.5 Hz, 2H : ArNCH₂); 5.20 (dd, J = 12.5 and 4 Hz, 1H : 4α); 6.23 and 6.52
10 (broad d and dt respectively, J = 16.5 and 5.5 Hz and J = 16.5 Hz, 1H each : CH=CH); 6.68 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 7.07 (d, J = 8 Hz, 2H : aromatic H at position 4δ); from 7.25 to 7.40 (mt, 5H : aromatic H of phenyl).

15 **Example F**

- By carrying out the procedure as in Example A but starting with 1 g of pristinamycin I_B in 3 cm³ of dry dimethylformamide and 240 mg of benzyl bromide, 0.85 g of a white solid is obtained after 72 hours at
20 room temperature, which solid is purified by flash chromatography (eluent: dichloromethane-methanol 97/3) to give 0.64 g of 4-N-benzylpristinamycin I_B in the form of a white solid melting at a temperature greater than 260°C.

- 25 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm): 2.86 (dd, J = 12.5 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.10 (s, 3H : ArNCH₃); 3.26 (s, 3H : NCH₃); 3.32 (t, J = 12.5 Hz, 1H : the other H of CH₂ at position

002280" 0614960

4 β); 4.52 and 4.69 (2 d, $J = 18$ Hz, 1H each : ArNCH₂);
 5.16 (dd, $J = 12.5$ and 4 Hz, 1H : 4 α); 6.59 (d,
 $J = 8$ Hz, 2H : aromatic H at position 4 ϵ); 7.01 (d,
 $J = 8$ Hz, 2H : aromatic H at position 4 δ); 7.18 (mt,
 5 2H : H at the ortho position of the benzyl); 7.28 (mt,
 2H : H at the meta position of the benzyl); 7.40 (t,
 $J = 7.5$ Hz, 1H : H at the para position of the benzyl).

Example G

By carrying out the procedure as in Example A
 10 but starting with 1 g of pristinamycin I_B in 3 cm³ of
 dry dimethylformamide and 200 mg of ethyl iodide,
 0.65 g of a pale-yellow solid is obtained after 5 hours
 at 60°C and then 72 hours at room temperature and after
 adding an additional 20 mg of ethyl iodide and heating
 15 at 60°C for 4 hours, which solid is purified by flash
 chromatography (eluent: dichloromethane-methanol 97/3)
 to give 0.37 g of 4-N-ethylpristinamycin I_B in the form
 of a white solid melting at a temperature greater than
 260°C.

20 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 1.10 (t, $J = 7$ Hz, 3H : CH₃ of ethyl); 2.87 (s, 3H :
 ArNCH₃); 2.90 (dd, $J = 12.5$ and 4 Hz, 1H : 1H of CH₂ at
 position 4 β); 3.25 (s, 3H : NCH₃); 3.32 (t, $J = 12.5$ Hz,
 1H : the other H of CH₂ at position 4 β); 3.39 (mt, 2H :
 25 ArNCH₂); 5.21 (dd, $J = 12.5$ and 4 Hz, 1H : 4 α); 6.60 (d,
 $J = 8$ Hz, 2H : aromatic H at position 4 ϵ); 7.04 (d,
 $J = 8$ Hz, 2H : aromatic H at position 4 δ).

09643197 082200

Example H

1 g of pristinamycin I_B in 3 cm³ of dry dimethylformamide is placed in a three-necked flask maintained under a nitrogen atmosphere, and then 175 mg of a mixture of about 20% 4-bromo-1-butene, 15% of bromomethylcyclopropane and 65% of bromocyclobutane and 195 mg of sodium iodide are added. The mixture is stirred for 72 hours at room temperature and then heated for 7 hours at 60°C. 175 mg of this mixture are again added and then the stirring is continued for 48 hours. The reaction mixture is diluted with 50 cm³ of distilled water, with stirring, and then extracted with twice 20 cm³ of ethyl acetate. The aqueous phase is decanted off and then the organic phase is washed with twice 10 cm³ of distilled water, decanted off, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 800 mg of a white powder which is purified by flash chromatography (eluent: dichloromethane-methanol 98/2) and then by high-performance liquid chromatography (HPLC) to give 220 mg of 4-N-(but-2-enyl)pristinamycin I_B in the form of a white solid melting at 190°C.

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):
2.29 (mt, 2H : CH₂); 2.88 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4β); 2.90 (s, 3H : ArNCH₃); 3.25 (s, 3H : NCH₃); 3.31 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β); 3.38 (mt, 2H : ArNCH₂); 5.05 and 5.10 (2 dd, respectively J = 10.5 and 2 Hz and J = 16.5 and

002280 264960

2 Hz, 1H each : =CH₂); 5.20 (dd, J = 12 and 4 Hz, 1H : 4α); 5.78 (mt, 1H : CH=); 6.62 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 7.04 (d, J = 8 Hz, 2H : aromatic H at position 4δ).

5 **Example I**

1 g of pristinamycin I_B in 3 cm³ of dry dimethylformamide is placed in a three-necked flask maintained under a nitrogen atmosphere, and then 175 mg of a mixture of about 20% 4-bromo-1-butene, 15% of
10 bromomethylcyclopropane and 65% of bromocyclobutane and 195 mg of sodium iodide are added. The mixture is stirred for 72 hours at room temperature and then heated for 7 hours at 60°C. 175 mg of this mixture are again added and then the stirring is continued for
15 48 hours. The reaction mixture is diluted with 50 cm³ of distilled water, with stirring, and then extracted with twice 20 cm³ of ethyl acetate. The aqueous phase is decanted off and then the organic phase is washed with twice 10 cm³ of distilled water, decanted off, dried
20 over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 800 mg of a white powder which is purified by flash chromatography (eluent: dichloromethane-methanol 98/2) and then by HPLC chromatography to give 222 mg of
25 4-N-cyclopropylmethylpristinamycin I_B in the form of a white solid melting at 190°C.

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):
0.20 and 0.53 (2 mts, 2H each : CH₂ of cyclopropane);

09643197-032200

5

Example J

15

2.90 (dd, $J = 12.5$ and 4 Hz, $1H : 1H$ of CH_2 at position 4β); 3.07 (s, $3H : ArNCH_3$); 3.27 (s, $3H : NCH_3$); 3.32

(t, $J = 12.5$ Hz, 1H : the other H of CH_2 at position 4β); 4.50 and 4.63 (2 d, $J = 17$ HzHz, 1H each : ArNCH_2); 5.16 (dd, $J = 12.5$ and 4 Hz, 1H : 4α); 6.59 (d, $J = 8$ Hz, 2H : aromatic H at position 4ϵ); 7.01 (d, $J = 8$ Hz, 2H : aromatic H at position 4δ); 7.13 (d, $J = 5.5$ Hz; 2H : H at position β of pyridine); 8.60 (d, $J = 5.5$ Hz; 2H : H at position α of pyridine).

Example K

By carrying out the procedure as in Example A but starting with 1 g of pristinamycin I_B in 3 cm^3 of dry dimethylformamide and 237 mg of iodobutane, 0.94 g of a pale-yellow solid is obtained after 48 hours at 60°C and then 72 hours at room temperature, which solid is purified by flash chromatography (eluent: dichloromethane-methanol 98/2) to give 0.23 g of Hz4-N-butylpristinamycin I_B in the form of a white solid melting at 170°C .

^1H NMR spectrum (300 MHz, CDCl_3 , δ in ppm): 0.95 (t, $J = 7.5$ Hz, 3H : CH_3 of butyl); 1.35 and 1.55 (2 mts, 2H each : CH_2CH_2 of butyl); 2.90 (s, 3H : ArNCH_3); 2.90 (dd, $J = 12.5$ and 4 Hz, 1H : 1H of CH_2 at position 4β); from 3.20 to 3.40 (mt, 3H : the other H of CH_2 at position 4β and ArNCH_2); 3.28 (s, 3H : NCH_3); 5.21 (dd, $J = 12.5$ and 4 Hz, 1H : 4α); 6.60 (d, $J = 8$ Hz, 2H : aromatic H at position 4ϵ); 7.05 (d, $J = 8$ Hz, 2H : aromatic H at position 4δ).

Example L

By carrying out the procedure as in Example A

002280" 267E4960

but starting with 3 g of pristinamycin I_B in 15 cm³ of dry dimethylformamide and 720 mg of iodopropane, 2.07 g of a pale-yellow oil are obtained after 22 hours at 50°C, which oil is purified by 2 flash chromatographies (eluent: dichloromethane-methanol 98/2 and dichloromethane-methanol 99/1) to give 0.49 g of 4-N-propylpristinamycin I_B in the form of a white solid melting at 220°C (dec.).

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):

0.95 (t, J = 7.5 Hz, 3H : CH₃ of propyl); 1.58 (mt, 2H : CH₂ of propyl); 2.88 (mt, 1H : 1H of CH₂ at position 4β); 2.90 (s, 3H : ArNCH₃); from 3.15 to 3.40 (mt, 3H : the other H of CH₂ at position 4β and ArNCH₂); 3.25 (s, 3H : NCH₃); 5.20 (dd, J = 12.5 and 4 Hz, 1H : 4α); 6.60 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 7.03 (d, J = 8 Hz, 2H : aromatic H at position 4δ).

Example M

By carrying out the procedure as in Example A but starting with 2 g of pristinamycin I_B in 5 cm³ of dry dimethylformamide and 480 mg of 2-iodopropane, 2.07 g of a pale-yellow oil are obtained after 6 hours at 60°C and then 17 hours at room temperature, which oil is purified by flash chromatography (eluent: dichloromethane-methanol 97/3) to give 0.19 g of 4-N-isopropylpristinamycin I_B in the form of a white solid melting at 220°C (dec.).

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):

1.14 and 1.17 (2 d, J = 6.5 Hz, 6H : CH₃ of isopropyl);

002280" 2674960

2.68 (s, 3H : ArNCH₃); 2.88 (dd, J = 12 and 4 Hz, 1H :
 1H of CH₂ at position 4β); 3.23 (s, 3H : NCH₃); 3.30 (t,
 J = 12 Hz, 1H : the other H of CH₂ at position 4β); 3.90
 (mt, 1H : ArNCH); 5.20 (dd, J = 12 and 4 Hz, 1H : 4α);
 5 6.68 (d, J = 8 Hz, 2H : aromatic H at position 4ε);
 7.03 (d, J = 8 Hz, 2H : aromatic H at position 4δ).

Example N

By carrying out the procedure as in Example A
 but starting with 3 g of pristinamycin I_B in 15 cm³ of
 10 dry dimethylformamide and 780 mg of 3-methyl-2-propane
 iodide, 3.86 g of a solid are obtained after 70 hours
 at room temperature and then addition of an additional
 160 mg of 3-methyl-2-propane iodide and heating at 50°C
 for 24 hours, which solid is purified by flash
 15 chromatography (eluent: dichloromethane-methanol 98/2)
 to give 690 mg of 4-N-isobutylpristinamycin I_B in the
 form of a white solid melting at 190°C (dec.).

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):
 0.93 (d, J = 7 Hz, 6H : CH₃ of isobutyl); 2.05 (mt, 1H :
 20 CH of isobutyl); 2.92 (dd, J = 12.5 and 4 Hz, 1H : 1H
 of CH₂ at position 4β); 2.98 (s, 3H : ArNCH₃); 3.10 and
 3.18 (2 dd, J = 15 and 7.5 Hz, 1H each : ArNCH₂); 3.30
 (s, 3H : NCH₃); 3.35 (t, J = 12.5 Hz, 1H : the other H
 of CH₂ at position 4β); 5.20 (dd, J = 12.5 and 4 Hz,
 25 1H : 4δ); 6.60 (d, J = 8 Hz, 2H : aromatic H at
 position 4ε); 7.03 (d, J = 8 Hz, 2H : aromatic H at
 position 4δ).

002280" 26T4960

Example O

3 g of pristinamycin I_B in 15 cm³ of dry dimethylformamide are placed in a three-necked flask maintained under a nitrogen atmosphere, and then 690 mg of 3-chloromethylpyridine hydrochloride and 350 mg of sodium iodide are added. The mixture is stirred for 24 hours at 60°C and then for 48 hours at room temperature. The reaction mixture is poured over 50 cm³ of distilled water supplemented with sodium bicarbonate and then extracted with 3 times 50 cm³ of ethyl acetate. The aqueous phase is decanted off and then the organic phase dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 2.96 g of a yellow solid which is purified by flash chromatography (eluent: dichloromethane-methanol 98/2) to give 409 mg of 4-N-(3-pyridylmethyl)pristinamycin I_B in the form of a white solid melting at 186°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 2.87 (dd, J = 12.5 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.05 (s, 3H : ArNCH₃); 3.23 (s, 3H : NCH₃); 3.29 (t, J = 12.5 Hz, 1H : the other H of CH₂ at position 4β); 4.50 and 4.65 (2 d, J = 18 Hz, 1H each : ArNCH₂); 5.15 (dd, J = 12.5 and 4 Hz, 1H : 4α); 6.62 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 7.05 (d, J = 8 Hz, 2H : aromatic H at position 4δ); 7.35 (mt, 1H : H at position 5 of pyridine); 7.42 (broad d, J = 8 Hz, 1H : H at position 4 of pyridine); 8.45 (broad d, J = 5 Hz, 1H : H at position 6 of pyridine);

8.58 (broad s, 1H : H at position 2 of pyridine).

Example P

3 g of pristinamycin I_B in 15 cm³ of dry dimethylformamide are placed in a three-necked flask maintained under a nitrogen atmosphere, and then 690 mg of 2-chloromethylpyridine hydrochloride and 70 mg of sodium iodide are added. The mixture is stirred for 2 hours at 60°C and then an additional 0.48 g of sodium iodide is added and the stirring is maintained for 23 hours at 60°C. The reaction mixture is poured over 150 cm³ of distilled water supplemented with sodium bicarbonate and then extracted with 3 times 100 cm³ of ethyl acetate. The aqueous phase is decanted off and then the organic phases are pooled and then washed with an aqueous solution of sodium sulphite. The organic phase is decanted off, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 3.34 g of a yellow solid which is purified by flash chromatography (eluent: dichloromethane-methanol 98/2) to give 1.16 g of 4-N-(2-pyridylmethyl)pristinamycin I_B in the form of a white solid melting at 190°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

2.85 (dd, J = 12.5 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.15 (s, 3H : ArNCH₃); 3.24 (s, 3H : NCH₃); 3.29 (t, J = 12.5 Hz, 1H : the other H of CH₂ at position 4β); 4.55 and 4.83 (2 d, J = 18 Hz, 1H each : ArNCH₂); 5.10 (dd, J = 12.5 and 4 Hz, 1H : 4α); 6.57 (d,

J = 8 Hz, 2H : aromatic H at position 4 ϵ); 6.99 (mt, 1H : H at position 3 of pyridine); 7.00 (d, J = 8 Hz, 2H : aromatic H at position 4 δ); 7.08 (dd, J = 7.5 and 5 Hz; 1H : H at position 5 of pyridine); 7.80 (dt, 5 J = 7.5 and 1 Hz, 1H : H at position 4 of pyridine); 8.57 (broad d, J = 5 Hz; 1H : H at position 6 of pyridine).

Example Q

5 g of pristinamycin I_B in 7 cm³ of dry
 10 dimethylformamide are placed in a three-necked flask maintained under a nitrogen atmosphere, and then 0.66 g of 1-chloro-3-hydroxypropane, 50 mg of sodium iodide and 580 mg of potassium bicarbonate are added. The mixture is stirred for 22 hours at 70°C. The reaction
 15 mixture is cooled, poured over 30 cm³ of distilled water and then extracted with 3 times 40 cm³ of ethyl acetate. The aqueous phase is decanted off and then the organic phase dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give
 20 5.41 g of a solid which is purified by flash chromatography (eluent: dichloromethane-methanol 98/2) to give 0.28 g of 4-N-(3-hydroxy-3-propyl)pristinamycin I_B in the form of a white solid melting at 186°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

25 1.75 (mt, 2H : central CH₂ of propyl); 2.88 (mt, 1H : 1H of CH₂ at position 4 β); 2.90 (s, 3H : ArNCH₃); 3.24 (s, 3H : NCH₃); 3.30 (t, J = 12.5 Hz, 1H : the other H of CH₂ at position 4 β); 3.43 and 3.62 (2 mts, 2H each :

002280" 46TCH960

ArNCH₂ and CH₂O); 5.20 (dd, J = 12.5 and 4 Hz, 1H : 4α);
6.68 (unresolved complex, 2H : aromatic H at position
4ε); 7.03 (d, J = 8 Hz, 2H : aromatic H at position
4δ).

5 Example R

By carrying out the procedure as in Example Q
but starting with 4 g of pristinamycin I_B, 1.7 cm³ of
3-(dioxo-1,2-ethylene)bromopropane in 12 cm³ of dry
dimethylformamide, 3.8 g of a yellow solid are obtained
10 after heating for 24 hours at 60°C, which solid is
purified by flash chromatography (eluent:
dichloromethane-methanol 97/3) to give 0.81 g of
4-N-[2-(1,3-dioxolan-2-yl)ethyl]pristinamycin I_B in the
form of a white solid melting at a temperature greater
15 than 260°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
1.91 (mt, 2H : central CH₂); 2.87 (s, 3H : ArNCH₃); 2.88
(dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4β);
3.25 (s, 3H : NCH₃); 3.29 (t, J = 12 Hz, 1H : the other
20 H of CH₂ at position 4β); 3.35 to 3.55 (mt, 2H :
ArNCH₂); 3.87 and 3.97 (2 mts, 2H each : OCH₂CH₂O); 4.92
(t, J = 4 Hz, 1H : OCHO); 5.21 (dd, J = 12 and 4 Hz, 1H
: 4α); 6.64 (d, J = 8 Hz, 2H : aromatic H at position
4ε); 7.04 (d, J = 8 Hz, 2H : aromatic H at position
25 4δ).

Example S

By carrying out the procedure as in Example A
but starting with 0.53 g of 4ε-chloropristinamycin I_B,

002280" 26TEH960

0.082 cm³ of allyl bromide in 3 cm³ of dry dimethylformamide, a solid is obtained after 7 hours at 50°C and then addition of an additional 0.5 cm³ of allyl bromide and heating for 2 hours 30 minutes, which solid is purified by flash chromatography (eluent: dichloromethane-methanol 98/2) to give 77 mg of 4-N-allyl-4ε-chloropristinamycin I_B in the form of a very light yellow solid melting at 175°C (dec.).

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):

2.71 (s, 3H : ArNCH₃); 2.93 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.21 (s, 3H : NCH₃); 3.33 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β); 3.58 (d, J = 6 Hz, 2H : ArNCH₂); 5.20 and 5.27 (2 dd, respectively J = 11 and 1 Hz and J = 16 and 1 Hz, 1H each : =CH₂); 5.30 (dd, J = 12 and 4 Hz, 1H : 4α); from 5.75 to 5.95 (mt, 1H : CH=); 6.95 (d, J = 8 Hz, 1H : aromatic H at position 4ε); 7.03 (dd, J = 8 and 1.5 Hz, 1H : aromatic H at position 4δ); 7.18 (d, J = 1.5 Hz, 1H : aromatic H at position 4δ and at the ortho position with respect to the Cl).

4ε-Chloropristinamycin I_B may be prepared as described in Patent Application EP 772630.

Example T

0.3 g of 4-N-ethoxycarbonylmethyl-pristinamycin I_B in 3.5 cm³ of dichloromethane is placed in a round-bottomed flask and then 51 mg of N-chlorosuccinimide are added. The mixture is stirred for 5 days at room temperature. The reaction mixture is

002280" 46F4960

concentrated to dryness under reduced pressure
 (2.7 kPa) at 30°C. The solid obtained is stirred 3
 times in 5 cm³ of distilled water, filtered, washed with
 3 times 3 cm³ of ether to give a yellow solid which is
 5 recrystallized from 4 cm³ of ethanol. After filtration
 of the crystals and drying under reduced pressure
 (135 Pa) at 50°C, 0.15 g of 4ε-chloro-(4-N-ethoxy-
 carbonylmethyl)pristinamycin I_B is obtained in the form
 of light beige crystals melting at 176°C.

10 ¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):
 1.34 (t, J = 7 Hz, 3H : CH₃ of ethyl); 2.95 (dd, J = 12
 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.05 (s, 3H :
 ArNCH₃); 3.32 (s, 3H : NCH₃); 3.38 (t, J = 12 Hz, 1H :
 the other H of CH₂ at position 4β); 3.85 and 4.19 (2 d,
 15 J = 17.5 Hz, 1H each : ArNCH₂); 4.22 (q, J = 7 Hz, 2H :
 CH₂ of ethyl); 5.29 (dd, J = 12 and 4 Hz, 1H : 4α); 7.10
 (d, J = 8.5 Hz, 1H : aromatic H at position 4ε); 7.25
 (mt, 2H : aromatic H at position 4δ).

 4-N-Ethoxycarbonylmethylpristinamycin I_B may
 20 be prepared as described below in Example AD.

Example U

 By carrying out the procedure as in Example T
 but starting with 0.3 g of 4-N-ethylpristinamycin I_B and
 0.545 g of N-chlorosuccinimide in 3.5 cm³ of
 25 dichloromethane, 0.33 g of a solid is obtained after
 stirring for one week at room temperature, which solid
 is recrystallized from 6 cm³ of ethanol. After
 filtration of the crystals and drying under reduced

002280" 46Feb96 09643197 082200

pressure (135 Pa) at 50°C, 0.15 g of 4ε-chloro-4-N-ethylpristinamycin I_B is obtained in the form of light beige crystals melting at > 260°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):

5 1.16 (t, J = 7 Hz, 3H : CH₃ of ethyl); 2.70 (s, 3H : ArNCH₃); 2.92 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.00 (q, J = 7 Hz, 2H : NCH₂ of ethyl); 3.22 (s, 3H : NCH₃); 3.33 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β); 5.22 (dd, J = 12 and 4 Hz, 1H : 4α); 6.95 (d, J = 8 Hz, 1H : aromatic H at position 4ε); 7.03 (dd, J = 8 and 1.5 Hz, 1H : aromatic H at position 4δ); 7.23 (d, J = 1.5 Hz, 1H : aromatic H at position 4δ and at the ortho position with respect to the Cl).

15 Example V

By carrying out the procedure as in Example T but starting with 200 mg of 4-N-isobutylpristinamycin I_B, 44 mg of N-chlorosuccinimide and 3 cm³ of dichloromethane, 99 mg of a white solid are obtained after stirring for 36 hours at room temperature and then for 40 minutes under reflux, which solid is stirred in 10 cm³ of water, filtered and then rinsed to give 690 mg of 4-N-isobutylpristinamycin I_B in the form of a white solid melting at 190°C (dec.).

25 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm): 0.88 (d, J = 7 Hz, 6H : CH₃ of isobutyl); 1.80 (mt, 1H : CH of isobutyl); 2.69 (s, 3H : ArNCH₃); 2.75 (limiting AB, 2H : ArNCH₂); 2.95 (dd, J = 12 and 4 Hz, 1H : 1H of

002280" 46Feb96

CH₂ at position 4β); 3.25 (s, 3H : NCH₃); 3.34 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β); 5.27 (dd, J = 12 and 4 Hz, 1H : 4α); 6.99 (d, J = 8 Hz, 1H : aromatic H at position 4ε); 7.06 (broad d, J = 8 Hz, 1H : aromatic H at position 4δ); from 7.25 to 7.40 (mt, 1H : aromatic H at position 4δ and at the ortho position with respect to the Cl).

Example W

By carrying out the procedure as in Example T but starting with 224 mg of 4-N-(4-pyridylmethyl)-pristinamycin I_B, 32 mg of N-chlorosuccinimide and 3 cm³ of acetonitrile, a beige solid is obtained after stirring for 2 hours at 65°C, which solid is stirred in 10 cm³ of water, filtered and then rinsed and then purified by flash chromatography (eluent: dichloromethane-methanol 98/2) to give 190 mg of 4ε-chloro-4-N-pyridylmethyl)pristinamycin I_B in the form of a white pale-yellow solid melting at 232°C (dec.).

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm): 2.67 (s, 3H : ArNCH₃); 2.97 (dd, J = 12.5 and 4 Hz, 1H : 1H of CH₂ at position 4β); 3.24 (s, 3H : NCH₃); 3.32 (t, J = 12.5 Hz, 1H : the other H of CH₂ at position 4β); 4.10 (s, 2H : ArNCH₂); 5.29 (dd, J = 12.5 and 4 Hz, 1H : 4α); 6.99 (d, J = 8 Hz, 1H : aromatic H at position 4ε); 7.06 (broad d, J = 8 and 1.5 Hz, 1H : aromatic H at position 4δ); from 7.15 to 7.40 (mt, 1H : aromatic H at position 4δ and at the ortho position with respect to the Cl); 7.37 (d, J = 6 Hz; 2H : H at position β of

002280" 26754960

pyridine); 8.57 (d, $J = 6$ Hz; 2H : H at position α of pyridine).

Example X

By carrying out the procedure as in Example T but starting with 260 mg of 4-N-(3-pyridylmethyl)-pristinamycin I_B, 37 mg of N-chlorosuccinimide and 3 cm³ of acetonitrile, 270 mg of a white solid are obtained after stirring for 20 hours at 65°C, which solid is stirred in 10 cm³ of water, filtered and then rinsed to give 120 mg of 4 ϵ -chloro-4-N-(3-pyridylmethyl)-pristinamycin I_B in the form of a white solid melting at 258°C (dec.).

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):
 2.65 (s, 3H : ArNCH₃); 2.98 (dd, $J = 12$ and 4 Hz, 1H : 1H of CH₂ at position 4 β); 3.23 (s, 3H : NCH₃); 3.33 (t, $J = 12$ Hz, 1H : the other H of CH₂ at position 4 β); 4.13 (s, 2H : ArNCH₂); 5.19 (dd, $J = 12$ and 4 Hz, 1H : 4 α); 7.00 (d, $J = 8$ Hz, 1H : aromatic H at position 4 ϵ); 7.08 (dd, $J = 8$ and 1.5 Hz, 1H : aromatic H at position 4 δ); from 7.15 to 7.40 (mt, 2H : aromatic H at position 4 δ and at the ortho position with respect to the Cl and H at position 5 of pyridine); 7.80 (mt, 1H : H at position 4 of pyridine); 8.55 (broad d, $J = 6$ Hz; 1H : H at position 6 of pyridine); 8.65 (broad s, 1H : H at position 2 of pyridine).

Example Y

2 g of pristinamycin I_B in 6 cm³ of dry dimethylformamide are placed in a three-necked flask

002280" 26754960

maintained under a nitrogen atmosphere, and then 1.46 g of 4-pyridylmethyl bromoacetate hydrobromide and 0.33 cm³ of triethylamine are added. The mixture is stirred for 18 hours at 60°C. The reaction mixture is cooled, poured over 100 cm³ of distilled water and then extracted with 4 times 30 cm³ of ethyl acetate. The aqueous phase is decanted off and then the organic phase washed again with 3 times 10 cm³ of distilled water, decanted off and then dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 1.2 g of a pale-yellow solid which is purified by flash chromatography (eluent: dichloromethane-methanol 97/3) to give 0.53 g of a solid which is repurified by HPLC to give 197 mg of (4-N-pyridylmethoxycarbonylmethyl)pristinamycin I_B in the form of a white powder melting at 252°C.

4-Pyridylmethyl bromoacetate hydrobromide may be prepared in the following manner:

1.09 g of 4-hydroxymethylpyridine dissolved in 20 cm³ of chloroform (dry over amylene) are placed in a three-necked flask maintained under a nitrogen atmosphere and then 0.88 cm³ of bromoacetyl bromide dissolved in 2 cm³ of chloroform is added over 1 hour at room temperature. After stirring for 24 hours, an additional 10% bromoacetyl bromide is added and then the stirring is continued for 24 hours. The reaction mixture is filtered, taken up in chloroform and then in ether. The resulting solid is dried under reduced

002280" 2674960

pressure to give 2.1 g of a solid which is used as it is in the next step.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
2.92 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position
5 4β); 3.08 (s, 3H : ArNCH₃); 3.27 (s, 3H : NCH₃); 3.33
(t, J = 12 Hz, 1H : the other H of CH₂ at position 4β);
4.17 (s, 2H : ArNCH₂); 5.19 (s, 2H : COOCH₂); 5.25 (dd,
J = 12 and 4 Hz, 1H : 4α); 6.67 (d, J = 8.5 Hz, 2H :
aromatic H at position 4ε); 7.07 (d, J = 8.5 Hz, 2H :
10 aromatic H at position 4δ); 7.22 (d, J = 5.5 Hz, 2H : H
β of pyridine); 8.59 (d, J = 5.5 Hz, 2H : H α of
pyridine).

Example Z

By carrying out the procedure as in Example Y
15 but starting with 1.5 g of pristinamycin I_B and 640 mg
of N-methyl-N-(1-methylpiperid-4-yl)bromoacetamide
hydrobromide in 4.5 cm³ of dry dimethylformamide and
after stirring for 72 hours at room temperature, a
solution is obtained after evaporation of a portion of
20 the dimethylformamide at 50°C under a partial pressure,
which solution is taken up in 15 cm³ of distilled water.
The reaction mixture is washed with twice 15 cm³ of
ethyl acetate. The aqueous phase is decanted off,
adjusted to pH 5-6, washed again with ethyl acetate and
25 then alkalized to pH 8 with 0.1 N sodium hydroxide.
The aqueous phase is supplemented with sodium chloride
and then extracted with 15 cm³ of methylene chloride.
The organic phase is washed with 2 cm³ of water,

002280 2644960

decanted off, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 1.1 g of a pale-yellow solid which is dissolved in 30 cm³ of a methylene chloride/methanol concentrated ammonia mixture (70/20/1 by volume) and then supplemented with 5.5 g of silica. After stirring for 45 minutes, the mixture is filtered, rinsed with twice the same volume of mixture of solvents and then concentrated to dryness. The product obtained is concreted from 15 cm³ of ether and then filtered to give 680 mg of [N-(1-methylpiperid-4-yl)-N-methylamino-carbonylmethyl]pristinamycin I_B in the form of a white solid melting at 210°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 from 1.60 to 2.10 and from 2.75 to 3.00 (2 mts, respectively 6H and 2H : CH₂CH₂N of piperidine); 2.30 (s, 3H : NCH₃ of piperidine); 2.85 (s, 3H : CONCH₃); from 2.80 to 3.00 (mt, 1H : 1H of CH₂ at position 4β); 3.00 (s, 3H : ArNCH₃); 3.22 (s, 3H : NCH₃); 3.28 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β); 4.04 (s, 2H : ArNCH₂); 4.45 (mt, 1H : CONCH); 5.25 (dd, J = 12 and 4 Hz, 1H : 4α); 6.60 (d, J = 8.5 Hz, 2H : aromatic H at position 4ε); 7.00 (d, J = 8.5 Hz, 2H : aromatic H at position 4δ).

N-Methyl-N-(1-methylpiperid-4-yl)bromo-acetamide hydrobromide may be obtained in the following manner:

1.45 g of 1-methyl-4-methylaminopiperidine in

002280" 26T4960

30 cm³ of dry dimethylformamide are placed in a three-necked flask maintained under nitrogen at 5°C and then 0.95 g of bromoacetyl bromide dissolved in 10 cm³ of chloroform is added over 1 hour. After 18 hours at room temperature, the reaction mixture is concentrated, the residue taken up in 30 cm³ of ether and then stirred for 3 hours. The resulting solid is filtered, washed with ether and then dried under reduced pressure (2.7 kPa) to give 3.2 g of N-methyl-N-(1-methylpiperid-4-yl)-bromoacetamide hydrobromide in the form of a pale-yellow solid which is used as it is.

Example AA

By carrying out the procedure as in Example Y but starting with 2.4 g of pristinamycin I_B and 0.91 g of (1-ethoxycarbonylpiperid-4-yl)bromoacetamide in 7.5 cm³ of dry dimethylformamide and after stirring for 96 hours at room temperature, a solution is obtained which is diluted with 80 cm³ of distilled water. The mixture is adjusted to pH 8 with sodium bicarbonate, supplemented with sodium chloride and then extracted with twice 20 cm³ of ethyl acetate. The aqueous phase is decanted off and then re-extracted with twice 20 cm³ of ethyl acetate. The organic phases are pooled, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give a pale-yellow solid which is taken up in ether to give after filtration and drying 2.6 g of a pale-yellow powder which is purified by flash chromatography (eluent:

002220 2674960

dichloromethane-methanol 97/3) to give 1.1 g of [N-(1-ethoxycarbonylpiperid-4-yl)aminocarbonylmethyl]pristinamycin I_B in the form of a white solid melting at 195°C.

- 5 ¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
 1.23 (t, J = 7 Hz, CH₃ of ethyl); from 1.20 to 1.50 and from 1.70 to 1.95 (2 mts, 2H each : CH₂ of piperidine); 2.85 and from 3.90 to 4.15 (mt and unresolved complex respectively, 2H and 3H respectively : NCH₂ and NCH of
 10 piperidine); 2.95 (dd, J = 12.5 and 4 Hz, 1H : 1H of CH₂ at position 4β); 2.97 (s, 3H : ArNCH₃); 3.25 (s, 3H : NCH₃); 3.34 (t, J = 12.5 Hz, 1H : the other H of CH₂ at position 4β); 3.79 and 3.90 (2 d, J = 18 Hz, 1H each : ArNCH₂); 4.20 (q, J = 7 Hz, 2H : COOCH₂ of ethyl); 5.19
 15 (dd, J = 12.5 and 4 Hz, 1H : 4α); 6.55 (mt, 1H : CONH); 6.63 (d, J = 8 Hz, 2H : aromatic H at position 4ε); 7.15 (d, J = 8 Hz, 2H : aromatic H at position 4δ).

(1-Ethoxycarbonylpiperid-4-yl)bromoacetamide may be prepared in the following manner:

- 20 860 mg of 1-ethoxycarbonyl-4-aminopiperidine and then 15 cm³ of dry chloroform (over amylene) and 0.84 cm³ of triethylamine are placed in a three-necked flask maintained over nitrogen. The mixture is cooled to 5°C and then 0.48 cm³ of bromoacetyl bromide
 25 dissolved in 2 cm² of dry chloroform is added over 45 minutes and the stirring is continued for 5 hours at room temperature. The chloroform is evaporated off under reduced pressure and the mixture taken up in

20 cm³ of ethyl acetate and 120 cm³ of distilled water. The organic phase is decanted off, washed with twice 5 cm³ of water and then dried over magnesium sulphate, filtered, concentrated under reduced pressure (2.7 kPa) to give a pale-yellow solid which is taken up in ether to give after filtration and drying 970 mg of (1-ethoxycarbonylpiperid-4-yl)bromoacetamide in the form of a white powder which is used as it is.

Example AB

10 By carrying out the procedure as in Example Y but starting with 3 g of pristinamycin I_B and 1.53 g of N-(1-benzylpiperid-4-yl)bromoacetamide hydrobromide in 9 cm³ of dry dimethylformamide and after stirring for 72 hours at room temperature, a solution is obtained
15 which is diluted with 120 cm³ of distilled water. The mixture is adjusted to pH 8 and then extracted with 3 times 30 cm³ of ethyl acetate. The organic phase is decanted off, washed with 30 cm³ of water and then dried over magnesium sulphate, filtered and then concentrated
20 under reduced pressure (2.7 kPa) to give a pale-yellow solid which is taken up in ether to give after filtration and drying 3.3 g of a white powder which is purified by flash chromatography (eluent: dichloromethane-methanol 97/3) to give 0.95 g of
25 [(1-benzylpiperid-4-yl)aminocarbonylmethyl]-pristinamycin I_B in the form of a white solid melting at 195°C.

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):

002280 2674960

from 1.35 to 1.65 and from 1.95 to 2.20 (2 mts, 2H each : CH₂ of piperidine); from 2.70 to 2.85 and from 3.25 to 3.40 (2 mts, 2H : NCH₂ of piperidine); 2.95 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4β); 2.97 (s, 3H : ArNCH₃); 3.26 (s, 3H : NCH₃); 3.35 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β); 3.47 (s, 2H : NCH₂Ar); 3.80 and 3.90 (2 d, J = 18 Hz, 1H each : ArNCH₂); from 3.75 to 3.95 (mt, 1H : NCH of piperidine); 5.25 (dd, J = 12 and 4 Hz, 1H : 4α); 6.50 (d, J = 7.5 Hz, 1H : CONH); 6.65 (d, J = 8.5 Hz, aromatic H at position 4ε); 7.15 (d, J = 8.5 Hz, 2H : aromatic H at position 4δ); from 7.15 to 7.40 (mt, 5H : aromatic H of benzyl).

N-(1-Benzylpiperid-4-yl)bromoacetamide

hydrobromide may be obtained in the following manner:

950 mg of 4-amino-1-benzylpiperidine and then 15 cm³ of dry chloroform (over amylene) are placed in a three-necked flask maintained under nitrogen. The mixture is cooled to 5°C and then 0.47 cm³ of bromoacetyl bromide dissolved in 5 cm³ of dry chloroform is added over 45 minutes and the stirring is continued for 30 minutes at 5°C. The chloroform is evaporated under reduced pressure and the mixture is taken up in 15 cm³ of ether to give after filtration and drying 2 g of N-(1-benzylpiperid-4-yl)bromoacetamide hydrobromide in the form of a white powder which is used as it is.

Example AC

605 mg of [(1-benzylpiperid-4-yl)amino-

002280" 082200

carbonylmethyl]pristinamycin I_B in 12 cm³ of methanol and 6 cm³ of dichloromethane, 120 mg of 10% palladium on carbon and then 0.22 cm³ of 2.5 N hydrochloric ether are placed in a three-necked flask maintained under
5 nitrogen. The mixture is placed under a hydrogen atmosphere at 18°C and then heated to 33°C. After 3 days the mixture is purged with nitrogen, filtered on Clarcel®, concentrated under reduced pressure and then taken up in 15 cm³ of water. The solution is adjusted to
10 pH 8 with 1 N sodium hydroxide, supplemented with sodium chloride and then extracted with dichloromethane. The organic phase is decanted off, washed with water saturated with sodium chloride, dried over magnesium sulphate, filtered and then concentrated
15 under reduced pressure (2.7 kPa) to give a solid which is stirred for 18 hours in 11.2 cm³ of 0.1 N hydrochloric acid. The medium is adjusted to pH 8 by addition of 11.2 cm³ of 0.1 N sodium hydroxide and then supplemented with 3.6 g of sodium chloride. After
20 stirring for 2 hours, the precipitate is filtered, rinsed with a minimum of ice-cold water and then taken up in ether. The solid is taken up in dichloromethane, dried over magnesium sulphate, filtered and then dried at 35°C under reduced pressure (90 Pa) to give 270 mg
25 of [(4-piperidinyl)aminocarbonylmethyl]pristinamycin I_B in the form of a cream-coloured solid melting at 230°C.

¹H NMR spectrum (400 MHz, CDCl₃, δ in ppm):
from 1.45 to 1.65 and from 1.80 to 2.00 (2 mts, 2H each

002280" 26TE460

: CH₂ of piperidine); from 2.65 to 2.85 and from 3.05 to 3.25 (2 mts, 2H each : NCH₂ of piperidine); 2.95 (dd, J = 12 and 4 Hz, 1H : 1H of CH₂ at position 4β); 2.98 (s, 3H : ArNCH₃); 3.27 (s, 3H : NCH₃); 3.32 (t, J = 12 Hz, 1H : the other H of CH₂ at position 4β); 3.80 and 3.88 (2 d, J = 18 Hz, 1H each : ArNCH₂); 3.95 (mt, 1H : CONCH of piperidine); 5.22 (dd, J = 12 and 4 Hz, 1H : 4α); 6.63 (d, J = 8.5 Hz, 2H : aromatic H at position 4ε); 6.68 (d, J = 8 Hz, 1H : CONH); 7.10 (d, J = 8.5 Hz, 2H : aromatic H at position 4δ).

Example AD

15 g of pristinamycin I_A in 30 cm³ of dry dimethylformamide are placed in a three-necked flask maintained under a nitrogen atmosphere and then 2.2 cm³ of ethyl bromoacetate are added. The mixture is stirred for 22 hours at 80°C. After cooling, the reaction mixture is diluted with 300 cm³ of distilled water and then stirred. The precipitate formed is filtered, rinsed with 3 times 50 cm³ of distilled water and then with ether. The resulting solid is solubilized in ethyl acetate, filtered and then washed in a separating funnel with 3 times 50 cm³ of distilled water. The organic phase is decanted off, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 7.2 g of a brown oil which is purified by flash chromatography (eluent: dichloromethane-methanol 98/2) to give 3.2 g of 4-N-(ethoxycarbonylmethyl)pristinamycin I_B in the form

002280" 082200

of a white solid melting at 244°C.

^1H NMR spectrum (400 MHz, CDCl_3 , δ in ppm):

1.28 (t, $J = 7$ Hz, 3H : CH_3 of ethyl); 2.90 (dd,
 $J = 12.5$ and 4 Hz, 1H : 1H of CH_2 at position 4 β); 3.05
 5 (s, 3H : ArNCH_3); 3.26 (s, 3H : NCH_3); 3.34 (t,
 $J = 12.5$ Hz, 1H : the other H of CH_2 at position 4 β);
 4.02 and 4.08 (2 d, $J = 18$ Hz, 1H each : ArNCH_2); 4.20
 (q, $J = 7$ Hz, 2H : CH_2 of ethyl); 5.22 (dd, $J = 12.5$ and
 4 Hz, 1H : 4 α); 6.62 (d, $J = 8.5$ Hz, 2H : aromatic H at
 10 position 4 ϵ); 7.07 (d, $J = 8.5$ Hz, 2H : aromatic H at
 position 4 δ).

Example AE

By carrying out the procedure as in
 Example AD but starting with 1.5 g of pristinamycin I_A
 15 in 3 cm³ of dry dimethylformamide and 240 mg of
 bromoacetonitrile, 0.8 g of a white solid is obtained
 after 6 hours at 80°C which is purified by flash
 chromatography (eluent: dichloromethane-methanol 97/3)
 to give 0.48 g of 4-N-cyanomethylpristinamycin I_B in the
 20 form of a white solid melting at 258°C.

^1H NMR spectrum (300 MHz, CDCl_3 , δ in ppm):

2.95 (dd, $J = 12$ and 4 Hz, 1H : 1H of CH_2 at position
 4 β); 2.97 (s, 3H : ArNCH_3); 3.20 (s, 3H : NCH_3); 3.32
 (t, $J = 12$ Hz, 1H : the other H of CH_2 at position 4 β);
 25 4.10 (limiting AB, $J = 18$ Hz, 2H : ArNCH_2); 5.23 (dd,
 $J = 12$ and 4 Hz, 1H : 4 α); 6.75 (d, $J = 8$ Hz, 2H :
 aromatic H at position 4 ϵ); 7.09 (d, $J = 8$ Hz, 2H :
 aromatic H at position 4 δ).

Example AF

5δ-Methylenepristinamycin I_B may be obtained in the following manner.

10 cm³ of methanol and 1 cm³ of morpholine are
5 placed in a three-necked flask maintained under a
nitrogen atmosphere and then 0.6 cm³ of methanesulphonic
acid is slowly added while the temperature is
maintained below 20°C. 0.17 g of polyoxymethylene and
then 1 g of pristinamycin I_B are then added with
10 stirring. The milky suspension obtained is heated for
4 hours at 40°C and then stirred for 12 hours at room
temperature. The mixture is concentrated to dryness,
taken up in 20 cm³ of ethyl acetate and 20 cm³ of
distilled water, filtered on Clarcel® and then decanted
15 off. The aqueous phase is extracted with twice 10 cm³ of
ethyl acetate and then the organic phases are pooled,
washed with 30 cm³ of an aqueous solution of sodium
chloride, decanted off, dried over sodium sulphate and
then concentrated under reduced pressure (2.7 kPa) to a
20 volume of 50 cm³. The organic phase of 50 cm³ thus
concentrated is added, in a three-necked flask, with
stirring, to 35 cm³ of distilled water, 1.3 cm³ of
acetic acid and 0.16 g of sodium acetate trihydrate.
The mixture is heated for 3 hours at 40-45°C and then
25 after cooling, a saturated sodium bicarbonate solution
is added to a pH of 5-6. The aqueous phase is decanted
off, extracted with 20 cm³ of ethyl acetate and then the
organic phases are combined and washed with 30 cm³ of

002280" 26TE4860

bicarbonated distilled water. The aqueous phase is decanted off and then extracted with 20 cm³ of ethyl acetate. All the organic phases are pooled, washed with a saturated aqueous sodium chloride solution, dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure to give 1.03 g of a solid which is purified by two successive flash chromatographies (eluent: methylene chloride-methanol 96/4) to give 0.21 g of a product which is concreted from 5 cm³ of diethyl ether. After filtration and drying at 50°C under reduced pressure (90 Pa), 169 mg of 5δ-methylenepristinamycin I_B are obtained in the form of an off-white solid melting at 210°C (not very sharp).

¹H NMR spectrum (300 MHz, CDCl₃, δ in ppm):

0.66 (dd, J = 16.5 and 6 Hz, 1H : 1H of CH₂ at position 5β); 0.91 (t, J = 7.5 Hz, 3H : CH₃ at position 2γ); from 1.15 to 1.35 (mt, 2H : 1H of CH₂ at position 3β and 1H of CH₂ at position 3γ); 1.33 (d, J = 7 Hz, 3H : CH₃ at position 1γ); from 1.50 to 1.85 (mt : 3H corresponding to the other H of CH₂ at position 3γ and to the CH₂ at position 2β); 2.03 (mt, 1H : the other H of CH₂ at position 3β); 2.50 (d, J = 16.5 Hz, 1H : the other H of CH₂ at position 5β); 2.81 (s, 3H : ArNCH₃); 2.88 (dd, J = 12 and 4.5 Hz, 1H : 1H of CH₂ at position 4β); from 3.20 to 3.35 (mt, 2H : 1H of CH₂ at position 3δ and the other H of CH₂ at position 4β); 3.26 (s, 3H : NCH₃); 3.52 (mt, 1H : the other H of CH₂ at position 3δ); 3.59 (broad d, J = 16.5 Hz, 1H : 1H of CH₂ at position 5ε);

from 3.65 to 3.90 (broad unresolved complex, 1H :
 ArNH); 4.60 (dd, J = 9 and 6 Hz, 1H : CH at position
 3 α); 4.82 (mt, 1H : CH at position 2 α); 4.88 (dd,
 J = 10 and 1 Hz, 1H : CH at position 1 α); 5.05 (dd,
 5 J = 12 and 4.5 Hz, 1H : CH at position 4 α); 5.28 (broad
 d, J = 16.5 Hz, 1H : the other H of CH₂ at position 5 ϵ);
 5.28 (d, J = 6 Hz, 1H : CH at position 5 α); 5.35 and
 6.17 (2 broad s, 1H each : =CH₂); 5.84 (d, J = 9 Hz, 1H
 : CH at position 6 α); 5.90 (dq, J = 7 and 1 Hz, CH at
 10 position 1 β); 6.46 (d, J = 8 Hz, 2H : aromatic H at
 position 4 ϵ); 6.50 (d, J = 10 Hz, CONH at position 2);
 6.91 (d, J = 8 Hz, 2H : aromatic H at position 4 δ);
 from 7.15 to 7.35 (mt: the 5 aromatic H at position 6);
 7.47 (limiting AB, 2H : 1'H₄ and 1'H₅); 7.82 (dd, J = 4
 15 and 2 Hz, 1H : 1'H₆); 8.38 (d, J = 10 Hz, 1H : CONH at
 position 1); 8.73 (d, J = 9 Hz, 1H : CONH at position
 6); 11.60 (s, 1H : OH).

The products of the above examples may be
 treated by analogy with the methods described in
 20 Examples 1 to 33 in order to prepare the streptogramin
 derivatives of general formula (I).

The present invention also relates to the
 pharmaceutical compositions containing at least one
 streptogramin derivative according to the invention, in
 25 the pure state, combined with at least one group A
 streptogramin derivative, where appropriate in salt
 form, and/or in the form of a combination with one or
 more compatible and pharmaceutically acceptable

002230 "082200"

diluents or adjuvants.

The compositions according to the invention may be used by the oral, parenteral, topical or rectal route or in the form of aerosols.

- 5 As solid compositions for oral administration, tablets, pills, gelatin capsules, powders or granules may be used. In these compositions, the active product according to the invention, generally in the form of a combination, is mixed with
- 10 one or more inert diluents or adjuvants, such as sucrose, lactose or starch. These compositions may comprise substances other than diluents, for example a lubricant such as magnesium stearate or a coating intended for a controlled release.
- 15 As liquid compositions for oral administration, there may be used solutions which are pharmaceutically acceptable, suspensions, emulsions, syrups and elixirs containing inert diluents such as water or paraffin oil. These compositions may also
- 20 comprise substances other than diluents, for example wetting, sweetening or flavouring products.

- Compositions for parenteral administration may be emulsions or sterile solutions. As solvent or vehicle, there may be used propylene glycol, a
- 25 polyethylene glycol, vegetable oils, in particular olive oil, or injectable organic esters, for example ethyl oleate. These compositions may also contain adjuvants, in particular wetting, isotonizing,

0022280" 26T4960

emulsifying, dispersing and stabilizing agents.

Sterilization may be carried out in several ways, for example with the aid of a bacteriological filter, by irradiation or by heating. They may also be
5 prepared in the form of sterile solid compositions which may be dissolved at the time of use in sterile water or any other injectable sterile medium.

Compositions for topical administration may be, for example, creams, ointments, lotions or
10 aerosols.

Compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active ingredient, excipients such as cocoa butter, semisynthetic glycerides or polyethylene
15 glycols.

The compositions may also be aerosols. For use in the form of liquid aerosols, the compositions may be stable sterile solutions or solid compositions which are dissolved at the time of use in apyrogenic
20 sterile water, in saline or any other pharmaceutically acceptable vehicle. For use in the form of dry aerosols intended to be directly inhaled, the active ingredient is finely divided and combined with a water-soluble solid diluent or vehicle with a particle size
25 distribution of 30 to 80 μm , for example dextran, mannitol or lactose.

In human therapy, the new streptogramin derivatives according to the invention are particularly

0022280" 26E4960

useful in the treatment of infections of bacterial origin. The doses depend on the desired effect and the duration of treatment. The doctor will determine the dosage which he judges to be the most appropriate depending on the treatment, depending on the age, weight and degree of infection and other factors specific to the subject to be treated. Generally, the doses are between 1 and 3 g of active product in 2 or 3 doses per day orally for an adult.

10 The following example illustrates a composition according to the invention.

EXAMPLE

 Tablets containing a dose of 250 mg of active ingredient and having the following composition are prepared according to the usual technique:

- 2"-methylpyrido[2,3-5 γ ,5 δ]pristinamycin I_E .. 75 mg
- pristinamycin II_B..... 175 mg
- excipient: starch, hydrated silica,
dextrin, gelatin, magnesium
- 20 stearate: qs..... 500 mg

002280" 267E4960